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SUMMARY 
Proteins from the Argonaute (Ago) family act as key factors of small RNA function. In 
mammalian somatic cells, the predominant class of small inhibitory RNAs is constituted by 
microRNAs (miRNAs) with a size of 21-24 nucleotides. They are bound by Ago proteins and 
guide them to their target mRNAs, thereby facilitating regulation of transcription, mRNA 
stability and translational repression. The complexity of miRNA-guided cellular events implies 
that a considerable number of additional factors is involved in controlling and fine-tuning 
these processes. Details on the underlying regulatory mechanisms, however, remain largely 
unknown. 
Therefore, protein complexes containing Ago1 or Ago2 were analyzed for their RNA content 
as well as for associated protein factors and enzymatic activities. Gradient centrifugation of 
lysates from human cells revealed three distinct Ago-containing complexes, termed 
complex I-III, which differed in catalytic activities. While only the smallest complex 
(complex I) was cleavage competent, both complex I and the largest complex III were able to 
process a miRNA precursor into mature miRNA. Complex I consists of multiple sub-
complexes with distinct enzymatic activities. While all three complexes contain miRNAs, only 
complex III associates with a translationally repressed mRNA target.  
For a comprehensive proteomic analysis, proteins that co-purified with ectopically expressed 
FLAG/HA-tagged Ago1 and Ago2 were identified by mass spectrometry. Besides factors with 
reported functions in the miRNA pathway, the majority of Ago-associated proteins were 
implicated in mRNA binding or RNA metabolism. DEAD/DEAH-box containing proteins and 
heterogeneous nuclear ribonucleoprotein particles were represented in large numbers as 
well as ribosomal proteins. Ago interaction was verified for a subset of the identified proteins 
using immunoprecipitation and in vitro pull-down approaches.  
Luciferase reporter experiments supported a functional relevance for the RNA binding protein 
RBM4 in miRNA-mediated repression. Moreover, in vitro pull-down approaches confirmed 
the interaction of RBM4 with all four human Ago proteins. Furthermore, the interaction 
interface could be narrowed down to the PIWI domain of Ago2, presumably with minor 
contributions of the N-terminal domain. RBM4 binding appears to be mediated by the second 
of the two RNA recognition motifs of RBM4 in concert with the Zinc finger domain and the 
intermediate linker region. Attempting to finally clarify the molecular mechanism of Ago 
binding to RBM4, first approaches were made towards the identification of common in vivo 
mRNA targets as well as mRNA binding requirements that allow for efficient interaction of 
RBM4 and Ago proteins. While a relevance in small RNA biogenesis or RISC activity was not 
observed, RBM4 might cooperate with Ago proteins in target binding and stabilize the Ago-
target interaction, thereby increasing the effectiveness of miRNA-mediated gene regulation. 
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 INTRODUCTION 1.
Systematic analysis of the human genome suggested that more than 93 % of the DNA is 
transcribed into RNA. Less than 2 % is actually translated into protein (Birney et al., 2007). 
Non-coding RNAs (ncRNAs) play an essential role in a multitude of cellular processes 
including RNA biogenesis, splicing and translation. In recent years, the relevance of a group 
of small ncRNAs, also referred to as small inhibitory RNAs, in the down-regulation of gene 
expression has become more and more apparent.  
Effects of small inhibitory RNA functions were first observed in 1990, when Napoli and 
colleagues reported that overexpression of a pigment synthesis enzyme in petunia flowers 
resulted in partly or completely white petals (Napoli et al., 1990). Yet, the underlying 
mechanisms were not understood at the time. A first deliberate and efficient knock-down of 
target genes was performed in 1998 by Fire and Mellow in Caenorhabditis elegans 
(C. elegans) using long double-stranded RNA (Fire et al., 1998). In subsequent experiments 
in plants and Drosophila melanogaster extracts, it was demonstrated that the introduced long 
dsRNAs were processed into shorter fragments of about 22 nucleotides (nt) in length 
(Hamilton and Baulcombe, 1999; Hammond et al., 2000; Zamore et al., 2000). These 
fragments, termed small interfering RNAs (siRNAs), were shown to induce sequence-specific 
degradation of complementary target RNAs in a process termed RNA interference. For 
application in the mammalian system, however, this method proved to be inapt as 
transfection of long dsRNA into cultured mammalian cells resulted in an interferon response 
and subsequent cell death (Stark et al., 1998). Elbashir and colleagues were able to show 
that efficient RNA silencing in mammalian cells could be achieved by transfection of base-
paired 21-nucleotide siRNA duplexes with symmetric 2 nt 3‟ overhangs (Elbashir et al., 
2001a).  
Meanwhile, small interfering RNAs have become an essential tool for the characterization of 
protein function and cellular processes. Moreover, several other classes of endogenous 
small inhibitory RNAs have been identified with functions reaching far beyond cleavage-
induced destruction of a complementary target RNA and many aspects of their functions still 
remain to be elucidated. Their defining characteristics, however, comprise an RNA size of 
about 20-30 nucleotides and their association with members from the Argonaute protein 
family, which in turn are essential components of the effector protein complexes guided by 
small RNAs. 
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1.1. CLASSES OF SMALL RNAS 
Small interfering RNAs can be grouped into classes according to their distinct biogenesis 
pathways as well as their biological functions, which are also dependent on the constitution 
of their Argonaute containing effector complexes. In the subsequent paragraphs, the major 
small RNA classes and their characteristics are 
outlined. 
 
1.1.1. Small inhibitory RNAs (siRNAs) 
Small inhibitory RNAs (siRNAs) guide 
endonucleolytic cleavage of their complementary 
target RNAs (Hammond et al., 2000; Zamore et al., 
2000). SiRNAs originate from double stranded RNA 
(dsRNA) from either endogenous or exogenous 
sources, e.g. viral or transgene RNA. 
Exogenous double-stranded siRNA precursors are 
recognized and cleaved by the dsRNA-specific 
RNase III enzyme Dicer yielding an RNA duplex of 
21 nucleotides, each strand bearing a 5‟ phosphate 
and a two nucleotide (2 nt) overhang at the 3‟ end 
(Figure 1; Bernstein et al., 2001; Elbashir et al., 
2001b; Elbashir et al., 2001c). The duplex is 
subsequently transferred to a member of the 
Argonaute (Ago) protein family, the core protein of 
the RNA-induced silencing complex (RISC; 
Hammond et al., 2000). One of the strands, termed 
the guide strand, is bound by the Ago protein, while 
the other strand, the so-called passenger strand, is 
ultimately degraded, thereby rendering the RISC 
complex active (Matranga et al., 2005; Miyoshi et 
al., 2005; Rand et al., 2005). The incorporated 
siRNA eventually acts in guiding the RISC complex to a perfect complementary target, 
thereby initiating endonucleolytic cleavage and subsequent degradation of its target RNA 
(Elbashir et al., 2001b; Elbashir et al., 2001c; Schwarz et al., 2002). Notably, only one of the 
human Ago proteins, Ago2, is endonucleolytically active and capable of target cleavage 
(chapter 1.2.2.1, Liu et al., 2004; Meister et al., 2004). Further, in plants and flies, siRNAs are 
 
 
Figure 1: Biogenesis and function of 
siRNAs from exogenous sources of 
double-stranded RNA.  
Taken from Jinek and Doudna, 2009. 
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stabilized by methylation at the 3‟ end prior to loading into Ago proteins (Li et al., 2005; Yu et 
al., 2005; Horwich et al., 2007; Pelisson et al., 2007; Ramachandran and Chen, 2008).  
Initially, the existence of endogenously derived siRNAs seemed to be restricted to C. elegans 
and plants (Hamilton et al., 2002; Ambros et al., 2003). Recently, however, endo-siRNAs 
have also been detected in Drosophila and mammalian systems, suggesting general 
functions of this small RNA class in higher eukaryotes (Kim et al., 2009). 
In plants and nematodes, endo-siRNA production involves RNA dependent RNA 
polymerases (RdRPs), that allow for the creation of an RNA double strand from a single-
stranded RNA template. In C. elegans, Argonaute-associated primary siRNAs bind to target 
mRNAs and recruit the RdRP complex which synthesizes antisense siRNAs to the target 
mRNA without the requirement of primers (Smardon et al., 2000; Aoki et al., 2007; Pak and 
Fire, 2007; Sijen et al., 2007). The siRNAs resulting from this process are referred to as 
secondary siRNAs. In plants, the RdRP complex is recruited upon siRNA-induced target 
cleavage and produces a long RNA double strand, that is subsequently cleaved by a Dicer-
like protein into secondary siRNA duplexes, followed by loading of single stranded siRNAs 
into Argonaute proteins (Ghildiyal and Zamore, 2009). In both systems, the RdRP synthesis 
step allows for a self-amplification of the silencing response. In both plants and nematodes, 
even a spreading of siRNAs from cell to cell has been observed, allowing for a systemic 
response to exogenous RNA (Voinnet, 2005). 
Endo-siRNAs in plants can be distinguished according to their origin and function (reviewed 
in Kim et al., 2009). Natural antisense transcript-derived siRNAs (natsiRNAs) originate from 
convergent transcription of a constitutively transcribed RNA strand and a complementary 
strand that is transcribed in response to cellular stress. Trans-acting siRNAs (tasiRNAs) are 
produced upon cleavage of a pre-tasiRNA. Subsequently, a complementary RNA strand is 
generated and cleaved into 21 nt tasiRNAs. Both natsiRNAs and tasiRNAs guide cleavage of 
their respective target RNAs. Cis-acting siRNAs (casiRNAs), in contrast, arise from 
transposons or repetitive elements and initiate heterochromatin formation via DNA 
methylation and histone modification at their homologous loci. A similar function has also 
been reported for centromeric repeat-derived dsRNAs in Schizosaccharomyces pombe 
(Volpe et al., 2003; Moazed, 2009). This regulatory mechanism has been termed RNA 
induced transcriptional silencing. 
In Drosophila and in mammalian systems, however, RNA dependent RNA polymerases 
appear to be missing. Here, endo-siRNAs arise from different sources, e.g. from bidirectional 
transcription, as described for siRNAs against the L1 retrotransposon detected in human cell 
cultures (reviewed in Ghildiyal and Zamore, 2009). Other endo-siRNAs may arise from RNA 
transcripts containing intramolecularly paired hairpins, so-called “structured loci”, from 
convergent transcription or read-through transcription of transposons placed in inverted 
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orientation. Further, a gene transcript may partially pair with that of a cognate pseudogene 
transcribed in inverted orientation. These endo-siRNAs are believed to maintain genomic 
stability by repressing mobile genetic elements. Interestingly, some endo-siRNAs in flies also 
derive from mRNAs, suggesting a possible role in regulating protein expression (Ghildiyal et 
al., 2008). Except for secondary siRNAs in C. elegans, which adhere to specific biogenesis 
rules, the processing of endo-siRNAs appears to involve Dicer-mediated dsRNA cleavage 
and subsequent incorporation into Ago proteins as described before.  
Current work suggests that abundant expression of endo-siRNAs in mice is restricted to 
oocytes and embryonic stem cells (Babiarz et al., 2008; Tam et al., 2008; Watanabe et al., 
2008). In flies, however, endo-siRNAs have also been detected in somatic cells (Ghildiyal et 
al., 2008). 
 
 
1.1.2. MicroRNAs (miRNAs) 
In animals, the most prevalent class of small RNAs in somatic cells is constituted by 
microRNAs (miRNAs). Hundreds of miRNAs have been described in various organisms and 
viruses and more continue to be discovered, probably regulating more than 60 % of all 
protein-coding genes on a post-transcriptional level in animals (Friedman et al., 2009). 
 
1.1.2.1. MiRNA biogenesis 
MiRNAs are usually transcribed as long, often poly-cistronic, primary miRNAs (pri-miRNAs) 
by RNA polymerase II in the nucleus (Lee et al., 2002; Lee et al., 2004a). Carrying 5‟ cap 
structures as well as introns and poly(A)-tails, these transcripts largely resemble mRNAs 
(Rodriguez et al., 2004). Additionally, a considerable number of miRNAs is encoded in the 
intronic regions of protein-coding transcripts. 
In a first processing step, the stem-loop-structured miRNA precursors (pre-miRNAs) are 
liberated from the primary transcript (Figure 2, left and upper right panel). The cleavage 
reaction is performed by a multiprotein complex termed microprocessor containing the 
RNase III enzyme Drosha and its double-stranded RNA binding domain (dsRBD)-containing 
partner DGCR8 (or Pasha in Drosophila) (Lee et al., 2003; Denli et al., 2004; Gregory et al., 
2004; Han et al., 2004; Landthaler et al., 2004). This cleavage yields hairpin-structured pre-
miRNAs of a size of 60-70 nucleotides with a 2 nt 3‟ overhang as is characteristic for 
products of RNase III enzymes. They are recognized by the nuclear export factor Exportin 5 
and transferred to the cytoplasm in a Ran-GTP dependent manner (Yi et al., 2003; Bohnsack 
et al., 2004; Lund et al., 2004). Another RNase III enzyme, Dicer, and its dsRBD partner 
 INTRODUCTION  
9 
 
TRBP (or the homologous Loqs in Drosophila), removes the hairpin from the pre-miRNA, 
yielding a short-lived duplex intermediate that consists of the mature miRNA and the 
miRNA*, which usually is degraded subsequently. Mature miRNAs – and in some cases also 
miRNA*s (Packer et al., 2008) - are then incorporated into their effector complexes termed 
microRNA containing ribonucleoprotein particles (miRNPs) and guide them to their target 
mRNAs, which are subsequently regulated on the level of translational inhibition and/or 
mRNA degradation (Fabian et al., 2010).  
 
 
Figure 2: MiRNA biogenesis pathways 
(a) MiRNA processing from a non-coding RNA transcript, (b) Biogenesis of an intronic miRNA, (c) Drosha-
independent miRNA biogenesis from a “mirtron” (modified from Kim et al., 2009). 
 
Moreover, alternative miRNA processing pathways have been discovered in the meantime. 
Some miRNAs are produced in a Drosha-independent manner from pre-miRNA-resembling 
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introns, so-called “mirtrons” (Figure 2, lower right panel). They are liberated from protein-
coding transcripts during nuclear pre-mRNA splicing and primarily accumulate as branched 
pre-mirtrons (Okamura et al., 2007; Ruby et al., 2007; Babiarz et al., 2008). After 
debranching and sometimes also trimming, the resulting pre-miRNAs are exported into the 
cytoplasm and further processed by Dicer. Other studies identified small nucleolar RNAs 
(snoRNAs) as sources of small RNAs with miRNA-like functions (Ender et al., 2008; Saraiya 
and Wang, 2008; Taft et al., 2009). Recently, a Dicer-independent miRNA biogenesis 
pathway has been described for miR-451 (Cheloufi et al., 2010; Cifuentes et al., 2010; Yang 
et al., 2010). Both miR-144 and miR-451 are cleaved from a poly-cistronic primary transcript 
by the Drosha complex. While the miR-144 precursor enters the canonical miRNA 
biogenesis pathway, pre-miR-451 is directly loaded into Ago2 in the cytoplasm. Bypassing 
Dicer processing, the miR-451 precursor is cleaved by Ago2 and probably trimmed by an 
unknown exonuclease to yield the mature miR-451.  
MiRNA function is highly regulated cell-specifically as well as temporally (Landgraf et al., 
2007). This is also reflected in the post-transcriptional regulation of miRNA biogenesis. As an 
example, maturation of miRNA let-7 in murine embryonic stem cells is prevented on the pri- 
as well as on the pre-miRNA level by Lin28 (Heo et al., 2008; Newman et al., 2008; 
Viswanathan et al., 2008). Contrarily, the proteins hnRNP A1 as well as the RNA helicase 
p68 have been reported to enhance pri-miRNA processing (Guil and Caceres, 2007; Davis et 
al., 2008). 
 
1.1.2.2. MiRNA binding to target mRNAs 
In contrast to siRNAs, miRNAs usually exhibit only partial complementarity to the binding 
sites on their target RNAs. Perfect pairing of 5‟ nucleotides 2-8 of the miRNA, the so-called 
“seed” sequence, is, however, of particular importance for miRNA function (Lewis et al., 
2005; Rajewsky, 2006). Complementarity of the 3‟ nucleotides is in many cases of minor 
importance for miRNA function, though it may stabilize the interaction (Fabian et al., 2010). 
As a rule, miRNA-mRNA duplexes contain mismatches or bulges in the central region, 
preventing endonucleolytic cleavage of the mRNA in an siRNA-like manner. As partial 
complementarity is sufficient for miRNA targeting, a single miRNA may control a large 
number of mRNAs (Bartel and Chen, 2004). This consideration illustrates the impressive 
regulatory potential of this small RNA class, but, on the other hand, the difficulties in the 
prediction of target mRNAs. 
Most miRNA binding sites are located in the 3‟-untranslated regions (3‟-UTRs) of mRNAs. 
They are frequently found in AU-rich regions in close proximity to the open reading frame 
(ORF) and/or the 3‟ end of the 3‟-UTR (Rajewsky, 2006; Grimson et al., 2007; Nielsen et al., 
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2007). In many cases, multiple sites for a single or different miRNA are clustered and act 
cooperatively to increase functional efficiency (Doench and Sharp, 2004; Grimson et al., 
2007). More rarely, miRNA binding sites in the 5‟-UTR or the coding region of mRNAs have 
been reported as well (Kloosterman et al., 2004; Easow et al., 2007; Orom et al., 2008; Gu et 
al., 2009; Rigoutsos, 2009). 
Despite their distinct biogenesis, siRNA and miRNA pathways are not strictly separated. In 
rare cases, mammalian miRNAs have been reported to induce cleavage of highly 
complementary targets (Doench et al., 2003; Yekta et al., 2004; Davis et al., 2005), whereas 
siRNA binding to imperfectly matching target RNAs can influence their translation and/or 
turnover rate. While this opens up additional regulatory options, it also poses a considerable 
problem for the use of siRNAs as a scientific tool, as so-called “off-target effects” caused by 
imperfect binding of the guide strand to a number of unintended targets may overlap with 
actual siRNA effects (Jackson and Linsley, 2004). 
 
1.1.2.3. Mechanisms of miRNA function 
1.1.2.3.1. Translational repression 
While the repressive effect on translation is a widely acknowledged function of miRNAs, the 
mechanisms by which it is achieved continue to be under debate (Figure 3).  
Some studies observed a miRNA-mediated decrease in translation initiation. For efficient 
translation initiation of capped mRNAs, several initiation factors are required: among them, 
eIF4A destroys secondary structures in the 5‟-UTR of the mRNA through its RNA helicase 
function, allowing for AUG-scanning by the small ribosomal subunit. EIF4G acts as a scaffold 
that binds eIF4A and the m7G-cap-binding factor eIF4E as well as the poly(A)-binding protein 
(PABP) at the 3‟ poly(A)-tail of the mRNA, thereby circularizing the mRNA and enhancing 
translation initiation rates (Fabian et al., 2010). Transfection of miRNA target reporter 
constructs resulted in a shift of the respective mRNAs to lighter fractions in polysome 
gradients, presumably caused by a block of ribosome subunit joining to the mRNA (Pillai et 
al., 2005; Bhattacharyya et al., 2006a). This was attributed to miRNA interference with eIF4E 
binding to the 5‟ cap (Humphreys et al., 2005). Further, the Ago effector complex might 
disturb the association of eIF4G with PABP, thereby preventing mRNA circularization 
(Humphreys et al., 2005). This theory was supported by observations that mRNAs either 
lacking a functional 5‟ cap or possessing certain internal ribosome entry sites (IRES) were 
either not or only weakly affected by miRNA-mediated repression (Humphreys et al., 2005; 
Pillai et al., 2005; Wang et al., 2006; Mathonnet et al., 2007; Thermann and Hentze, 2007; 
Wakiyama et al., 2007). Another theory assumes that Ago directly binds to the cap-structure 
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and thereby displaces eIF4E. The Ago MID domain shows limited sequence homology with 
eIF4E and mutation of two aromatic residues within this sequence impaired translation 
repression (Kiriakidou et al., 2007). However, this model was questioned as mutation of said 
residues interfered with binding of an essential Ago partner, GW182 (Eulalio et al., 2008); 
moreover, no significant structural similarities could be observed between human Ago2 and 
eIF4E (Kinch and Grishin, 2009). Some data suggest that 60S ribosomal subunit joining and 
subsequent formation of the 80S ribosome might be another process disturbed by miRNAs 
(Mathonnet et al., 2007; Thermann and Hentze, 2007; Wang et al., 2008a). This was also 
supported by co-immunoprecipitation results that found eIF6, a translational regulator that 
can associate with the 60S subunit and prevent its premature joining to the 40S subunit, to 
be associated with the ternary Ago2-Dicer-TRBP complex (Chendrimada et al., 2007).  
 
 
Figure 3: Mechanisms of miRNA-mediated translational repression.  
MiRNPs may interfere with efficient translation by competition of Ago with eIF4E for cap binding (upper left), by 
preventing 60 S ribosomal subunit joining (lower left), by blocking mRNA circularization through competition for 
PABP (lower middle) or by facilitating premature ribosome drop-off (lower right). Alternatively, mRNA decay may 
be promoted by a concerted process of deadenylation, decapping and subsequent degradation (taken from 
Carthew and Sontheimer, 2009). 
 
A number of studies proposed that miRNA-mediated translational repression might function 
at post-initiation steps. Polysome sedimentation analyses found repressed miRNA target 
mRNAs in fractions also containing actively translating polysomes, supporting the idea that 
miRNAs might function in blocking translation elongation (Olsen and Ambros, 1999; 
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Seggerson et al., 2002; Maroney et al., 2006; Nottrott et al., 2006; Petersen et al., 2006; Gu 
et al., 2009). In contrast to aforementioned studies on IRES-dependent translation, some 
groups also observed IRES-driven translation to be repressed by miRNAs (Seggerson et al., 
2002; Lytle et al., 2007) and therefore claimed that translation inhibition may take place at a 
step other than initiation. Another approach concluded that miRNAs may act by causing 
premature translation termination and subsequent ribosome drop-off (Petersen et al., 2006). 
Nottrott and colleagues finally proposed that repression is facilitated via co-translational 
degradation of the nascent polypeptide chain (Nottrott et al., 2006). This theory is 
controversial as, accordingly, degradation should not occur with polypeptides targeted to the 
endoplasmatic reticulum (ER); however, miRNA-mediated repression remained unaffected 
by ER targeting. Further, translation of a high number of membrane and ER proteins was 
shown to be regulated by miRNAs (Pillai et al., 2005; Selbach et al., 2008). 
The present data are in many points controversial or even contradictory. Partly, this may be 
attributed to differing experimental approaches. However, it seems plausible that miRNAs 
interfere with translation in multiple ways to facilitate target mRNA repression. It is even 
conceivable that repression modes vary in dependence of the present mRNA target. For 
example, Kong et al. have proposed that the promotor of an mRNA might influence whether 
miRNA repression occurs on translation initiation or elongation levels (Kong et al., 2008). 
Further, other factors may influence accessibility of miRNA binding sites, e.g. under 
conditions of cellular stress, thereby adding another layer of complexity to the regulation of 
translation (Bhattacharyya et al., 2006b). Other proteins might either positively or negatively 
interfere with the function of certain miRNAs by interacting with miRNA-associated protein 
factors, as described for murine Ago1 and TRIM32 or the C. elegans TRIM-NHL and the 
nematode Ago proteins ALG-1/2 and AIN-1 (Hammell et al., 2009; Schwamborn et al., 2009). 
 
1.1.2.3.2. mRNA deadenylation and decay 
A second functional miRNA mechanism is marked by a decrease of target mRNA levels due 
to degradation (Behm-Ansmant et al., 2006; Giraldez et al., 2006; Wu et al., 2006). MiRNA-
mediated mRNA decay is a concerted process that requires both Ago and GW182 family 
proteins and usually starts with the removal of the poly(A)-tail by the CCR4-NOT1 complex of 
3‟-5‟ exoribonucleases (Behm-Ansmant et al., 2006). Subsequently the mRNA is either 
degraded in 3‟-5‟ direction or decapped by the DCP1-DCP2 decapping enzyme complex 
followed by complete degradation by the 5‟-3‟ exonuclease Xrn1 (Orban and Izaurralde, 
2005). MiRNAs were associated with deadenylation and destruction of a variety of mRNA 
targets in many organisms. During development and cell differentiation, for example, 
miRNAs control the destruction of maternal mRNAs and transiently required transcripts 
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(Giraldez et al., 2006; Wu et al., 2006; Wakiyama et al., 2007; Fabian et al., 2009; Iwasaki et 
al., 2009).  
The ribonuclease CAF1, an essential component of the CCR4-NOT1 complex, interacts with 
Ago proteins (Fabian et al., 2009). Another crucial protein factor for deadenylation is the 
poly(A)-binding protein PABP, that directly interacts with GW182, placing the mRNA poly(A)-
tail in close proximity to the deadenylase complex and at the same time blocking translation 
initiation and termination (Tarun and Sachs, 1996; Uchida et al., 2002; Kahvejian et al., 2005; 
Fabian et al., 2009). Translational repression and deadenylation are not strictly separated 
processes but may occur subsequently or even simultaneously (Wu et al., 2006; Fabian et 
al., 2009; Hu et al., 2009). In some cases, the two mechanisms complement each other while 
regulation of other miRNAs seems to be restricted to either of the processes (Selbach et al., 
2008; Fabian et al., 2009). 
 
1.1.2.3.3. Translational activation 
Occasionally, miRNAs have also been reported to act as activators of translation rather than 
as repressors. As an example, the miRNA-regulated translation of the TNFα mRNA was 
increased in growth arrested cells. In proliferating cells, however, translation of the same 
mRNA was repressed (Vasudevan and Steitz, 2007; Vasudevan et al., 2007). 
Moreover, mRNAs with 5‟-UTR miRNA binding sites have been associated with translational 
activation as well (Henke et al., 2008; Orom et al., 2008). 
Still, reports on miRNA-mediated translational activation have been rather rare and further 
investigations will be necessary to clarify the underlying mechanisms and also the relevance 
of this miRNA function. 
 
 
1.1.3. Piwi-interacting RNAs (piRNAs) 
Another class of small RNAs with a size of 25-30 nucleotides is implicated in germ line 
development and maintenance of genomic stability (Aravin et al., 2006; Girard et al., 2006; 
Lau et al., 2006; Siomi and Siomi, 2009). These small RNAs associate with the Piwi 
subfamily of Argonaute proteins and accordingly have been termed Piwi-interacting RNAs 
(piRNAs). PiRNA expression seems to be restricted to germ cells and is particularly 
prominent in testes. While piRNA sequences are highly diverse, they mostly map to a few 
hundred discrete genomic clusters (Aravin and Hannon, 2008). They are not conserved 
across species, but still are expressed from syntenic regions. In Drosophila, piRNA 
biogenesis was proposed to function via an amplification loop according to the so-called 
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“ping-pong” mechanism that requires neither Dicer processing (Vagin et al., 2006) nor small 
dsRNA intermediates (reviewed in Kim et al., 2009). The Drosophila Piwi subfamily is 
constituted by the proteins Piwi, Aubergine (AUB) and Ago3. Piwi and AUB typically bind 
piRNAs with a sequence antisense to transposon transcripts and a strong nucleotide bias 
towards uracil at their 5‟ end, whereas Ago3-associated piRNAs arise mostly from sense 
transcripts and carry an adenine at nucleotide position 10 (Brennecke et al., 2007; 
Gunawardane et al., 2007). Strikingly, the first 10 nucleotides of AUB-associated piRNAs are 
usually complementary to Ago3-associated piRNAs. Based on these observations and the 
detection of endonucleolytic Piwi-activity (Saito et al., 2006; Gunawardane et al., 2007), it 
was proposed that AUB or Piwi loaded with antisense piRNA might cleave sense 
retrotransposon transcripts, thereby creating the 5‟ ends of a sense piRNA that can associate 
with Ago3. In turn, Ago3 cleaves antisense retrotransposon transcripts, producing the 5‟ end 
of the antisense piRNA that subsequently binds to AUB or Piwi, ultimately resulting in an 
amplification of the piRNA population (Brennecke et al., 2007; Gunawardane et al., 2007). 
Drosophila and mammalian piRNAs are 3‟ methylated, similar to siRNA modifications in 
C. elegans and plants (reviewed in Siomi and Siomi, 2009). The mechanism defining the 
3‟ ends of the newly created piRNAs has yet to be determined. Initiation of the ping-pong 
cycle during development was attributed to maternal inheritance of piRNAs as well as AUB 
and probably also Piwi proteins (Brennecke et al., 2007; Nishida et al., 2007; Brennecke et 
al., 2008).  
In mammals, piRNAs can be grouped into two classes that act in distinct stages of sperm 
development. Mouse piRNAs, that are expressed before meiotic pachytene and – in analogy 
to Drosophila piRNAs - originate from repeat- and transposon-rich clusters, are presumably 
created via a ping-pong-resembling mechanism (Watanabe et al., 2006; Aravin et al., 2007; 
Aravin et al., 2008). These pre-pachytene piRNAs interact with the murine Piwi proteins MILI 
and MIWI2. Intriguingly, MILI and MIWI2 also display DNA methylation activity in fetal male 
germ cells, indicating their importance for transcriptional silencing rather than degradation of 
abundant transposon transcripts (Aravin et al., 2008; Kuramochi-Miyagawa et al., 2008). The 
second piRNA class is very abundant in spermatocytes in the pachytene stage and 
associates with MIWI and MILI (Girard et al., 2006; Aravin et al., 2007; Aravin et al., 2008). 
However, pachytene piRNAs do not adhere to the sequence characteristics described for 
Drosophila but rather seem to be derived from large genomic clusters with marked strand 
asymmetry and a lower repeat frequency (Aravin et al., 2006; Girard et al., 2006). The exact 
function of pachytene piRNAs in mammals still remains elusive.  
While piRNAs are predominantly detected in mammalian testes, female germ cells are 
strikingly enriched in endo-siRNAs (Tam et al., 2008; Watanabe et al., 2008), indicating a 
possible cooperation of both pathways in transposon repression (Ender and Meister, 2010). 
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1.2. PROTEINS INVOLVED IN SMALL RNA FUNCTION 
1.2.1. The RNase III ribonucleases Drosha and Dicer 
SiRNA- and miRNA biogenesis generally requires the endonucleolytic cleavage of dsRNA 
precursors by proteins of the RNase III family: Dicer and Drosha. Both Drosha and Dicer are 
monomeric proteins with two tandemly arranged RNase III domains that constitute the 
catalytic site (Figure 4). As all RNase III-processed RNAs, their products are characterized 
by a monophosphorylated 5‟ end and a 2 nt overhang at the 3‟ ends (MacRae and Doudna, 
2007). 
The nuclear RNase III protein Drosha acts in liberating miRNA precursors from primary 
transcripts in an initial cleavage reaction (Lee et al., 2003). Its substrate specificity, however, 
is dependent on association with the dsRBD protein DGCR8 (DiGeorge syndrome critical 
region 8) or its homologue Pasha in Drosophila in a complex termed microprocessor (Giot et 
al., 2003; Gregory et al., 2004; Han et al., 2004; Landthaler et al., 2004). By binding to the 
base of the pri-miRNA hairpin, DGCR8 positions Drosha to cleave the primary transcript at a 
distance of 11 base pairs from the junction between hairpin structure and flanking single-
stranded RNA regions, releasing the respective pre-miRNA (Han et al., 2006). 
Dicer, the second RNase III enzyme involved in small RNA biogenesis, uses long dsRNAs as 
well as pre-miRNAs as substrates, creating short dsRNA fragments with a defined length of 
21-25 nucleotides, depending on the organism studied (Bernstein et al., 2001). In Drosophila, 
miRNA and siRNA processing is performed by two distinct Dicer proteins – Dcr-1 and Dcr-2, 
respectively (Lee et al., 2004b). Nematodes and mammals, however, possess only one Dicer 
protein that acts indiscriminately on both small RNA classes (Hutvagner et al., 2001; Ketting 
et al., 2001; Knight and Bass, 2001). Human Dicer is characterized by an N-terminal 
DEXD/H box, a Domain of Unknown Function (DUF) and a PAZ domain, followed by a 
connector helix, two RNase III domains and the C-terminal dsRBD (Figure 4, Jinek and 
Doudna, 2009). 
 
 
Figure 4: Schematic depiction of the human RNase III enzymes Drosha and Dicer.  
DUF: Domain of Unknown Function, PAZ: Piwi-Argonaute-Zwille domain, RNase IIIa and -b: RNase domains, 
dsRBD: double-stranded RNA binding domain. Modified from Jinek and Doudna 2009. 
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While Dicer structures from higher eukaryotes have not been solved to date, crystal 
structures of Dicer from the unicellular eukaryote Giardia intestinalis as well as biochemical 
approaches elucidated some of the mechanistic details of Dicer function (Zhang et al., 2004; 
Macrae et al., 2006). The G. intestinalis Dicer lacks the DEXD/H box as well as DUF and 
dsRBD domains, providing a minimal Dicer protein. The PAZ domain is connected with the 
tandem RNase III domains via a connector helix that is not conserved through species. The 
PAZ domain acts in anchoring the 3‟ end of the RNA duplex. The RNA establishes 
electrostatic interactions with a number of positively charged residues, while the 
intramolecular RNase III domain dimer cuts the double strand in dependence of Mg2+ cations, 
creating characteristic double-stranded RNA intermediates of a defined size carrying the 
RNase III specific 5‟ phosphate-2 nt 3‟ overhang pattern (Macrae et al., 2006; MacRae et al., 
2007). The distance from PAZ (3‟ RNA anchor) to RNase III domains (5‟ cleavage site) – 
which is mainly defined by the connector helix - thereby acts as a molecular ruler that 
determines the product size (MacRae et al., 2007). The dsRBD appears to act as a clamp 
that locks the RNA substrate; deletion of the dsRBD from human Dicer decreases enzyme 
efficiency while substrate affinity remains unaffected (Ma et al., 2008). Moreover, the 
DEXD/H box domain was proposed to have auto-inhibitory functions, implying that a 
conformational change occurs prior to substrate binding (Ma et al., 2008). A possible function 
of the DEXD/H box in duplex unwinding during small RNA loading to Argonaute proteins still 
awaits closer examination.  
Apart from RNA duplex cleavage, Dicer also participates in the loading of Ago proteins and 
selection of the miRNA or guide strand, respectively. Just as Drosha, Dicer functions in 
tandem with a dsRBD protein. In Drosophila, the dsRBD partner of Dcr-1 in the miRNA 
pathway is an isoform of the protein Loquatious, Loqs-PB (Forstemann et al., 2005; Saito et 
al., 2005), while Dcr-2 associates with R2D2 in RISC assembly (Liu et al., 2003; Tomari et 
al., 2004b). Interestingly though, the endo-siRNA pathway in Drosophila appears to require 
the interaction of Dcr-2 with the Loquacious isoform Loqs-PD (Zhou et al., 2008; Hartig et al., 
2009; Hartig and Forstemann, 2011). The human Dicer-associated dsRBD proteins TRBP 
and PACT reside independently in a complex with Ago2 and Dicer and depletion of either 
TRBP or PACT resulted in defects in miRNA processing and function (Chendrimada et al., 
2005; Haase et al., 2005; Lee et al., 2006; Paroo et al., 2009). For TRBP, a function in strand 
selection from the RNA duplex intermediate has been proposed in analogy to R2D2. Guide 
strand selection in most cases depends on differences in the thermodynamic stability of the 
RNA duplex ends (Khvorova et al., 2003; Schwarz et al., 2003). In Drosophila, R2D2 binds to 
the more stable end of the duplex while Dicer associates with the opposing end (Liu et al., 
2003; Tomari et al., 2004b). In a concerted process, the duplex is transferred to an Ago 
protein where the strand whose 5‟ end is less stably paired is preferentially incorporated into 
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the effector complex while the passenger strand is cleaved by Ago2 or removed by passive 
unwinding (Khvorova et al., 2003; Schwarz et al., 2003). 
 
 
1.2.2. Argonaute proteins 
Proteins of the Argonaute family are essential components of small RNA guided effector 
complexes. They are conserved throughout species; however, the number of encoded 
Argonaute proteins varies considerably (Hock and Meister, 2008). Schizosaccharomyces 
pombe possesses one Ago protein, as well as some species of the budding yeast (though 
not Saccharomyces cerevisiae). 10 Ago proteins were found in Arabidopsis thaliana and five 
in Drosophila melanogaster. C. elegans even encodes for 27 Argonaute proteins that mainly 
act in the secondary siRNA pathway.  
In mice and humans, 8 Ago proteins were identified that can be further grouped into two 
subclasses. The human Ago subclass comprises 4 members, Ago1 through -4, and is 
expressed ubiquitously. The expression of the Piwi subclass members - HILI, HIWI, HIWI2 
and HIWI3 in humans (Sasaki et al., 2003) - however, appears to be restricted to germ cells, 
where they associate with piRNAs. In C. elegans, a third subclass is constituted by the 
WAGO clade, whose members are loaded with secondary siRNAs resulting from RdRP 
synthesis through an unknown mechanism (Pak and Fire, 2007; Sijen et al., 2007; Tolia and 
Joshua-Tor, 2007; Hutvagner and Simard, 2008).  
 
1.2.2.1. Structure of Argonaute proteins 
Ago proteins contain four defined domains: An N-terminal domain and the highly conserved 
PAZ (Piwi-Argonaute-Zwille), MID and PIWI domains (Figure 5a). Crystallization attempts of 
complete Argonaute proteins from higher eukaryotes have not yet been successful, however, 
structural analysis of isolated domains and archaeal and bacterial Argonaute proteins have 
shed some light on the properties of the protein (Ma et al., 2004; Song et al., 2004; Parker et 
al., 2005; Yuan et al., 2005; Wang et al., 2008b; Wang et al., 2008c).  
N-terminal and PAZ domains as well as MID and PIWI domains constitute a bilobal structure 
(Figure 5b). The PAZ domain was revealed to contain a specific binding pocket that anchors 
the characteristic 2nt 3‟ overhangs produced by RNase III cleavage during siRNA and 
miRNA biogenesis (Lingel et al., 2003; Song et al., 2003; Yan et al., 2003; Lingel et al., 2004; 
Ma et al., 2004). At the opposite end, the phosphorylated 5‟ terminal nucleotide of the small 
RNA is buried in a deep pocket within the MID domain, which also explains the minor 
importance of the 5‟ nucleotide for “seed” formation with the miRNA target. The two lobes 
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form a positively charged tunnel in which miRNA nucleotides 2-6 contact the Ago protein via 
their sugar-phosphate backbone. They fold into a semi-helical conformation that allows for 
hydrogen bonding of their bases with those of the target mRNA. Target binding is 
accompanied by a significant conformational change that moves the lobe containing N-
terminal and PAZ domains away from MID and PIWI domain, thereby reaching a more open 
conformation (Wang et al., 2008b). The PIWI domain, finally, displays an RNase H fold and 
contains the catalytic center that – in the case of Ago2 - cleaves the target mRNA between 
nucleotides 10 and 11 of the guide RNA (Elbashir et al., 2001b; Haley and Zamore, 2004; 
Wang et al., 2008b; Wang et al., 2008c), producing a 5‟ RNA fragment with a 3‟ hydroxyl 
group and a 3‟ fragment with a 5‟ phosphate (Martinez and Tuschl, 2004; Schwarz et al., 
2004).  
 
 
Figure 5: Argonaute protein structure.  
(a) Schematic depiction of the Argonaute domain structure. (b) Crystal structure of Thermus thermophilus Ago in 
complex with a 5‟-phosphorylated 21 nt guide DNA strand (grey backbone) and a 20 nt target RNA (blue). 
Structural rearrangements of the PAZ domain upon target binding are indicated by an arrow (modified from Jinek 
and Doudna, 2009). 
 
The cleavage reaction requires Mg2+ ions and is ATP independent. Within the active center of 
human Ago2, the residues Asp597, Asp669 and His807 have been identified as the catalytic triad 
(Song et al., 2004; Rivas et al., 2005). However, only one out of four human Ago proteins, 
Ago2, exhibits cleavage activity when binding to perfect or nearly perfect complementary 
targets (Liu et al., 2004; Meister et al., 2004). In Ago1 and Ago4, this catalytic inactivity can 
be attributed to a variation of the catalytic DDH triad towards a DDR or GDR motif, 
respectively. Strikingly though, Ago3 is cleavage incompetent despite the presence of the 
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DDH motif (Liu et al., 2004; Meister et al., 2004); while the reason for this behavior has not 
been clarified yet, it suggests that Ago activity might be controlled by posttranslational 
modifications or interaction with additional protein factors. However, as siRNA-induced target 
cleavage is a rather rare event in mammalian somatic cells, Ago cleavage (in)competence 
might simply reflect the major importance of miRNA-mediated repression. 
In Drosophila, Ago1 and Ago2 differ in their preference to bind miRNAs or siRNAs, 
respectively (Forstemann et al., 2007; Tomari et al., 2007). Further, the terminal nucleotides 
of the guide strand play a role in Ago loading (Czech et al., 2009). Similar distinctions have 
also been reported in C. elegans (Steiner et al., 2007; Jannot et al., 2008). In contrast, 
mammalian Ago proteins do not show loading preferences and to a considerable degree 
appear to be functionally redundant (Meister et al., 2004; Yoda et al., 2010). Ago2, however, 
seems to take an exceptional position among members of the Ago subfamily due to its 
cleavage compentence. Effects of Ago2 knock-down on miRNA-mediated repression exceed 
those of depletion of the other Ago proteins (Schmitter et al., 2006). Further, it is essential for 
murine hematopoiesis (O'Carroll et al., 2007), presumably due to its role in Dicer-
independent maturation of mammalian miR-451 (Cheloufi et al., 2010).  
Furthermore, Argonaute function may be regulated by protein modifications. For Piwi 
proteins, dimethylarginine modifications catalyzed by the methyltransferase PRMT5 proved 
to be important for protein stability, localization and function (Kirino et al., 2009; Reuter et al., 
2009; Vagin et al., 2009). Hydroxylation of human Ago2 in Pro700 appears to be of 
importance for protein stability (Qi et al., 2008). Phosphorylation of Ser387, on the other hand, 
seems to be related to P body localization (Zeng et al., 2008). In contrast, phosphorylation of 
Tyr529 in the 5‟ binding pocket of the MID domain can interfere with small RNA binding and 
may play a role in Ago loading (Rudel et al., 2010). 
 
1.2.2.2. Argonaute loading 
During RISC or miRNP formation, Ago proteins are loaded with the small RNA duplex 
intermediate that results from Dicer processing in a concerted process that requires ATP 
(Nykanen et al., 2001; Pham et al., 2004; Yoda et al., 2010). In several organisms, 
Argonaute proteins were recently reported to interact with the heat shock protein HSP90 or a 
chaperone complex involving the heat shock cognate 70 (HSC70) as well as HSP90 during 
this process (Iki et al., 2010; Iwasaki et al., 2010; Johnston et al., 2010; Miyoshi et al., 2010). 
This resulted in a model proposing that binding of the chaperone complex might bring the 
Ago protein into an “open” conformation that allows for loading of a small RNA duplex. Upon 
ATP hydrolysis and subsequent dissociation of the chaperone complex, the miRNA* or 
passenger strand is discarded or cleaved, respectively, rendering the RISC/miRNP complex 
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active. The removal of the miRNA* strand seems to be achieved by a passive, ATP-
independent unwinding process, possibly facilitated by the mismatches within the miR/miR* 
duplex resulting in the degradation of the miRNA* upon its release (Forstemann et al., 2007; 
Kawamata et al., 2009; Yoda et al., 2010). Another theory proposes the involvement of a yet 
unknown RNA helicase in the unwinding process.  
The minimal complex required for RISC cleavage is composed of Ago2 in concert with a 
single-stranded RNA (Rivas et al., 2005). For loading with an RNA duplex, a trimeric RISC 
complex comprising Ago2, Dicer and its dsRBD partner TRBP (or R2D2 in Drosophila) is 
required, constituting a trimeric RISC complex (Gregory et al., 2005; Maniataki and 
Mourelatos, 2005). Still, efficient incorporation and RISC activity presumably involves a 
number of additional proteins. For example, the Drosophila RNA helicase Armitage and its 
human homologue MOV10 were implicated in siRNA function though their specific modes of 
action remain elusive (Tomari et al., 2004a; Meister et al., 2005; Klattenhoff et al., 2007). 
Moreover, the endoribonuclease C3PO enhanced RISC activity in flies by removing siRNA 
passenger strand fragments (Liu et al., 2009). A homologous factor in mammals, however, 
has not yet been described. 
 
1.2.2.3. Argonaute localization to processing bodies 
Cytoplasmic localization studies demonstrated Ago proteins to accumulate in distinct 
cytoplasmic foci called processing bodies (P bodies). These structures seem to be involved 
in storage and degradation of translationally repressed mRNAs (Eulalio et al., 2007a; Parker 
and Sheth, 2007). According to their integral protein component GW182, P bodies are 
sometimes also referred to as GW bodies. GW182 belongs to the TNRC6 (trinucleotide 
repeat containing 6) protein family which comprises three members in the mammalian 
system: TNRC6A (GW182), TNRC6B and TNRC6C. For Ago function in translation inhibition 
and deadenylation, its interaction with the GW182 protein family is crucial (Eulalio et al., 
2009c).  
GW182 possesses several N-terminal glycine-tryptophan (GW) repeats, a ubiquitin-
associated domain (UBA) and a glutamine (Q)-rich domain. These domains are required for 
localization GW182 to P bodies (Behm-Ansmant et al., 2006). Further, GW182 contains a 
Domain of Unknown Function (DUF) and a C-terminal RNA recognition motif (RRM). It binds 
to the Ago PIWI domain via its N-terminal GW repeats and interacts with the poly(A)-binding 
protein (PABP) via its DUF (Figure 6, Till et al., 2007; Eulalio et al., 2009a).  
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Figure 6: Schematic depiction of Ago and GW182.  
Regions relevant for mutual interaction as well as functional regions of GW182 are denoted by arrows. UBA: 
ubiquitin-associated domain, DUF: domain of unknown function, RRM: RNA recognition motif (modified from 
(Fabian et al., 2010). 
 
The repressive function of GW182 is mediated by the C-terminus containing the DUF and an 
RNA recognition motif (RRM) domain that, together with its adjacent regions, acts in protein 
rather than RNA binding (Eulalio et al., 2009b; Fabian et al., 2010). GW182 is the actual 
effector of miRNA-mediated posttranscriptional gene silencing (Behm-Ansmant et al., 2006). 
Ago proteins located on 3‟-UTR miRNA-binding sites act in recruiting GW182 which in turn 
through its interaction with PABP can disrupt translation initiation and/or recruit the 
deadenylase complex. When GW182 is tethered to the 3‟-UTR of an mRNA, repression can 
even take place independently of Ago binding (Baillat and Shiekhattar, 2009; Zipprich et al., 
2009). 
P bodies are highly enriched in translationally repressed mRNAs as well as in proteins 
involved in mRNA deadenylation, decapping and degradation, e.g. the DCP1-DCP2 
complex, the exonuclease Xrn1 and the Lsm protein family (Eulalio et al., 2007a; Parker and 
Sheth, 2007). Ribosomes and the majority of translation initiation factors, however, were not 
found in P bodies. P bodies are highly dynamic structures and can adjust in number and size 
according, for example, to the translational status of the cell or to the stage of the cell cycle 
(Lian et al., 2006; Pauley et al., 2006; Eulalio et al., 2007a; Eulalio et al., 2007b; Parker and 
Sheth, 2007). Still, they are not essential for miRNA-mediated repression itself but rather 
seem to occur as a consequence of this process. Depletion of GW182 or other proteins 
involved in the miRNA pathway disrupts visible P bodies. However, submicroscopic 
complexes of P body components may persist and facilitate miRNA function (Pauley et al., 
2006; Eulalio et al., 2007b). Together with the observation that many P body components are 
also present in the cytosol (Eulalio et al., 2007a), this suggests that miRNA-mediated 
repression starts in the cytosol and repressed mRNAs are subsequently transported to 
P bodies where they may be either stored in a translationally blocked state or be subjected to 
degradation. However, translation repression and P body localization is not an irreversible 
process, as repressed mRNAs may be released from P bodies upon cellular signals and 
resume translation (Bhattacharyya et al., 2006a). 
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1.3. THE RNA BINDING PROTEIN RBM4 
The RNA binding protein RBM4 - in Drosophila and mice termed LARK - is an evolutionarily 
highly conserved protein. In humans, two highly related copies of RBM4, RBM4a and 
RBM4b, are present on chromosome 11q13.2; however, only RBM4a has been investigated 
to date and will subsequently be referred to as RBM4 in this work. The human RBM4 protein 
is about 40 kDa in size and carries two N-terminal RNA recognition motifs (RRMs) and a 
CCHC-type zinc finger domain (Figure 7). The C-terminal part of the protein contains three 
alanine-rich stretches and has been shown to be involved in protein-protein interaction as 
well as correct nuclear localization (Lai et al., 2003; Markus and Morris, 2006). 
 
 
Figure 7: Schematic depiction of the RBM4 protein. 
RRM1 and -2: RNA recognition motifs (taken from Markus and Morris, 2009). 
 
LARK was first identified in a genetic screen for mutations that perturb the circadian 
regulation of Drosophila adult eclosion (Newby and Jackson, 1993). It is an essential factor in 
Drosophila embryogenesis and both maternal and zygotic LARK expression are required for 
normal development (Newby and Jackson, 1993, 1996; McNeil et al., 1999). LARK 
abundance oscillates in a circadian manner in flies as well as in the mammalian system and 
protein levels of murine LARK (mLARK) where shown to be related to the length of circadian 
periods in cycling cells (McNeil et al., 1998; Kojima et al., 2007). mLARK further was 
demonstrated to bind to the 3‟-UTR of the Period1 (Per1) mRNA and to regulate its 
expression. Per1 is an essential factor for maintenance of circadian rhythms, itself 
possessing a rhythmic transcription coupled to delayed protein expression. This 
posttranscriptional regulation strengthens the functional relevance of mLARK in the circadian 
system. Another function of Drosophila LARK was described by Sofola and colleagues 
(Sofola et al., 2008). LARK was shown to bind and stabilize dFMR and to collectively 
regulate eye development and circadian behavior in adult flies.  
Human RBM4 has been described as a ubiquitously expressed nucleocytoplasmic shuttling 
protein with a predominantly nuclear localization to speckles and regulatory functions in pre-
mRNA splicing and 5‟ splice site and exon selection (Lai et al., 2003; Kar et al., 2006). 
Exemplary, RBM4 was presented to activate the selection of skeletal muscle-specific exons 
in the α-tropomyosin pre-mRNA by antagonizing the splicing regulator PTB (pyrimidine tract 
binding protein) through binding to intronic pyrimidine-rich elements (Lin and Tarn, 2005). In 
alternative splicing, RBM4 function was further demonstrated to be affected by a specific 
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isoform of Wilms tumor protein 1 (WT1), an RNA-binding post-transcriptional regulator that 
interacts with splicing components (Markus et al., 2006). This points towards a more complex 
interplay of RNA processing factors in the modulation of alternative splicing. 
 
 
Figure 8: Known cellular functions of RBM4.  
RBM4 is a nucleocytoplasmic shuttling protein with nuclear concentration in speckles and nucleoli. Its functions 
range from splicing regulation to cytoplasmic translation control, suppressing cap-dependent translation and, 
upon cellular stress, activating IRES-dependent translation (modified from Markus and Morris, 2009). 
 
Apart from interfering with splicing of pre-mRNAs, RBM4 has also been implied in 
translational control. As mentioned before, RBM4 regulates expression of murine Per1 in a 
Cap/poly(A)-dependent manner (Kojima et al., 2007). The aforementioned interaction of 
Drosophila LARK with dFMR (Sofola et al., 2008), an established translational regulator, may 
also imply a participation of RBM4 in translational control. Further, phosphorylated RBM4 
was shown to translocate to the cytoplasm and cytoplasmic stress granules and to inhibit 
translation of cap-dependent mRNAs under cellular stress conditions, while concomitantly 
facilitating IRES-mediated translation (Lin et al., 2007). Activation of internal ribosome entry 
sites (IRES) is presumably mediated by stabilizing eIF4A-containing initiation complexes.  
RBM4 therefore exhibits a complex functional pattern within numerous cellular processes 
(Figure 8). 
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1.4. AIM OF THE THESIS 
In recent years, small inhibitory RNAs have emerged as key players in a large number of 
cellular events including transcriptional and post-transcriptional regulation. Argonaute 
proteins act as binding partners of small RNAs and their significance as effectors of small 
RNA-mediated silencing is undisputed. However, to allow for the large variety of observed 
small RNA functions, effector complexes are bound to include various additional factors that 
allow for specific regulation of individual events.  
Therefore, the aim of this work was to characterize Ago1- and Ago2-containing protein 
complexes by investigating their sedimentation behavior in sucrose gradients, their mRNA- 
as well as miRNA content and their catalytic activities. Further, Ago-associated proteins were 
to be identified in a comprehensive approach to acquire an overview on the protein network 
involved in small RNA function. The thereby established protein interactions were to be 
verified by various experimental approaches. Finally, this work attempted to demonstrate the 
functional relevance of Ago-interacting proteins in miRNA-mediated regulation of target 
mRNAs. 
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2. RESULTS 
2.1. ANALYSIS OF ARGONAUTE CONTAINING mRNA-PROTEIN COMPLEXES 
2.1.1. Human Ago1 and Ago2 form distinct protein complexes 
Previously, it has been demonstrated that mammalian Ago proteins and miRNAs sediment 
with polyribosomes (Kim et al., 2004; Nelson et al., 2004; Maroney et al., 2006; Nottrott et al., 
2006). In other studies, however, the majority of Ago proteins and miRNAs migrate together 
with untranslated ribonucleoproteins (mRNPs; Kim et al., 2004; Nelson et al., 2004). For a 
detailed characterization of Ago protein complexes, Ago sedimentation in polyribosome 
fractionations was revisited (Figure 9A). Extracts from human embryonic kidney (HEK) 293 
cells were separated on a sucrose gradient ranging from 0.5 M to 1.5 M sucrose. Fractions 
were analyzed by western blotting against the ribosomal protein S6 (rpS6) to identify 
ribosome-containing fractions. RpS6 was detected in fractions 10-12, representing ribosomal 
subunits as well as monosomes, and in fractions 14-27, indicating polyribosomes. Probing 
with antibodies against Ago1 showed that human Ago1 predominantly migrated in fractions 
with low sucrose density corresponding to mRNPs and to some extent also with monosomes. 
Only a small portion of Ago1 was found in higher molecular weight fractions also containing 
polyribosomes (fractions 14-27). 
For a closer analysis of Ago-containing mRNPs, lysis buffer as well as gradient conditions 
were modified to allow for further separation of the mRNP pool (Figure 9B). Due to the 
presence of EDTA in the buffer, polyribosomes were not preserved in these experiments. 
HEK 293 lysate was loaded onto a 15-55 % sucrose gradient and fractionated by 
centrifugation for 18 h. To roughly estimate the size range of Ago protein complexes, marker 
proteins of known size were separated by gradient centrifugation under the same conditions 
and visualized by coomassie staining. Western blotting using α-Ago1 and α-Ago2 antibodies 
showed that both Ago1 and Ago2 sedimented in three distinct complexes which are 
furthermore referred to as Ago complexes I-III. A large portion of Ago1 or Ago2 was found in 
complex I, which has a molecular mass of about 250-350 kDa (lanes 2-7). Complex II 
constitutes a second prominent peak, which sediments similarly to a 19 S particle and is 
about 600-700 kDa in size (lanes 10-13). Complex III peaks in fractions 15 and 16 indicative 
of a molecular mass of more than 900 kDa or 25-30 S (lanes 15-16).  
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Figure 9: Association of human Ago1 and Ago2 with distinct protein complexes 
(A) Individual fractions of polyribosome gradients were analyzed by western blotting against endogenous Ago1 
(upper panel) and rpS6 (lower panel). (B) Lysates from wild-type HEK 293 cells were separated by sucrose 
density centrifugation under conditions that allow for separation of mRNPs. Endogenous Ago1 and Ago2 were 
analyzed using specific antibodies. 
 
The migration of Ago proteins with mRNPs in polyribosome gradients implied that Ago 
complexes I-III contain mRNAs and form mRNPs. To assay this, HEK 293 cell lysates were 
subjected to RNase A treatment prior to separation by gradient centrifugation. Ago1 
complexes II and III were clearly visible in untreated lysates (Figure 10, upper panel), but not 
in RNase-treated extracts (lower panel), indicating that complexes II and III indeed constitute 
RNA-containing protein complexes. 
 
 
Figure 10: RNase sensitivity of Ago complexes II and III 
Lysates from wild-type HEK 293 cells were separated by sucrose gradient centrifugation as in (9B) and analyzed 
for endogenous Ago1. Lysates shown in the lower panel were treated with 100 μg/ml RNase A prior to 
centrifugation. 
 
For further evaluation of the aforementioned experiments, it was necessary to use tagged 
Ago proteins. Therefore, HEK 293 cells were transiently transfected with 
FLAG/haemagglutinin (HA)-tagged Ago1 through -4 and lysates were subjected to gradient 
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centrifugation as before. Subsequent western blotting against the HA-tag produced a distinct 
complex pattern similar to that of endogenous Ago1 and -2 (Figure 11). Individual gradient 
fractions were subjected to western blotting using antibodies against the HA-tag. All four 
FLAG/HA-tagged Ago proteins yielded three complexes in lanes 3-8 (complex I), lanes 11-13 
(complex II) and lanes 15-17 (complex III), indicating that the tagged proteins associated with 
native protein complexes and were suitable for further analysis. 
 
 
Figure 11: Protein distribution of FLAG/HA-Ago1-4 on sucrose gradients 
Lysates from HEK 293 cells transiently transfected with FLAG/HA-Ago1-4 were separated by sucrose gradient 
centrifugation as in (9B). The presence of FLAG/HA-Ago1-4 was analyzed by western blotting using α-HA 
antibodies. 
 
As a control, HEK 293 cells were transfected with FLAG/HA-tagged green fluorescent protein 
(GFP). Separation of FLAG/HA-GFP lysates yielded strong signals in the low density 
fractions, whereas no protein was shifted to the higher fractions corresponding to 
complexes II and III.  
In summary, endogenous as well as ectopically expressed Ago1 through -4 could be 
separated into three distinct complexes by gradient centrifugation. The smallest complex, 
complex I, appeared to be resistant to RNase treatment while complexes II and III were 
dependent on RNA. 
 
2.1.2. Ago distribution in nuclear and cytoplasmic extracts 
It has been shown that Ago proteins can be found in the nucleus as well as the cytoplasm of 
human cells (Meister et al., 2004; Robb et al., 2005; Janowski et al., 2006; Rudel et al., 
2008). To further characterize the observed Ago protein complexes, nuclear and cytoplasmic 
extracts were prepared from HEK 293 cells.  
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Figure 12: Distribution of endogenous Ago1 and -2 in nuclear and cytoplasmic fractions 
(A) Nuclear and cytoplasmic extracts from HEK 293 cells were subjected to gradient centrifugation as described 
in (9B). Fractions were analyzed by western blotting for endogenous Ago1 (upper panels) and Ago2 (lower 
panels). (B) Nuclear and cytoplasmic gradients from HEK 293 lysates containing FLAG/HA-Ago2 were analyzed 
by western blotting using α-HA antibodies. (C) Nuclear (NE) and cytoplasmic (CE) extracts from (A) before 
gradient centrifugation were analyzed for alpha-tubulin (upper panel), RCC1 (middle panel) and SMNRP (lower 
panel) by western blotting. 
 
Gradient centrifugation and subsequent western blotting showed that endogenous Ago1 and 
Ago2 from nuclear extracts is restricted to low density fractions (Figure 12A, lanes 2-5). 
Cytoplasmic extracts also show signals in higher fractions corresponding to complexes II 
and III. Notably, in the cytoplasmic complex I, Ago1 and Ago2 signals were shifted slightly 
towards higher fractions so that nuclear and cytoplasmic signals (lanes 2-5 and lanes 5-9, 
respectively) only partially overlapped. 
Transient overexpression of FLAG/HA-Ago2 yielded similar results: FLAG/HA-Ago2 was 
present only in the nuclear fractions corresponding to complex I, while it was detectable in all 
three complexes in cytoplasmic extracts (Figure 12B). A clear shift of the nuclear signals to 
lower molecular weight was not detectable with these samples; however, this could be due to 
FLAG/HA-Ago2 overexpression. 
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As a control for successful extract preparation, nuclear (NE) and cytoplasmic (CE) extracts 
were subjected to western blotting using antibodies against alpha-tubulin, RCC1, and 
SMNRP (Figure 12C). As expected, alpha-tubulin could be detected in cytoplasmic, but not 
in nuclear extracts. RCC1, a chromatin-bound nuclear protein, was restricted to nuclear 
extracts. The nucleoplasmic protein SMNRP, which is not tightly associated with nuclear 
structures, could be detected in both nuclear and cytoplasmic extracts. Therefore, even 
though the separation of nuclear and cytoplasmic extracts was not complete, nuclear 
extracts are not contaminated by cytoplasmic proteins and the results concerning nuclear 
Ago gradient migration can be regarded as reliable.  
 
2.1.3. Ago complexes I-III associate with miRNAs 
As Ago proteins are the binding partners of mature miRNAs, Ago complexes were also 
analyzed for their miRNA content. HEK 293 lysates containing FLAG/HA-Ago1 or FLAG/HA-
Ago2 were separated by gradient centrifugation. Proteins were immunoprecipitated from 
individual fractions using FLAG-antibodies and associated RNA was extracted, reverse 
transcribed and analyzed by semi-quantitative PCR for miR-16 or let-7a, respectively. Both 
miR-16 and let-7a were found in all Ago-containing fractions, whereas only weak signals 
were found in other fractions (Figure 13A). 
MiRNA distribution was also analyzed by northern blotting. HEK 293 cells were transiently 
transfected with FLAG/HA-Ago1, -Ago2 or -GFP. Lysates were subjected to gradient 
centrifugation and complex fractions were pooled. FLAG/HA-tagged proteins were 
immunoprecipitated from the pooled fractions, RNA was extracted and northern blotting for 
miR-19b, a miRNA abundant in HEK 293 cells, was performed. MiRNA-19b signals could be 
detected in all three complexes of FLAG/HA-Ago1 and -Ago2 in amounts that roughly 
corresponded to the protein abundance in the respective complexes visualized by western 
blotting against the HA-tag (Figure 13B). As expected, co-immunoprecipitation of miR-19b 
with FLAG/HA-GFP could not be detected despite the high protein expression level. 
Taken together, miRNAs could be shown to specifically associate with all three Ago 
complexes. MiRNA levels visualized by northern blotting correlated with Ago protein levels. 
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Figure 13: Distribution of miRNAs on FLAG/HA-Ago1 and -2 gradients 
(A) Lysates from HEK 293 cells expressing FLAG/HA-Ago1 or -Ago2 were separated as in (9B). Individual 
fractions were subjected to immunoprecipitation using α-FLAG antibodies. RNA was extracted and the presence 
of endogenous let-7a (upper panel, FLAG/HA-Ago1-IP) and miR-16 (lower panel, FLAG/HA-Ago2-IP) was 
determined using semi-quantitative RT-PCR. (B) Sucrose gradient centrifugation was performed as described in 
(9B) using lysates from HEK 293 cells containing FLAG/HA-Ago1, -2 and -GFP. Fractions corresponding to 
complexes I to III were pooled individually and immunoprecipitation was performed using FLAG agarose. Co-
precipitated miR-19b was analyzed by northern blotting (lowest panel). 20 % of the beads were used for western 
blotting against the HA-tag (upper and middle panel). 
 
 
2.1.4. Ago complex III co-sediments with the KRAS mRNA 
Small RNA effector complexes exert their regulatory functions by binding to target mRNAs. 
As RNase treatment of cell lysates prior to gradient centrifugation had eliminated 
complexes II and III, it was tempting to speculate that these complexes contain translationally 
repressed mRNAs. To address this, gradient samples were analyzed for their association 
with a known miRNA target mRNA. HeLa cells were transiently transfected with a luciferase 
reporter construct carrying the 3‟-untranslated region (3‟-UTR) of the Kirsten rat sarcoma 
viral oncogene homologue (KRAS). KRAS has been shown to be translationally regulated by 
let-7a in human cells (Johnson et al., 2005). Cell lysates were separated on a 15-55 % 
sucrose gradient, RNA was extracted from individual fractions, reverse transcribed and 
analyzed by quantitative PCR (qPCR). While KRAS mRNA was absent from the fractions 
corresponding to Ago complex I, fractions 10-13 (complex II) contained small amounts of the 
target mRNA (Figure 14). Strikingly, high amounts of KRAS mRNA co-sedimented with Ago 
complex III, suggesting that this complex forms large mRNPs with miRNA target mRNAs. 
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Figure 14: KRAS 3’-UTR distribution in HEK 293 gradients 
A reporter construct containing the KRAS 3‟-UTR was transfected into HEK 293 cells and lysates were separated 
as in (9B). Total RNA was extracted from the individual fractions and analyzed by qPCR. The distribution of the 
KRAS 3‟-UTR is shown as a percentage of the total amount of the KRAS reporter construct. 
 
 
2.1.5. Analysis of Ago-associated RISC and Dicer activity 
Ago2 has been shown to be the endonucleolytic component of the human RNA induced 
silencing complex (RISC; Liu et al., 2004; Meister et al., 2004). Therefore, the observed 
Ago2 complexes were tested for association with RISC activity. 
 
 
Figure 15: RISC assay analysis of FLAG/HA-Ago2 gradient fractions 
Lysates from FLAG/HA-Ago2 transfected HEK 293 cells were separated as in (9B) and subjected to 
immunoprecipitation using FLAG agarose. Immunoprecipitates were incubated with a 
32
P-cap-labeled RNA, which 
contained a perfect complementary sequence to the endogenous miR-19b. Lanes indicated with T1 show 
RNase T1 digestions of the RNA substrate. The RNA sequence complementary to miR-19b is indicated by a 
black bar to the right. 
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Lysate from HEK 293 cells transfected with FLAG/HA-Ago2 was fractionated by gradient 
centrifugation and FLAG/HA-Ago2 complexes were immunoprecipitated from individual 
fractions using FLAG antibodies. Immunoprecipitates were incubated with a 32P-cap labeled 
RNA complementary to miR-19b (Figure 15). Fractions 3-6, as well as the total lysate prior to 
gradient centrifugation (load), showed strong cleavage activity, whereas no cleavage was 
observed in higher molecular weight fractions, indicating that Ago2 complex I represents 
active human RISC. 
 
It has been demonstrated that human Ago proteins stably associate with Dicer and that this 
complex is able to generate small RNAs from double-stranded RNA (dsRNA) precursors 
(Gregory et al., 2005; Meister et al., 2005). Hence, individual Ago complexes were also 
tested for Dicer activity. HEK 293 lysates containing FLAG/HA-Ago1 were fractionated and 
immunoprecipitated as described above. Immunoprecipitates were incubated with an 
internally 32P-labeled primary miR-27a precursor and accumulation of mature miR-27a was 
analyzed by denaturing RNA polyacrylamide gel electrophoresis (RNA-PAGE; Figure 16A). 
Ago1 complex I (fractions 3-7) as well as Ago1 complex III (fractions 15-17) was associated 
with Dicer activity, whereas only very weak Dicer activity was observed in Ago1 complex II 
(fractions 10-13). Similar results were obtained when using FLAG/HA-Ago2 lysates (data not 
shown). 
 
 
Figure 16: Analysis of Dicer activity and distribution on sucrose gradients 
(A) FLAG/HA-Ago1 containing HEK 293 lysate was separated and immunoprecipitated as in (15). The 
immunoprecipitates or recombinant Dicer were incubated with an internally 
32
P-labeled pri-miR-27a substrate. A 
21-nucleotide marker is shown to the left. (B) Lysates from HEK 293 cells expressing FLAG/HA-Dicer were 
separated as in (9B). Fractions were analyzed for FLAG/HA-Dicer by western blotting using α-HA antibodies. 
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This was also consistent with results from a gradient fractionation of HEK 293 lysate 
containing FLAG/HA-Dicer (Figure 16B). Western blot analysis using antibodies against the 
HA-tag showed a strong Dicer signal in complex I as well as a weaker signal in complex III. 
In complex II, however, Dicer could not be detected. 
To exclude that the observed pattern of RISC and Dicer activity was mainly due to the Ago 
protein abundance in the respective complexes, both experiments were repeated with 
adjusted Ago protein levels (Figure 17). Lysate from FLAG/HA-Ago2 containing HEK 293 
cells was separated by gradient centrifugation, the fractions of each complex were pooled 
and Ago2 levels in the pooled fractions were estimated by western blotting. The volumes of 
the pooled complexes used for immunoprecipitation were adjusted to give approximately 
equal Ago2 levels in all three samples. As a control, fractions 20-23 were pooled and a 
volume equal to that of complex III was used. RISC and Dicer assays were performed as 
described above.  
 
 
Figure 17: RISC and Dicer assays with adjusted Ago2 levels in pooled complex fractions 
FLAG/HA-Ago2 containing HEK 293 lysates were separated as in (9B). Fractions corresponding to complex I 
(fractions 3-6), complex II (fractions 11-13), complex III (fractions 15-17) and fractions 20-23 (as a control) were 
pooled. To adjust for equal Ago2 amounts, different volumes from pooled complex fractions were subjected to 
immunoprecipitation using α-FLAG antibodies. The volume of the control fraction equaled the pooled complex III 
sample volume. Subsequently, RISC (left panel) and Dicer (upper right panel) assays were performed as 
described in (15) and (16A). FLAG/HA-Ago2 levels were checked by western blotting using α-HA antibodies 
(lower right panel). The RNA sequence complementary to miR-19b is indicated by a black bar to the right (left 
panel). 
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Though FLAG/HA-Ago2 levels in the adjusted samples proved not to be as equal as 
intended (Figure 17, lower right panel), Ago2 levels in complexes II and III were considerably 
higher than in complex I and therefore, samples should be suitable for the indented 
experiment. Indeed, RISC activity could only be detected in complex I while higher molecular 
weight complexes were not cleavage competent (left panel). Also, even with high FLAG/HA-
Ago2 levels in the complex II sample, Dicer activity could not be detected (upper right panel). 
Therefore, the RISC and Dicer activity pattern observed in Figure 15 and Figure 16 cannot 
simply be attributed to Ago protein abundance in the samples, but is specific to the distinct 
Ago complexes. 
Taken together, these experiments demonstrate that the identified Ago complexes I-III 
contain distinct enzymatic activities. Ago2 complex I contains a low molecular weight RISC 
whereas Ago complexes I and III are associated with Dicer. Interestingly, Ago complex II 
does not contain RISC and shows only little detectable Dicer activity. 
 
 
2.2. ARGONAUTE PROTEINS AND THEIR INTERACTION PARTNERS 
2.2.1. Proteomic analysis of Ago complexes I-III 
In order to identify co-factors that function together with Ago1 and Ago2, the protein 
composition of Ago complexes I-III was analyzed using a proteomic approach. FLAG/HA-
Ago1 or FLAG/HA-Ago2 was transiently expressed in HEK 293 cells, and the lysates were 
separated by sucrose gradient centrifugation. Fractions 3-8, 10-13 and 15-18, representing 
Ago complexes I, II and III, respectively, were combined and Ago complexes were 
immunoprecipitated using FLAG antibodies.  
While in a previous study the investigation of Ago-associated proteins had been restricted to 
only a few visible gel bands (Meister et al., 2005), the aim was now to analyze all proteins 
that were present in the Ago immunoprecipitates. Therefore, co-immunoprecipitated proteins 
were separated by SDS-PAGE and analyzed by mass spectrometry (Figure 18A). Antibodies 
not specific for the FLAG-tag were used for control purifications (Figure 18B).  
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Figure 18: Proteomic analysis of Ago complexes I, II and III. 
(A) Lysates from HEK 293 cells containing FLAG/HA-Ago1 or -Ago2 were separated on 15-55 % sucrose 
gradients. Fractions 3-8 (complex I), 11-13 (complex II) and 15-17 (complex III) were pooled and subjected to 
immunoprecipitation using α-FLAG antibodies. Immunoprecipitated FLAG/HA-Ago1 complexes (lanes 2, 4 and 6) 
or FLAG/HA-Ago2 complexes (lanes 7, 9 and 11) were separated by SDS-PAGE and proteins were analyzed by 
ESI TOF mass spectrometry. Lanes 1, 3, 5, 8, 10 and 12 show molecular weight markers (M). IgG as well as 
FLAG/HA-Ago1 and -Ago2 bands are indicated. (B) FLAG/HA-Ago2 gradient fractions were pooled as in (A) and 
immunoprecipitated using agarose coupled mouse IgG as control antibody. Proteomic analysis was performed as 
in (A). Lanes 2, 4 and 6 show immunoprecipitates from Ago complexes I, II and III, respectively. IgG bands are 
denoted to the right. Lanes 1, 3, 5 and 7 show molecular weight markers. 
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Table 1 shows a list of proteins that were specifically found in Ago samples, but not in control 
purifications (see also the supplementary tables in the appendix for a more detailed listing). 
 
Table 1: Proteins associated with human Ago1 and Ago2 
Name Domains/motif 
Ago1 
complex 
Ago2 
complex 
Accession No. 
Proteins involved in gene silencing 
Dicer 
DEAD box, RNase III, PAZ, dsRBD, 
DUF 
I, III I, III* gi|21665773/gi|5019620 
TNRC6B RRM - I gi|14133235 
MOV10 DExH box III III gi|14424568 
TRBP dsRBD I* I* gi|107904 
Gemin3 DEAD box - II* gi|14209614 
Gemin4 Leucin Zipper II*, III II, III gi|7657122 
DEAD/DEAH box containing proteins 
RNA helicase A 
(RHA)/DHX9 
DEAH box, helicase domain, 
dsRBD, DUF1605 
II, III II, III gi|1806048/gi|1082769 
DDX30 
DEAH box, helicase domain, 
dsRBD, DUF1605 
II, III II, III gi|20336294 
RENT1/Upf1 DEAD box, exoV III - gi|1575536 
DHX36 
DEAH box, helicase domain, 
DUF1605 
II*, III* II* gi|7959237/gi|23243423 
DDX21/ 
RNA helicase GuA 
DEAD box, helicase domain, GUCT II, III II gi|2135315 
DDX50/ 
RNA helicase GuB 
DEAD box, helicase domain, GUCT, 
RESIII 
III - gi|55664207 
DDX46 
DEAH box, helicase domain, 
DUF1605  
II* II* gi|2696613 
DDX48 DEAD box, helicase domain II*, III - gi|496902 
DDX18 DEAD box, helicase domain III - gi|1498229 
DDX5/p68 DEAD box, helicase domain - II* gi|57165052 
DDX39/BAT1 DEAD box, helicase domain III* II* gi|1905998 
DDX47 
DEAD box, helicase domain, 
Apolipoprotein L  
III - gi|20149629 
hnRNPs 
hnRNP-U SAP, SPRY, SCOP II, III II, III gi|32358 
hnRNP-U-like SAP, SPRY, SCOP I* - gi|3319956 
hnRNP-H2/H‟ RRM, RNPHF zinc finger II* - gi|6065880 
hnRNP-F RRM, RNPHF zinc finger II* I* gi|16876910 
hnRNP-C RRM II, III II, III gi|13937888/gi|14250048 
hnRNP-E2 KH1, KH2 III* - gi|460773 
NSAP1/SYNCRIP 
Phox-like, PX-associated motif, 
RRM 
II, III - gi|5031512 
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Name Domains/motif 
Ago1 
complex 
Ago2 
complex 
Accession No. 
hnRNP-L 
Enoyl-CoA hydratase/isomerase, 
RRM 
III* - gi|11527777 
mRNA binding proteins 
Poly(A)-binding 
proteins 
RRM II, III II, III gi|46367787/gi|693937 
Nuclear cap binding 
protein 80kDa 
MIF4G III - gi|3153873 
YB-1 Cold shock domain II II, III gi|181486/gi|55451 
FMRp Agenet, KH1 III* - gi|182673 
FXR1 Agenet, KH1 - III gi|1730139 
FXR2 Agenet, KH1 III - gi|4758410 
IMP1 RRM, KH1  II, III III gi|7141072/gi|56237027 
IMP3 RRM, KH1 III - gi|30795212 
HuR RRM III* - gi|1022961 
RBM4 RRM, Zn-finger - III* gi|4506445 
Proteins involved in RNA metabolism 
NF-90/ILF3/NFAR-1 dsRBD, DZF II, III II gi|1082856/gi|5006602 
NF-45/ILF2 DZF II, III II, III gi|532313 
SART3 Lsm interaction motif, RRM I, II, III - gi|7661952 
RBM10 
D111/G-patch, RRM, Zn finger, Ran 
binding 
- I*, II* gi|12644371 
Fibrillarin Fibrillarin motif - II*, III* gi|182592 
NOP56 
Pre-mRNA processing RNP, 
NOP5NT, NOSIC 
III - gi|2230878 
Nucleolin RRM III - gi|128841 
eIF2b Initiation factor 2B I* - gi|6563202 
eIF4b RRM - I* gi|288100 
PTCD3/FLJ20758 Pentatricopeptide repeat II II gi|38683855 
Other proteins 
Myb binding protein 1a DNA polymerase V III III* gi|7657351 
Matrin 3 RRM, Zn finger III* III* gi|6563246 
Motor protein - II, III - gi|516764 
ZNF326 AKAP95 II, III - gi|31807861/gi|47125447 
Ku70 Ku70/80 motif, DNA-binding SAP - II* gi|57165052 
DDB1 CPSF A subunit I I* gi|418316 
RuvB-like II AAA ATPase, Tip49b I I, II gi|5730023/gi|12653319 
Coatomer protein WD-40, COPB2 III II gi|1002369 
*identified by a single peptide 
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As expected from the Dicer activity assay as well as the western blotting results in Figure 16, 
Dicer was found only in Ago1/2 complexes I and III. TRBP, a protein that has been shown to 
be part of a minimal RISC complex (Gregory et al., 2005), was identified only in complex I of 
both Ago1 and Ago2. Moreover, with TNRC6B, MOV10, RNA helicase A (RHA), Gemin3 and 
Gemin4, a number of additional proteins that had been found in Ago complexes previously 
(Mourelatos et al., 2002; Meister et al., 2005; Robb and Rana, 2007) were among the 
identified proteins. Proteins that have not yet been implicated in RNA silencing in mammals 
were grouped according to their domains and function (Table 1). A prominent group among 
the identified proteins was constituted by the DEAD/DEAH box helicases. DDX5, an 
orthologue of Drosophila p68, which has been shown to associate with Drosophila Ago2 
(Meister and Tuschl, 2004), was found as well as DDX18, a putative helicase that has been 
implicated in Drosha function (Gregory et al., 2004) and DHX36 (RHAU), a protein involved 
in mRNA degradation (Tran et al., 2004). Another prominent protein group was formed by the 
heterologous nuclear ribonucleoprotein (hnRNP) family, which is known to associate with 
mRNAs and to have specific functions in the regulation of gene expression (Han et al., 
2010). Consistent with the hypothesis that Ago complexes II and III are mRNPs, various 
isoforms of poly(A)-binding proteins were identified, indicating that mRNAs were present in 
the purifications. Strikingly, many mRNA-binding proteins that are involved in translational 
regulation were identified, including FMRp and its homologues FXR1 and FXR2. It was 
reported previously that FMRp associates with Ago proteins as well as miRNAs in both 
human and Drosophila cells (Meister and Tuschl, 2004). Further identified proteins with 
regulatory functions in translation were NSAP1/SYNCRIP, YB-1, HuR, RBM4, IMP1 and 
IMP3. Furthermore, various ribosomal proteins were found in the Ago complexes (see 
supplementary tables), suggesting that ribosomal proteins might have other functions as 
components of mRNPs. 
Besides the known Ago interactors Dicer, TNRC6B and TRBP, a number of proteins were 
identified in Ago1/2 complex I. For example, hnRNP U-like, a protein that had been found in 
Drosha complexes in the nucleus (Gregory et al., 2004) was restricted to Ago1 complex I, 
consistent with the migration of nuclear Ago in complex I (Figure 12). DDB1, HSP70, HSP90 
and members of the solute carrier family were found in both Ago1 and Ago2 complex I. 
SART3, an RNA binding protein implicated in pre-mRNA splicing and transcription (Bell et 
al., 2002) as well as the eukaryotic initiation factor eIF2bδ was specific to Ago1 complex I. 
The RNA binding protein RBM10, however, was found in Ago2 complex I only. Complete lists 
of all identified proteins of Ago1 and Ago2 complex I are presented in Supplementary Table 1 
and Supplementary Table 4, respectively. 
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2.2.2. Ago complex I distribution into distinct subcomplexes 
The observation that the number of proteins identified would form a much larger complex 
than Ago complex I led to the question whether Ago complex I is formed from different 
subcomplexes. To investigate Ago complex I in more detail, FLAG/HA-Ago1 or -Ago2 were 
transfected into HEK 293 cells. Lysates were loaded onto a sucrose gradient ranging from 
5-25 % allowing for a better separation of smaller protein complexes. The individual fractions 
were first analyzed by western blotting using antibodies against the HA-tag (Figure 19A).  
 
 
Figure 19: Further division of Ago complex I into subcomplexes 
(A) HEK 293 cell lysates containing FLAG/HA-Ago1 (upper panel) or FLAG/HA-Ago2 (lower panel) were 
separated by sucrose gradient centrifugation ranging from 5 -25 %. Individual fractions were analyzed by western 
blotting using α-HA antibodies. (B) Wild-type HEK 293 lysate was separated as in (A) and analyzed by western 
blotting using specific antibodies against DDB1. 
 
As expected, Ago complexes II and III migrated into the highest fractions (lanes 21-23). Ago 
complex I was found in fractions 5 to 17. Interestingly, when HEK 293 lysate was separated 
on a 5-25 % sucrose gradient, western blotting of individual fractions using antibodies 
against the complex I component DDB1 yielded two signal peaks in fractions 5-7 and 
fractions 11-13 (Figure 19B), indicating that Ago complex I could further be divided into 
several subcomplexes. 
Next, endonucleolytic activity of Ago2 as well as Dicer activity in a 5-25 % sucrose gradient 
was analyzed. Again, FLAG/HA-Ago2 was immunoprecipitated from individual fractions of 
the gradient using α-FLAG antibodies. Immunoprecipitates were incubated with a 32P-cap 
labeled miR-19b substrate RNA. RISC activity was observed in fractions 4-14 with varying 
signal intensities (Figure 20A). Again, no cleavage signal was detected in the higher 
molecular fractions corresponding to complex II and III. 
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Figure 20: Analysis of Ago complex I subcomplexes for RISC and Dicer activities 
(A) FLAG/HA-Ago2 was immunoprecipitated from gradient fractions from (19A) using α-FLAG antibodies and 
incubated with a 
32
P-cap-labeled target RNA complementary to miR-19b. Cleavage products were analyzed by 
denaturing RNA-PAGE. T1 indicates RNase T1 digestion of the RNA substrate. The RNA sequence 
complementary to miR-19b is indicated by a black bar to the right. (B) FLAG/HA-Ago2 was immunoprecipitated 
from HEK 293 cells as in (A) and incubated with a 
32
P-labeled pri-miR-27a substrate. Dicer products were 
analyzed by 15 % denaturing RNA-PAGE. A 21-nucleotide marker is shown to the left. 
 
The analysis of Dicer activity resulted in a different picture. Dicer activity peaks in fractions 9-
11, with weaker activity also detectable in fractions 12-14 (Figure 20B). In fractions 5-8, 
which produce the strongest RISC signals, Dicer activity was hardly detectable. 
Taken together, these results indicate that Ago complex I indeed can be further divided into 
subcomplexes with different characteristics. Ago complex Ia (lanes 5-8) most likely forms a 
Dicer-free minimal RISC as described by Martinez et al. (Martinez et al., 2002). Ago2 
complex Ib (lanes 9-11) associates with Dicer as well as RISC and is presumably a trimeric 
complex formed by Ago2, Dicer and TRBP (Gregory et al., 2005). Ago2 complex Ic 
(lanes 12-15), which shows only low RISC and Dicer activities, presumably is formed by 
various Ago-protein interactions including the other protein factors identified by mass 
spectrometry analysis. 
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2.2.3. Sedimentation of co-purified proteins with Ago complexes 
In order to validate the mass spectrometry data, several different assays were performed. In 
a first approach, the identified factors were examined for specific co-sedimention with Ago-
containing fractions in sucrose gradients. HEK 293 lysates were subjected to gradient 
centrifugation followed by western blotting analysis using specific antibodies (Figure 21, 
upper panels). For several factors, antibodies were not available; hence FLAG-HA-tagged 
fusion proteins were expressed and analyzed by western blotting against the HA-tag (Figure 
21, lower panels). However, due to the large number of protein interactors, experiments were 
restricted to a selection of the identified factors.  
Consistent with the proteomic data, hnRNP-U, NF-90, IMP1 and IMP3 co-migrated with both 
Ago complexes II and III, whereas TRBP was found in low molecular weight fractions co-
migrating with Ago complex I. However, NF-45 and YB-1, which had been identified in 
complexes II and III by mass spectrometry, were detected in fractions containing Ago 
complex III only.  
 
 
Figure 21: Co-migration of Ago-interacting proteins with Ago complexes 
HEK 293 cell extracts were separated by gradient centrifugation and fractions were analyzed by western blotting 
against the proteins indicated to the left (upper panel). HEK 293 cells were transiently transfected with FLAG/HA-
tagged expression constructs as indicated to the left and analyzed by western blotting using α-HA antibodies 
(lower panel). 
 RESULTS  
43 
 
For further co-sedimentation studies the proteins DDX47, DHX36, DDX30, RHA (DHX9), 
hnRNP C, HuR and SART3 were expressed as FLAG/HA-fusion proteins. All tagged proteins 
migrated in fractions also containing Ago complexes II and III. Notably, while SART3 was the 
only of the mentioned proteins that had been identified in all three Ago complexes I-III, a 
large portion of the tagged proteins migrated at the top of the gradient, presumably owing to 
overexpression. 
Therefore, the migration behavior of the tested proteins largely corresponded with the mass 
spectrometry data. 
 
2.2.4. Verification of Ago-protein-interactions by co-immunoprecipitation 
To validate a specific interaction with Ago complexes, co-immunoprecipitation experiments 
were performed. Samples were further subjected to RNase A treatment to allow for a 
distinction of RNA-dependent and RNA-independent protein interactions. Again, due to the 
large number of identified proteins, co-immunoprecipitation experiments were focused on 
some exemplary proteins. 
FLAG/HA-Ago1 and -Ago2 were immunoprecipitated from transiently transfected HEK 293 
cell lysates using FLAG antibodies (Figure 22A). RNase A-treated and untreated samples 
were analyzed by western blotting for co-purified endogenous interaction partners. As 
negative controls, FLAG/HA-GFP as well as unloaded FLAG beads were used. HnRNP-
C1/C2, IMP1, IMP3 and YB-1 disappeared from the FLAG/HA-Ago1/2 immunoprecipitates 
when RNase A was added, indicating that the tested proteins were not associated with Ago 
proteins through protein-protein interactions, but bound to the same RNAs (Figure 22A, left 
panels). NF-90, SART3, DDX5 and DDB1 immunoprecipitated with both FLAG/HA-Ago1 and 
-Ago2 in the presence of RNase A, thus indicating protein-protein-interactions.  
A western blot using α-HA antibodies is shown in the upper right panel of Figure 22A, 
demonstrating that Ago1- and Ago2 levels in RNase A-treated and untreated samples are 
equivalent. Furthermore, the efficiency of RNase A treatment was examined by northern 
blotting. RNase A-treated and untreated FLAG/HA-Ago2 samples were separated by 
denaturing RNA PAGE and RNA was visualized by UV-illumination (Figure 22C, left panel). 
RNA fragmentation is clearly visible in the RNase-treated sample (lane 2). Also, endogenous 
miR-19b levels were massively decreased upon RNase-treatment, as analyzed by northern 
blotting (Figure 22C, upper right panel), indicative of effective RNA degradation even of Ago-
bound miRNAs. 
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Figure 22: Verification of Ago-protein interaction by co-immunoprecipitation 
(A) HEK 293 cells were transfected as indicated. Ago complexes were immunoprecipitated using α-FLAG 
antibodies and probed using specific antibodies with (+) or without (-) prior RNase A treatment (left panel). The 
asterisk denotes unspecific interactions of the IMP3 antibody. A western blot using α-HA antibodies is shown to 
the right. (B) HEK 293 cells were transfected with FLAG/HA-tagged expression constructs as indicated. 
Immunoprecipitations and RNase treatment were carried out as in (A). Wild-type HEK 293 lysate was used as a 
control. Interactions were analyzed by western blotting against Ago1 (upper panels), Ago2 (middle panels) or HA 
(control; lower panels). (C) Total RNA from HEK 293 cells was incubated with (+) or without (-) RNase A, 
separated by RNA PAGE and visualized by ethidium bromide staining (left panel). FLAG/HA-Ago2 lysates were 
immunoprecipitated using α-FLAG agarose (right panels). Beads were incubated with or without RNase A 
followed by RNA extraction and northern blotting against miR-19b (upper panel). As a loading control, 15 % of the 
beads were used for western blotting against the HA-tag (lower panel). 
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In a reverse co-immunoprecipitation experiment, Ago-interacting factors were expressed as 
FLAG/HA-fusion proteins and co-immunoprecipitated endogenous Ago1 and Ago2 was 
detected by western blotting using specific antibodies (Figure 22B, upper and middle panels). 
Wild-type HEK 293 lysate was used as a negative control and anti-HA western blots were 
performed to check for equal levels of the FLAG/HA-tagged proteins (lower panels). 
Endogenous Ago1 and Ago2 clearly co-precipitated with all FLAG/HA-tagged proteins except 
the FLAG/HA-GFP control (lanes 31-33). The binding of DDX30 (lanes 1-3), HuR 
(lanes 13-15), RBM4 (lanes 16-18), hnRNP F (lanes 25-27), PABP C1 (lane 28-30) and 
Matrin3 (lanes 19-21) to Ago1 and Ago2 was sensitive to RNase A treatment, whereas the 
binding of DDX47 (lanes 4-6), RHA (lanes 10-12) and UPF1/RENT1 (lanes 22-24) was not, 
suggesting protein-protein interactions. Interestingly, the binding behavior of DHX36 
(lanes 7-9) reproducibly differed with Ago1 and Ago2. While Ago1 binding seemed to be 
RNA-dependent, Ago2 binding was not, implying a distinct interaction mode with the different 
Ago proteins. 
In summary, the interaction of Ago1 and Ago2 with all of the tested proteins could be 
confirmed by co-immunoprecipitation. Still, results from RNase treated immunoprecipitates 
suggested that a number of the observed interactions is mediated by RNA rather than direct 
protein-protein interaction. 
 
2.2.5. Analysis of Ago-interactions by in vitro pull-down experiments 
As another approach to validate Ago interactions, in vitro pull-down experiments were 
performed with a small subset of proteins.   
To cross-examine its binding behavior to the Ago proteins, DHX36 was recombinantly 
expressed as a GST-fusion protein. His-tagged Ago1 through -4 as well as the negative 
control His-Sip1 were in vitro translated in presence of 35S-Methionine and subsequently 
incubated with GST-DHX36. In contrast to the co-immunoprecipitation experiments in Figure 
22B, GST-DHX36 did not show distinct binding to Ago2, but displayed binding to all four Ago 
proteins (Figure 23A, lanes 1-4). Control reactions where GST alone was immobilized did not 
yield any signal (lanes 6-9) and Ago input protein levels where equivalent (left panel). 
However, expression levels of GST-DHX36 were quite low and degradation products were 
visible in the coomassie staining, hence it cannot be excluded that the indiscriminate Ago 
binding observed in the in vitro pull-down assay might to some degree be unspecific.  
As mentioned before, TRBP has been demonstrated to form a complex with Ago2 and Dicer 
and to be part of a minimal RISC complex (Gregory et al., 2005). Consistently, in vitro pull-
down experiments showed a strong interaction of GST-TRBP with all four Ago proteins 
(Figure 23B). 
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Figure 23: Verification of Ago-protein interaction by in vitro pull-down experiments 
GST-DHX36 (A), -TRBP (B), -SART3 (C) and -Importin8 (D) fusion proteins (lanes 1-5) or GST alone (lanes 6-10) 
were immobilized on Glutathione sepharose beads and incubated with in vitro transcribed His-Ago1-4 or -Sip1. 
After separation by SDS-PAGE, bound proteins were detected by autoradiography. Coomassie staining of the 
immobilized proteins are shown below the respective panels. Left panels show 5 % (A, C, D) or 10 % (B) of the 
35
S-labeled proteins used in lanes 1-10. 
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While in the mass spectrometry analysis, SART3 could only be detected in Ago1 complexes, 
co-immunoprecipitation experiments also showed a RNA-independent interaction with Ago2. 
This was confirmed by the in vitro binding assay. Moreover, a consistent binding of GST-
SART3 to all four Ago proteins was observed (Figure 23C). 
In vitro interaction studies with Ago1-4 were also performed for Importin 8 (Ipo8), an import 
receptor that had been identified as interaction partner of Ago2, Ago3 and Ago4 by mass 
spectrometry (Supplementary Table 4; Weinmann et al., 2009). All four Ago proteins 
interacted with GST-Ipo8, whereas no signal was observed in control reactions where GST 
alone was supplied as binding partner (Figure 23D). 
 
2.2.6. Characterization of the Ago interaction factor PTCD3 
Mass spectrometry analysis identified the pentatricopeptide repeat domain protein PTCD3 as 
a component of Ago1/2 complex II. While functional details about PTCD3 were missing, its 
characteristic PPR domains have been implicated in RNA binding (Schmitz-Linneweber and 
Small, 2008). Therefore, the presence of PTCD3 in Ago complexes prompted us to 
investigate the possible role of this previously uncharacterized protein in Ago function. 
The PPR (pentatricopeptide repeat)-containing proteins constitute a large family of proteins 
involved in post-transcriptional processes. PPR proteins have been found in large numbers 
in plants and are predicted to be located primarily in organelles (Delannoy et al., 2007). In 
the human system, however, only seven PPR proteins were identified (Holzmann et al., 
2008; Lightowlers and Chrzanowska-Lightowlers, 2008) and PTCD3 was found to associate 
with the small ribosomal subunit of mitochondrial ribosomes in the meantime (Davies et al., 
2009). 
To validate the interaction between Ago1/2 and PTCD3, FLAG/HA-tagged PTCD3 was co-
transfected into HEK 293 cells together with myc-tagged Ago1, -Ago2 or -GFP. 
Immunoprecipitations were performed using anti-myc antibodies and samples were 
incubated in the presence or absence of RNase A as described before (Figure 24A). 
Western blotting for the HA-tag yielded a constant signal in both Ago1- and Ago2 samples, 
indicating a direct protein-protein interaction.  
However, these results could not be confirmed by in vitro pull-down experiments. Though 
recombinant expression of GST-PTCD3 yielded considerable protein amounts, binding to 
35S-labeled Ago1 through -4 could not be detected (Figure 24B). In vitro binding of RBM4 to 
His-Ago2, performed as a positive control, was clearly visible (lane 16, also compare Figure 
32). Failure of GST-PTCD3 to bind Ago proteins might be due to incorrect folding in E. coli. 
However, as both Ago and PTCD3 proteins were overexpressed in the co-
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immunoprecipitation experiment, it cannot be excluded that the observed signals are 
overexpression artefacts. 
 
 
Figure 24: Analysis of Ago interaction with PTCD3 
(A) FLAG/HA-tagged PTCD3 constructs were co-transfected into HEK 293 cells together with myc-tagged Ago1-, 
Ago2- and GFP-constructs. Lysates were subjected to immunoprecipitation using anti-myc antibodies and treated 
with RNase A as indicated (right panels). Samples were separated by SDS-PAGE and analyzed for co-
precipitated FLAG/HA-PTCD3 using α-HA antibodies (upper right panel). Expression of the myc-constructs was 
analyzed by myc-western blot (lower right panel). To the left, 10 % of the input volumes for immunoprecipitation 
were loaded for western blotting. h.c.: heavy chain (B) GST-PTCD3 (lanes 6-10) or GST alone (lanes 11-15) as 
well as GST-RBM4 (lane 16) were immobilized on Glutathione sepharose and incubated with in vitro transcribed 
His-Ago1-4 or -Sip1 as indicated. After SDS-PAGE, bound proteins were visualized by autoradiography. 
Immobilized proteins were visualized by coomassie staining (lower panels). Lanes 1-5 show 5 % of the 
35
S-labeled proteins used in lanes 6-16. 
 
Nevertheless, sub-cellular localization of PTCD3 and Ago2 was analyzed by confocal laser 
microscopy. HEK 293 cells were co-transfected with myc-Ago2 and FLAG/HA-PTCD3 
(Figure 25A). Cells were fixed and the tagged proteins were stained using α-HA or α-myc 
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antibodies. As expected, myc-Ago2 predominantly localized to cytoplasmic structures which 
are presumably P bodies. FLAG/HA-PTCD3 is diffusely localized to the cytoplasm, however, 
considerable amounts co-localized with myc-Ago2. P body localization could also be 
confirmed by co-localization of FLAG/HA-PTCD3 with the endogenous P body marker Lsm4 
(Figure 25B). 
Thus, PTCD3 can be regarded as a newly identified P body component. Its function related 
to Ago proteins, however, will have to be further elucidated. 
 
 
Figure 25: PTCD3 location within the cell 
(A) Myc-Ago2 was co-expressed with FLAG/HA-PTCD3 in HEK 293 cells. Fixed cells were stained with DAPI as 
well as with α-HA and α-myc antibodies and the corresponding TexasRed- and FITC-conjugated secondary 
antibodies. Cells were analyzed using confocal laser microscopy and projections of 20 z-sections are shown. (B) 
HEK 293 cells expressing FLAG/HA-PTCD3 were probed for endogenous Lsm4 and overexpressed PTCD3 using 
α-Lsm4 and α-HA antibodies as described in (A). 
 
 
2.3. RBM4 AND ITS FUNCTION AS ARGONAUTE INTERACTION PARTNER 
2.3.1. RBM4 is required for miRNA-guided gene silencing 
To investigate the relevance of identified Ago mRNP components for miRNA function, a 
luciferase construct containing a perfectly complementary miR-21 target site in the 3‟-UTR 
was generated. Binding of Ago complexes containing endogenous miR-21 to the reporter 
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mRNA results in target cleavage and -destruction and correspondingly in a decrease of 
luciferase levels. In combination with knock-down of Ago-associated proteins, the functional 
relevance of the respective interaction partner for Ago function can be tested. As a control, a 
mutant construct with imperfect miR-21 complementarity was cloned (Figure 26A).  
 
 
Figure 26: Effect of RBM4 knock-down on miRNA-guided gene silencing 
(A) Schematic depiction of the miR-21 reporter construct and the corresponding control construct carrying a 
mutated miR-21 binding site. (B) SiRNAs against the indicated proteins were pre-transfected into HeLa cells. 
After 2 days, luciferase reporter constructs containing a complementary (upper panel) or a mutated (lower panel) 
binding site for miR-21 or a control vector lacking the miR-21 binding site were transfected and luminescence was 
measured after 96 h. Luciferase assays were done in triplicates. Results from the complementary or mutant 
reporters were normalized to those of the empty vector. 
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As expected, knock-down of Ago1, Ago3 and Ago4 had no effect, whereas siRNAs against 
Ago2 or TNRC6B led to a significant increase of luciferase expression (Figure 26B, upper 
panel). Strikingly, knock-down of RBM4 resulted in a strong increase of luciferase activity, 
indicating that RBM4 modulates miR-21-guided RNA cleavage. No effect was observed with 
the corresponding construct containing a mutated miR-21 binding site (lower panel). 
 
To analyze whether RBM4 is also required for the regulation of natural miRNA targets, a 
luciferase construct containing the KRAS 3‟-UTR was utilized. As KRAS is known to be a 
target of the miRNA let-7a, the effect of a let-7a inhibition was tested in a first experiment. 
Indeed, transfection of a 2‟OMe-oligoribonucleotide antisense to let-7a resulted in a strong 
increase of luciferase signal, while translational repression was not affected by transfection 
of a control 2‟OMe-oligonucleotide (Figure 27A, right panel). 
 
 
Figure 27: Regulation of the KRAS 3’-UTR mediated by Ago-interacting proteins 
(A) The experiment was carried out as described in (26B). A luciferase reporter construct containing the 3‟-UTR 
of KRAS was used (left panel). 2‟OMe inhibitors of the indicated miRNAs were co-transfected into HeLa cells 
together with the KRAS 3‟-UTR reporter construct (right panel). Results were normalized to those of the empty 
vector. (B) HeLa cells were transfected with siRNAs against RBM4, YB-1, IMP3 and FMRp as well as a control 
siRNA (ctrl.) for 96 h. Total RNA was reverse transcribed and cDNA was amplified by qPCR with primers specific 
to the indicated proteins. mRNA levels relative to GAPDH mRNA were normalized to control transfections. The 
error bars are derived from three different experiments. 
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Next, the effects of the depletion of several proteins on the KRAS 3‟-UTR reporter construct 
were analyzed. Knock-down of TNRC6B, a protein known to be involved in miRNA function, 
resulted in a signal increase as expected (Figure 27A, left panel). Further, cells depleted for 
YB-1, RBM4 or IMP3 showed stronger activity of the KRAS reporter construct, suggesting a 
function of these proteins in miRNA-mediated target regulation. Knock-down of FMRp, 
however, did not result in increased luciferase levels. Knock-down of the mentioned proteins 
was monitored by qRT-PCR as depicted in Figure 27B.  
In an inverse experiment, luciferase levels were examined when RBM4 was overexpressed 
(Figure 28). Various amounts of FLAG/HA-RBM4 and -IMP3 were transfected into HeLa cells 
and luciferase activity was measured. Interestingly, IMP3 overexpression led to a slight 
increase in luciferase levels. RBM4 overexpression, however, resulted in a considerable 
decrease of luciferase activity, suggesting that RBM4 represses the KRAS 3‟-UTR in a dose-
dependent manner. Thus, results from RBM4 knock-down and overexpression experiments 
complement each other, confirming a function of RBM4 in the regulation of the KRAS 
3‟-UTR. 
 
 
Figure 28: KRAS 3’-UTR regulation in RBM4 overexpression background  
The indicated amounts of FLAG/HA-RBM4 and -IMP3 (control) encoding plasmids were co-transfected into HeLa 
cells together with the KRAS luciferase reporter plasmid. Luciferase assays were done in triplicates 48 h after 
transfection. KRAS data were normalized to those of the empty vector. 
 
HMGA2, SERBP1, DNAJB11 and Raver2 have been identified and validated as miRNA 
targets before (Beitzinger et al., 2007; Mayr et al., 2007). Therefore, the luciferase reporter 
constructs containing the respective 3‟-UTRs were transfected and luciferase activity was 
measured in an RBM4- or TNRC6B knock-down background (Figure 29). Indeed, luciferase 
activity was increased in the RBM4- and TNRC6B knock-down samples, indicating that 
RBM4 functions on various known miRNA targets.  
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Figure 29: Effects of RBM4 knock-down on Ago target mRNAs 
Experiments were carried out as in (26B). Luciferase reporter constructs carrying the 3‟-UTRs of the indicated 
Ago targets were transfected and results were normalized to control siRNA values and the empty vector. 
 
 
2.3.2. RBM4 characterization and Ago interaction 
RBM4 is an RNA binding protein with diverse functions within the cell. It was identified in 
association with Ago2 by mass spectrometry and the aforementioned luciferase reporter 
experiments point towards an additional role of RBM4 in regulation of a number of miRNA 
target mRNAs. Therefore, the RBM4 interaction with Ago proteins was addressed in more 
detail. 
Revisiting the RBM4 migration behavior in sucrose gradients, HEK 293 lysates were 
fractionated and subjected to western blotting using antibodies specific to endogenous Ago1 
and RBM4. RBM4 co-migrated with all three Ago complexes, a major share residing in 
complex III (Figure 30A) which is consistent with its identification in Ago2 complex III by 
mass spectrometry. 
As RBM4 is known to be a nuclear-cytoplasmic shuttling protein, RBM4 distribution was 
analyzed in both compartments as well. Similar to Ago2, RBM4 was restricted to low 
molecular weight fractions in nuclear extracts (Figure 30B, upper panel). In the cytoplasmic 
extract, RBM4 can be detected in the fractions of all three Ago complexes (lower panel), 
confirming that RBM4 is part of the mRNP fraction in the cytoplasm.  
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Figure 30: RBM4 gradient distribution 
(A) HEK 293 lysates were separated by 15-55 % gradient centrifugation and individual fractions were analyzed for 
endogenous Ago1 (upper panel) and RBM4 (lower panel) using specific antibodies. (B) Nuclear (upper panel) and 
cytoplasmic (lower panel) lysates from HEK 293 cells were separated as in (A) and western blotting for 
endogenous RBM4 was performed. 
 
Co-immunoprecipitation experiments reproducibly showed that FLAG/HA-RBM4 associates 
with endogenous Ago1 and Ago2 (Figure 22B, Figure 31, left panel). RNase treatment 
indicates that this interaction is at least partially RNA-dependent.  
Northern blot analysis revealed that FLAG/HA-RBM4 co-immunoprecipitated endogenous 
miR-19b (Figure 31, right panel). However, the amount of co-purified miR-19b is very low 
compared to the levels bound to FLAG/HA-Ago2. It might therefore result rather from co-
immunoprecipitated Ago proteins than from direct binding of RBM4 to miRNAs. 
 
 
Figure 31: Association of RBM4 with Ago1, Ago2 and miRNAs 
(A) FLAG/HA-RBM4 was immunoprecipitated as in (22B) and western blotting for endogenous Ago1 and Ago2 as 
well as the HA-tag of RBM4 (control) was performed. (B) Lysates from HEK 293 cells transfected with the 
indicated constructs were immunoprecipitated using α-FLAG antibodies and analyzed for miR-19b by northern 
blotting. 
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The RBM4 interaction with Ago proteins was further validated by in vitro pull-down 
experiments. Recombinant GST-RBM4 yielded a strong binding signal with His-Ago1 
through -4, but not with the control protein His-Sip1. Interaction was not dependent on the 
miRNA binding abilities of Ago as an Ago2 mutant that is incapable of binding small RNAs 
(paz9; Liu et al., 2005) (Figure 32, lane 5) showed a signal equivalent to wild-type Ago2 (lane 
2). Also, binding was specific for the RBM4 protein as control reactions supplying GST alone 
as binding partner did not yield any signal. 
 
 
Figure 32: Analysis of RBM4-Ago binding by in vitro pull-down assay 
GST-RBM4 (lanes 1-6) or GST (lanes 7-12) were immobilized on Glutathione sepharose and incubated with 
35
S-labeled His-Ago1-4 (lanes 1-4 and 7-10), His-Ago2-paz9 mutant (lanes 5 and 11) or His-Sip1 (lanes 6 
and 12). Bound proteins were separated by SDS-PAGE and visualized by coomassie staining (lower panels) or 
autoradiography (upper panels). The upper left panel shows 20 % of the 
35
S-labeled proteins used in lanes 1-12. 
 
RNase treatment during the incubation of the protein partners resulted in a clearly visible 
though slightly diminished binding signal (Figure 34C). This observation indicates that the 
Ago-RBM4 interaction may be stabilized by mRNA binding. Further, it confirms the data 
obtained by co-immunoprecipitation. 
 
2.3.3. Identification of the RBM4 domains involved in Ago2 binding 
To identify the domains necessary for establishment of the interaction between Ago2 and 
RBM4, in vitro binding experiments with various protein fragments and mutants were 
performed.  
35S-labeled His-Ago2 as well as His-tagged fusion proteins containing the N-terminus, PAZ-, 
MID- or PIWI domains of Ago2 were incubated with GST-RBM4 and binding was assayed by 
autoradiography (Figure 33). As expected, RBM4 strongly interacted with full-length His-
Ago2 (lane 1). Furthermore, binding was observed for His-PIWI and, though weaker, for the 
His-N-terminal domain (lanes 2 and 5). The PAZ- and MID domains seemed to be 
dispensable for GST-RBM4 binding (lanes 3 and 4). As a control for Ago protein levels, input 
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samples were analyzed (left panel). GST alone did not bind Ago or its fragments (lanes 7-
12), also, the control protein His-Sip1 did not bind GST-RBM4 (lane 6). 
 
 
Figure 33: Identification of Ago domains involved in RBM4 binding 
Experiments were carried out as in (32), except that Ago2 constructs for the N-terminal (lanes 2 and 8), PAZ- 
(lanes 3 and 9), MID- (lanes 4 and 10) and PIWI- (lanes 5 and 11) domains of Ago2 were used for 
35
S-labeling 
besides full-length His-Ago2 (lanes 1 and 7) and -Sip1 (lanes 6 and 12). Coomassie stained immobilized proteins 
are depicted in the lower panels. The upper left panel shows 20 % of the 
35
S-labeled proteins used in lanes 1-12. 
 
The determination of the RBM4 domains that are relevant for Ago2 binding was approached 
by cloning various fragments and deletion mutants as GST fusion proteins which are listed in 
Table 2 and depicted schematically in Figure 34A.  
35S-labeled proteins were incubated with full-length His-Ago2 as described before and 
interaction was visualized by autoradiography. Deletion of the complete N-terminal part of 
RBM4 (ΔN) as well as deletion of both RNA recognition motifs (ΔRRM) abolished binding to 
His-Ago2 (Figure 34B, upper panel, lane 3 and 2, respectively). Deletion of the C-terminal 
part (ΔC, lane 4), however, did not interfere with Ago2 interaction, while an RBM4 fragment 
lacking both the Zn finger domain and the C-terminus (RRM+L2) showed slightly diminished 
Ago2 binding. Moreover, neither of the RRMs nor the Zn finger alone could facilitate 
interaction (Δ1, Δ2, Δ5, lanes 6, 7 and 10).  
Removal of the Zn finger domain from the full-length protein led to a signal decrease, still, 
binding was not abolished completely (Δ6, lane 11), indicating a direct or indirect role for this 
domain in Ago2 interaction. This was also confirmed by mutant Δ14 carrying two mutations in 
the Zn finger domain that abolish its nucleic acid binding abilities (lane 19, Markus and 
Morris, 2006). Neither deletion of the RRM1 from the full-length protein nor from the N-
terminal protein fragment resulted in diminished Ago2 interaction (Δ7 and Δ4, lanes 12 and 
9). However, signal intensities decreased when the RRM2 was removed (Δ8 and Δ3, lanes 
13 and 8). Besides the RRM2 and the Zn finger domains, the second linker region (L2) also 
seems to be involved in Ago2 binding, as both its deletion (Δ9, lane 14 compared to 
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RRM+L2, lane 5) and its replacement with an alanine-glycine-sequence of identical length 
(Δ10, lane 15) completely abolished in vitro binding to Ago2. 
 
Table 2: Characteristics of the RBM4 mutants 
Name Schematic depiction 
Amino 
acid 
residues 
Internal 
deletions 
Mutations 
RBM4 
RRM1 
Linker L1 
RRM2 
Linker L2 
Zn finger 
 
1-364 
3-68 
69-78 
79-144 
145-159 
160-176 
- - 
ΔRRM  145-364 - - 
ΔN  177-364 - - 
ΔC  1-176 - - 
RRM+L2  1-159 - - 
Δ1  3-68 - - 
Δ2  79-144 - - 
Δ3  1-176 77-144 - 
Δ4  69-176 - - 
Δ5  159-176 - - 
Δ6  1-364 160-179 - 
Δ7  69-364 - - 
Δ8  1-364 78-144 - 
Δ9  1-144 - - 
Δ10  1-364 - 
L2 replaced by 
AAAAAAAGAAAAAAA 
sequence 
Δ11  69-215 - - 
Δ12  1-215 - - 
Δ13  1-215 77-144 - 
Δ14 
 
1-364 - 
Cys162  Tyr 
Cys165  Tyr 
Δ15  1-364 - 
Domain swap 
RRM1  RRM2 
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Figure 34: Identification of RBM4 motifs involved in Ago2 binding 
(A) Schematic depiction of RBM4 and RBM4 fragments and mutants cloned. RNA recognition motifs are denoted 
in orange, the Zn-finger domain in red. The green stretch in mutant 10 symbolizes an alanine/glycine-stretch 
replacing the second linker domain. Two asterisks in mutant 14 depict CysTyr mutations in positions 162 and 
165 of the protein. (B) Experiments were carried out as in (32), using 
35
S-labeled His-Ago2 (upper panels) or His-
Sip1 (middle panels) as well as the GST-tagged RBM4 mutants shown above and GST. Coomassie staining of 
the SDS PAGE gel is shown in the lowest panels. (C) Experiments were performed as in (32). GST-RBM4 ΔC 
was incubated with His-Ago1 and -Sip in presence (right panel) or absence (middle panel) of RNase A. 
 
As NMR measurements indicated that the deletion of the complete C-terminus might result in 
unfolding of the Zn finger domain (Birgitta Wöhrl, University of Bayreuth, personal 
communication), the mutants Δ4, ΔC and Δ3 were recloned carrying 11 additional amino acid 
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C-terminal of the Zn finger domain (Δ11, Δ12 and Δ13, respectively). However, this did not 
affect the binding behaviors in the in vitro pull-down experiments (compare lanes 16 and 9, 
lanes 17 and 4, lanes 18 and 8). 
To further characterize the significance of the individual RRM domains for Ago2 binding, a 
domain swap was performed in mutant Δ15, rendering the RRM2 at the N-terminus of the 
protein and the RRM1 next to the L2 sequence. Interestingly, this did not have an influence 
on the binding signal (lane 20). As both RRM domains are still present in the Δ15 mutant, the 
shifted RRM2 could still function in Ago2 binding. Also, the RRM1 had been shown to 
partially compensate for a deletion of RRM2 (mutants Δ3, Δ8, Δ13). However, it cannot be 
excluded that the signal decrease in the latter mutants could be due to the fact that only 
RRM2 but not the first linker sequence L1 was deleted. In the resulting protein fragment, 
RRM1 and the Zn finger domain were separated not only by the required L2 sequence, but 
additionally by L1 which may have interfered with correct establishment of the binding 
surface. 
To examine whether the in vitro binding properties of RBM4 could also be recapitulated with 
endogenous Ago from cell lysate, the immobilized RBM4 fragments were incubated with 
HEK 293 lysate and binding of Ago1 was analyzed by western blotting (Figure 35). 
Consistent with the in vitro data, Ago1 was co-purified with the ΔC- and RRM+L2 mutants as 
well as with the Δ4 and Δ7 mutants lacking RRM1. Weaker Ago1 signals, as might have 
been expected in analogy to the in vitro pull-down experiments, may not be visible due to 
background signals. 
 
 
Figure 35: Interaction of GST-RBM4 mutants with endogenous Ago1 
GST-RBM4, RBM4 mutants shown in (34A) and GST were immobilized on Glutathione sepharose and incubated 
with lysates from HEK 293 cells. Samples were analyzed for co-precipitated endogenous Ago1 by western 
blotting using specific antibodies. 
 
Together, the results from the in vitro binding experiments indicate that the interaction of 
RBM4 and Ago2 is facilitated by the N-terminal and PIWI domains of Ago2 while the minimal 
Ago2-binding RBM4 fragment comprises the Zn finger-domain and one RRM domain 
(presumably RRM2) as well as the second linker domain L2. 
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2.3.4. Effects of RBM4 on RISC activity, Dicer activity and binding 
As depicted in Figure 33, RBM4 interacts with the PIWI domain of Ago2. Interestingly, it has 
been shown that Dicer binding to Ago takes place at the PIWI domain as well (Tahbaz et al., 
2004). Therefore, we tested whether RBM4 binding might interfere with the Ago-Dicer 
interaction by competing for the binding to the Ago PIWI domain. To address this, RISC and 
Dicer activities as well as the level of co-immunoprecipitated Dicer were analyzed in 
presence of recombinant RBM4.  
 
 
Figure 36: Effect of RBM4 on RISC activity, Dicer activity and levels of Ago-associated Dicer  
(A) HEK 293 cell lysates were incubated with varying amounts of GST-RBM4 (lanes 4-8) or GST (lanes 9-11) 
prior to immunoprecipitation of endogenous Ago2. Ago2 from FLAG/HA-RBM4 or -GFP containing HEK 293 cell 
lysates (lanes 2 and 3) was immunoprecipitated directly. A RISC assay using a 
32
P-cap-labeled substrate of 
miR-19b was carried out as in (15). T1 indicates RNase T1 digestion of the RNA substrate (lane 1). The RNA 
sequence complementary to miR-19b is indicated by a black bar to the left. (B) Immunoprecipitations were 
performed as in (A). Samples were incubated with an internally 
32
P-labeled pri-miR-27a substrate and analyzed 
by RNA PAGE as in (16A). A 21-nucleotide marker is shown to both sides (M). (C) Immunoprecipitation was 
performed as in (A). Samples were analyzed for endogenous Dicer (upper panel), Ago2 (middle panel) and RBM4 
(lower panel) by western blotting using specific antibodies. 
 
HEK 293 lysate was incubated with varying amounts of GST-RBM4 prior to 
immunoprecipitation with antibodies specific to Ago2. Endonucleolytic activity was assayed 
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by incubation with a 32P-cap-labeled RNA substrate of miR-19b. Samples showed constant 
RISC activity independent of the level of GST-RBM4 introduced (Figure 36A, lanes 4-8), as 
did samples that had been pre-incubated with GST alone (lanes 9-11). Also, transient 
transfection of FLAG/HA-RBM4 (lane 2) did not interfere with endonucleolytic activity 
compared to the GFP control (lane 3).  
The same set of samples was used for assaying Dicer activity. Levels of mature miR-27a 
remained constant in presence of FLAG/HA- or GST-RBM4 (Figure 36B). 
Also, the levels of endogenous Dicer that co-immunoprecipitated with Ago2 did not change 
upon RBM4 addition as demonstrated by western blotting using specific antibodies (Figure 
36C). Notably, GST-RBM4 was hardly detectable by western blotting while overexpressed 
FLAG/HA-RBM4 clearly co-precipitated with Ago2.  
Together, binding of RBM4 to Ago2 did not displace Ago-Dicer interaction. Despite binding of 
both proteins to the same Ago domain, neither Dicer levels nor its activity was affected by the 
presence of RBM4. The same is also true for Ago2 RISC activity, indicating that RBM4 
function in relation to Ago proteins is restricted to transcriptional and/or translational 
regulation. 
 
2.3.5. RNA recognition motifs as a potential binding platform for Ago proteins 
Besides RBM4, a number of other RRM domain containing proteins were identified by mass 
spectrometry analysis of Ago1/2 complexes. This implied that RRM-containing proteins might 
act as a general binding platform for Ago proteins to their target mRNAs, possibly by 
promoting Ago complex binding or stabilizing an Ago-target mRNA interaction. 
To further examine the role of RRM domains in Ago binding, three proteins, which had been 
validated as Ago interactors by co-immunoprecipitation experiments (see Figure 22), were 
recombinantly expressed as GST fusion proteins (schematic depiction in Figure 37A). 
Moreover, the corresponding deletion mutants lacking the RRM domain were created.  
In vitro pull-down experiments using GST-IMP3, -SART3 and -Matrin3 together with 
35S-labeled His-Ago2 could not confirm the hypothesis that protein binding to Ago is 
generally mediated by the RRM-domain. Recombinant expression of GST-Matrin3 and its 
deletion mutant was not efficient, as observed by coomassie staining (Figure 37B, lanes 5 
and 6, lower panel); still, an interaction with Ago2 could not be detected at all (lanes 5 and 6, 
upper panel), not even by long-term film exposure (not shown). GST-IMP3 as well as GST-
SART3 interacted strongly with His-Ago2, though (lanes 3 and 7). However, deletion of the 
RRM domain from these proteins did not prevent their interaction with Ago2 (lanes 4 and 8), 
indicating that in these cases the RRM domain is not essential for Ago binding. 
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Figure 37: General influence of RRM domains on Ago binding 
(A) Schematic depiction of Ago-interacting proteins. (B) GST-IMP3, -Matrin3, -SART3 and the respective RRM-
deleted mutants as well as GST alone were immobilized on Glutathione sepharose and incubated with in vitro 
transcribed His-Ago2 or -Sip1. Protein separation and detection was performed as described in (23). 
 
 
2.3.6. Sequence and structure analysis of the RBM4 RNA recognition motifs 
While RRM domains apparently do not generally act in Ago binding, the aforementioned 
results still indicate that Ago binding to RBM4 requires the RRM domain 2 of RBM4, while 
the RRM domain 1 is dispensable. This could point towards distinct functions of the individual 
RRM domains, with RRM1 binding the target mRNA and RRM2 acting in protein-protein-
interaction with Ago. 
Generally, three different forms of RNA recognition motifs are distinguished: canonical and 
non-canonical RNA binding RRM domains as well as protein-binding RRM domains (Table 3, 
Maris et al., 2005; Eulalio et al., 2009b). As these forms differ in structure and sequence, the 
analysis of both RRM domains of RBM4 might provide closer insight on their function. The 
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structure of the complete RBM4 protein has not yet been published. However, the structure 
of both RRM domain 1 and 2 is available from the Protein Data Bank (PDB IDs: 2DGT and 
2DNQ, respectively).  
As characteristic for RNA recognition motifs, both RRM domains of RBM4 fold into a 
β1α1β2β3α2β4 topology in solution, with a four-stranded antiparallel β-sheet flanked on one 
side by two α-helices (Table 3; Maris et al., 2005). An additional third α-helix α3, as described 
for a number of RRM domains, is not visible from the structure models.  
Canonical RNA-binding RRM domains are characterized by two conserved sequence areas, 
RNP1 (ribonucleoprotein domain 1) (RK-G-FY-GA-FY-ILV-X-FY) on β-strand β3 
and RNP2 (ILV-FY-ILV-X-N-L) on β-strand β1, providing aromatic side chains to the 
surface of the β-sheet (positions depicted in bold; Maris et al., 2005) and thereby allowing for 
interaction with nucleic acids. In protein-binding RRMs as well as in non-canonical RNA-
binding RRMs, these aromatic residues are often replaced by aliphatic amino acids (Eulalio 
et al., 2009b).  
Comparison of the RRM domains of RBM4 with these conserved sequences revealed that 
RRM1 adheres to the sequence motifs very well, with all three aromatic residues in place. 
The RNP1 motif of RRM2 matched the classical motif as well, while the aromatic residue in 
position 2 of the RNP2 was missing.  
This rather points towards an RNA- or RNA/protein binding function of the RRM2 of RBM4, 
however, structural analysis of the RRM2 in complex with interacting proteins as Ago2 could 
clarify the exact binding properties of this domain. 
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Table 3: RRM domains - different interaction modes 
RRM binding 
properites 
Protein 
name 
PDB-
ID 
ribonucleoprotein 
domain 1 (RNP1) 
RNP2 RRM structure Reference 
RRM binding motif 
RK-G-FY-GA-
FY-ILV-X-FY 
ILV-FY-
ILV-X-N-L 
 
Reviewed in 
Maris et al., 
2005 
Canonical 
RNA binding 
U1A 
1FHT/ 
1URN 
R-G-Q-A-F-V-I-F I-Y-I-N-N-L 
 
Nagai et al., 
1990; Oubridge 
et al., 1994; 
Avis et al., 
1996 
Non-canonical 
RNA binding 
hnRNP F 
(qRRM1) 
2HGL S-G-E-A-F-V-E-L V-K-L-R-G-L 
 
Dominguez and 
Allain, 2006 
Protein 
binding 
Dm 
GW182 
2WBR Q-G-I-A-L-C-K-Y L-L-L-K-N-L 
 
Eulalio et al., 
2009 
 
RBM4 
RRM1 
2DNQ K-N-Y-G-F-V-H-I L-F-I-G-N-L 
 
PDB 
RBM4 
RRM2 
2DGT K-D-Y-A-F-V-H-M L-H-V-G-N-I 
 
PDB 
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2.3.7. Validation of translational effects of RBM4 on reported targets 
To identify further common mRNA targets of RBM4 and Ago proteins and to analyze RBM4-
Ago interactions on target mRNAs in detail, the 3‟-UTRs of human Period1 (Per1), Flotillin1 
(FLOT1) and Ras homolog C (RhoC) were cloned into a luciferase reporter construct. It was 
shown by others before that Per1 expression is translationally regulated by RBM4 (Kojima et 
al., 2007). FLOT1 and RhoC have been identified as targets of RBM4 as well (Lin and Tarn, 
2005). 
MiRNA target prediction by TargetScan and PicTar implied that all three 3‟-UTRs should be 
targeted by a number of miRNAs as listed in Table 4. Thus, Ago proteins should associate 
with these 3‟-UTRs. 
 
Table 4: Predicted miRNA-binding sites within the 3’-UTR of RBM4 targets 
mRNA RBM4 binding site Reference Predicted miRNA binding sites 
Per1 3‟-UTR 
5‟-UAUUUUUUUUUUAA- 
UACAAAAUGACAAAAU-3‟ 
Kojima et al., 2006 
miR-15b, miR-24, miR-29a/b/c, 
miR-133b, miR-136, miR-146a/b, 
miR-185 
FLOT1 3‟-UTR 5„-GCUCCCCUUG-3„ Lin and Tarn, 2005 miR-31, miR-124, miR-506 
RhoC 3‟-UTR 5‟-GCCUUUCCUA-3‟ Lin and Tarn, 2005 
miR-17-5P, miR-20a/b, miR-93, 
miR-106a/b, miR-138, miR-142-5P, 
miR-302a/b/c/d, miR-372 
 
To validate the 3‟-UTRs as Ago targets, several of the listed miRNAs were inhibited by 
transfection of 2‟OMe-antisense oligonucleotides. Values were normalized to those of HeLa 
cells not subjected to 2‟OMe-treatment (untransf.). Moreover, 2‟OMe-oligonucleotides 
against GFP and the Epstein Barr virus miRNAs BART5 and EBV-3P were used as controls.  
Surprisingly, miRNA inhibition did not have an effect on the expression levels of either 
reporter construct (Figure 38A, upper panels and lower left panel), even though - according 
to information from Ambion - some of the tested miRNAs are supposed to be moderately to 
strongly expressed in HeLa cells (http://www.ambion.com/techlib/resources/miRNA/ 
expression.html). HMGA2, which served as a positive control, was strongly up-regulated 
upon let-7a inhibition (Figure 38A, lower right panel), indicating that transfection was efficient.  
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Figure 38: RBM4-mediated regulation of reported mRNA targets 
(A) 2‟OMe inhibitors to the indicated miRNAs were co-transfected into HeLa cells together with pMIR-RNL-Tk 
luciferase constructs carrying the 3‟-UTRs of Per1 (upper left panel), FLOT1 (upper right panel), RhoC (lower left 
panel), HMGA2 (lower right panel) and a mutated HMGA2 3‟-UTR sequence lacking let-7a binding sites (mut, 
lower right panel) as in (27A). (B) SiRNAs against the indicated proteins were pre-transfected into HeLa cells. 
After 2 days, pMIR-RNL-Tk reporter constructs carrying the Per1-, FLOT1- and RhoC 3‟-UTRs were transfected 
and luminescence was measured 96 h after the first transfection. Luciferase assays were done in triplicates. 
Results were normalized to those of the empty vector. (C) HeLa cells were transfected with the indicated siRNAs 
and lysed after 96h. Lysates were subjected to western blotting using antibodies against RBM4 (upper panel) and 
beta-actin (control, lower panel). 
 
Nevertheless, regulation of Per1-, FLOT1- and RhoC 3‟-UTR reporter constructs was also 
analyzed in an RBM4 knock-down background (Figure 38B). While depletion of RBM4 was 
efficient (Figure 38C, upper panel, lanes 2 and 3), the luciferase signal was not significantly 
increased (Figure 38B). Hence, RBM4 knock-down could not be shown to interfere with 
translation regulation of these mRNAs in the utilized system. Notably, also TNRC6B 
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depletion did not influence luciferase levels, arguing again against miRNA-mediated 
regulation of Per1-, FLOT1- and RhoC 3‟-UTRs. Together, this suggests that miRNA target 
site prediction on these mRNAs was not accurate and the analyzed 3‟-UTRs were not 
regulated by the examined miRNAs. Still, in these cases RBM4 might exert its function via 
one of its additional regulatory pathways. 
 
2.3.8. Putative RBM4 binding motifs and their effect on translation 
A number of studies have been published concerning the RNA binding preferences of RBM4; 
however, their results are controversial. The Tarn lab reported a CU-rich RBM4 binding motif 
(Lin and Tarn, 2005), while analysis of RNA targets of the Drosophila homolog LARK pointed 
towards an A-rich binding element containing one or more ACAAA motifs (Huang et al., 
2007). A systematic analysis of RNA binding specificities of several RNA binding proteins, 
however, showed a binding preference of RBM4 towards GC-rich sequences within an 
unstructured sequence context (Ray et al., 2009; Kazan et al., 2010). 
Table 5 summarizes KD values obtained by anisotropy measurements of the RBM4 Δ4 
(RRM2-L2-Zn finger) fragment together with 6-FAM labeled CU-rich RNA fragments (Ströh, 
2009). However, binding of GC-rich RNAs to RBM4 Δ4 was not analyzed in this experiment. 
 
Table 5: Anisotropy measurements with RBM4 Δ4 fragment 
RNA sequence KD value (μM) 
RNA A 5‟-GGUCUCUCUG-3‟ 25.4 ± 1.3 
RNA B 5‟-UAGGGAACC-3‟ - 
RNA C 5‟-UGCUCUUUA-3‟ 49.1 ± 4.1 
RNA D 5‟-CACAUUCCA-3‟ - 
RNA E 5‟-AAAAUUAA-3‟ - 
 
In order to analyze the effect of different RNA motifs on translational regulation of RNA, 
luciferase reporter constructs were created, carrying a miR-21 binding site and a putative 
RBM4 binding motif within a 190 nt random DNA sequence in 3‟-position of the luciferase 
ORF. As controls, constructs carrying a control RNA (crtl. I) and additionally a mutated 
miR-21 binding site (ctrl. II) were used. Sequences of the tested putative RBM4 binding 
motifs and reporter constructs are schematically depicted in Figure 39A. 
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Figure 39: Regulation of an artificial RNA target by both RBM4 and Ago 
(A) Schematic depiction of luciferase constructs carrying a miR-21 binding site as well as a potential RBM4 
binding motif (as indicated) within a 190 nt random DNA sequence in 3‟ position to the luciferase ORF (upper 
panel). Control constructs either lack the RBM4 binding site (ctrl. I, middle panel) or additionally carry a mutated 
miR-21 binding site (ctrl. II, lower panel). (B) pMIR-RNL luciferase constructs indicated in (A) were transfected 
into HeLa cells depleted for the indicated proteins. Luminescence was measured 96 h after siRNA transfection. 
Luciferase assays were done in triplicates. Results were normalized to those of the empty vector. 
 
Transfection of the constructs into RBM4- or TNRC6B-depleted HeLa cells caused a 
moderate to strong increase of the luciferase signal. However, this was also true for the 
control constructs, indicating that this effect was not specific for Ago and RBM4 binding 
(Figure 39B). 
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Figure 40: Effects of the introduction of a putative RBM4 binding site into the HMGA2 3’-UTR 
(A) Schematic drawing of luciferase reporter constructs carrying a modified HMGA2 3‟-UTR with an artificially 
inserted potential RBM4 binding motif. Residual let-7a binding sites are indicated in green, the position of the 
respective RBM4 binding motif is indicated in blue. (B) Experiments were performed as in (39B). HMGA2 3‟-UTR, 
a mutated HMGA2 3‟-UTR lacking let-7a binding sites (mut) as well as the constructs indicated in (A) were 
transfected. (C) The indicated amounts of a FLAG/HA-RBM4-encoding plasmid were co-transfected into HeLa 
cells together with the indicated luciferase reporter plasmids. Luciferase assays were done in triplicates 48 h after 
transfection. Results were normalized to those of the empty vector. 
 
To place the putative RBM4 binding sites into a more natural context, the respective RNA 
motifs were cloned into the HMGA2 3‟-UTR (Figure 40A). Transfection of the constructs into 
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RBM4-depleted HeLa cells produced an up-regulation with siRNA #3. However, this effect 
was indiscriminate of the introduced RBM4 binding motifs and even the mutated let-7a 
binding sites, indicating that in the current position, the RBM4 binding site is not interfering 
with translational repression and that HMGA2 repression is also maintained in absence of 
let-7a binding sites under these conditions (Figure 40B), maybe by other miRNAs. 
A similar pattern was also detected when RBM4 was overexpressed. As described before for 
the KRAS reporter construct (Figure 28), overexpression of FLAG/HA-RBM4 resulted in a 
firefly signal decrease (Figure 40C). This was even more explicit with the constructs carrying 
the RBM4 binding motifs. However, the signal decrease was also visible when the mutated 
HMGA2 3‟-UTR was transfected.  
 
To analyze whether RBM4 binding to the mRNAs of the HMGA2 reporter constructs 
containing RBM4 binding motifs was detectable, HEK 293 cells were transfected and lysates 
were subjected to immunoprecipitation using antibodies specific to RBM4. Co-precipitated 
RNA was reverse-transcribed and mRNA levels were quantified by qPCR (Figure 41). 
Indeed, enrichment of HMGA2 mRNA containing RNA A or RNA G was detected while 
HMGA2 +RNA C mRNA levels equaled those of HMGA2 alone. The mutated HMGA2 mut 
mRNA was only slightly enriched.  
 
 
Figure 41: Binding of RBM4 to modified HMGA2 reporter mRNA 
HeLa cells were transfected with the pMIR-RNL luciferase constructs from (40). After 48h, cells were lyzed and 
lysates were subjected to immunoprecipitation using α-RBM4 antibodies. RNA was isolated from the beads and 
reverse transcribed. cDNA was amplified by qPCR with primers specific to the firefly luciferase ORF. mRNA levels 
were normalized to those of renilla luciferase mRNA.  
 
This is to a certain degree consistent with the aforementioned anisotropy results, as RNA C 
binding to RBM4 Δ4 was weaker than that of RNA A. RNA G binding had not been tested 
with this method.  
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Together, these results indicate that RBM4 shows an affinity to the GC-rich RNA G 
sequence. It also binds the RNA A motif which is CU-rich, but flanked by G residues. RBM4 
binding might therefore also be influenced by the presence of these G residues, as 
significant binding to RNA C, which predominantly consists of U residues, was not detected.  
However, an effect on miRNA-mediated translational regulation could not be shown, 
indicating that the sequence context might be important for RBM4 function as well.  
Thus, it would be interesting to identify common targets of RBM4 and Ago proteins in an in 
vivo context allowing for a detailed analysis or their interaction on a target mRNA. First 
attempts on this behalf have been made using the PAR-CLiP method (Hafner et al., 2010) in 
collaboration with Mihaela Zavolan (University of Basel). However, experimental conditions 
of this method will have to be further modified in order to gain information on potential target 
mRNAs. 
 
In summary, RBM4 was found to influence Ago function in luciferase systems using artificial 
as well as natural 3‟-UTR constructs. It strongly interacted with all four human Ago proteins, 
specifically via the Ago PIWI and – to a smaller extent – also the N-terminal domain. RBM4 
binding to the Ago PIWI domain did not interfere with Dicer binding to the same domain. 
RBM4 binding to Ago was mediated by the second RNA recognition motif (RRM2), the Zinc 
finger domain and the intermediate linker region, while the N-terminal RRM1 was 
dispensable for Ago interaction. However, distinct functions of the two RRM domains with 
respect to RNA or protein binding properties could not be deduced from sequence or 
structure of the isolated domains. Also, despite the considerable number of RRM containing 
proteins identified in Ago complexes, a general function of the RRM domain in Ago 
interaction could not be demonstrated. MiRNA effects on some known RBM4 targets could 
not be verified by a luciferase reporter approach, even though miRNA target prediction 
programs produced a number of potential miRNA binding sites in the 3‟-UTRs of the 
respective transcripts. Different RBM4 RNA binding motifs were tested in combination with 
miRNA binding sites in completely and partially artificial luciferase constructs. However, the 
requirements of efficient RBM4-Ago cooperation seem to be more complex and could not be 
efficiently mimicked. The sequence of the preferred RNA binding motif of RBM4 is still 
controversial. Therefore, additional experiments such as the PAR-CLiP approach will be 
necessary for a closer analysis of RBM4 binding preferences on target mRNAs also common 
to Ago proteins. Further, the identification of common RBM4 and Ago targets may allow for 
detailed investigation of the molecular interaction mechanism of RBM4 and Ago proteins. 
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3. DISCUSSION 
While small RNAs have become a widespread tool in the molecular analysis of proteins, 
many details about their endogenous functions in mammals are still elusive. 
Ago proteins directly interact with small RNAs and constitute the core of small RNA guided 
effector complexes. The regulation of their various functions presumably involves a large 
number of regulatory proteins. In order to analyze factors interacting with Ago proteins to 
facilitate regulation of gene expression, this work aimed at the identification and 
characterization of human Ago protein complexes using biochemical and proteomic 
approaches. 
 
3.1. CHARACTERIZATION OF HUMAN AGO COMPLEXES 
In a first approach, the incorporation of Ago proteins into protein complexes with distinct 
molecular weight was examined. Sucrose gradient results indicate that both Ago1 and Ago2 
reside in three distinct protein complexes ranging from about 11S to more than 30S. While all 
three complexes contain miRNAs, they differ in Dicer- and RISC activities. Moreover, both 
Ago1 and -2 were also detected in the low molecular weight fractions of gradients from 
nuclear extracts, underlining a role for Ago proteins in nuclear processes. This finding is 
consistent with observations by Ohrt and colleagues, who demonstrated the existence of a 
small nuclear Ago-containing complex of about 158 kDa in addition to a large cytoplasmic 
complex (about 3 MDa) using fluorescence correlation and cross-correlation spectroscopy 
(Ohrt et al., 2008). 
The smallest cytoplasmic Ago complex, termed complex I, contains the largest Ago portion 
and has a molecular weight of about 250-350 kDa. It is characterized by RISC- as well as 
Dicer activity and is insensitive to RNase treatment. Complex III, sedimenting at a molecular 
weight of more than 900 kDa, is associated with Dicer activity only. Further, it co-migrates 
with a miRNA target mRNA implying that Ago complex III consists of miRNA-regulated 
mRNPs. Consistently, both complex III and the smaller complex II (~600-700 kDa) are 
RNase sensitive. Complex II, however, is lacking Dicer and subsequently miRNA processing 
abilities as well as RISC activity. Hence, it may contain a Dicer-free miRNP population, for 
which also the size difference could account. However, further experiments will be necessary 
to investigate its functional relevance. 
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3.2. IDENTIFICATION OF AGO INTERACTION PARTNERS BY A PROTEOMIC 
APPROACH 
As a first approach, the incorporation of Ago proteins into protein complexes with distinct 
molecular weights was analyzed. Mass spectrometric analysis of pooled Ago complex 
fractions identified a large number of proteins associated with Ago1 and Ago2. Besides 
proteins that were known to participate in gene silencing, a major number of identified 
proteins could be assigned to the DEAD/DExH-box or heterogenous nuclear 
ribonucleoprotein (hnRNP) families. These two RNA binding protein families show high 
functional diversity and act on all aspects of eukaryotic RNA metabolism, including pre-
mRNA splicing, ribosome biogenesis, mRNA export, regulation of translation and mRNA 
degradation (Linder, 2006; Han et al., 2010). Furthermore, the majority of the remaining 
proteins can be assigned to mRNA binding and RNA metabolism as well. 
Interestingly, size addition of the proteins identified in Ago complex I would suggest a much 
bigger complex than 250-350 kDa, as was observed in the sucrose gradients. Indeed, 
complex I can be further subdivided into three complexes referred to as complex Ia-c with 
distinct RISC- and Dicer activities. Complex Ia probably contains a Dicer-free minimal RISC 
of about 200 kDa (Martinez et al., 2002; Haley and Zamore, 2004), hence it is able to cleave 
an RNA substrate but lacks Dicer activity. Complex Ib associates with Dicer as well as RISC 
activity and presumably corresponds to a trimeric Ago-Dicer-TRBP complex (Gregory et al., 
2005). In complex Ic, Ago might interact with other proteins identified by mass spectrometry. 
In Drosophila, an 80S Ago containing protein complex has been described which is 
endonucleolytically active and hence was termed “holo-RISC” (Pham et al., 2004). This holo-
RISC complex contains Dicer2, its function within the complex, however, remains unclear. In 
this work, a human Ago complex, termed complex III, was identified sedimenting with a 
S value of approximately 30-40. Strikingly, Ago complex III also associates with Dicer and is 
capable of generating mature miRNAs from pre-miRNAs. Yet, in contrast to Drosophila holo-
RISC, Ago2 complex III exhibits no RISC activity. This observation might be explained by 
association of the miRNA-containing Ago complexes with target mRNAs resulting in the 
formation of silenced mRNPs. While being loaded with a target mRNA, miRNA binding to an 
exogenous target RNA and its subsequent cleavage may not be possible. Consistent with 
this model, the known let-7a target KRAS (Johnson et al., 2005) was found to co-migrate 
with Ago complex III in sucrose gradients. In combination with the large number of co-purified 
RNA binding proteins, this observation indicates that Ago complex III consists of a variety of 
large mRNPs that contain presumably translationally repressed miRNA target mRNAs. 
Consistently, a number of proteins sedimenting in Ago complex III have been reported to be 
associated with mRNPs and also with small RNA function in different organisms.  
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Figure 42: Model of Ago protein complex organization in the cytoplasm of mammalian cells 
 
Among the DEAD/DExH-box containing proteins that co-purified with Ago was DDX5, an 
orthologue of Drosophila p68, which has been identified as a component of the Drosha-
containing microprocessor complex together with hnRNP U, hnRNP U-like, and the 
heterodimer NF-90/NF-45 (Gregory et al., 2004). Interestingly, NF-90 possesses a dsRNA 
binding domain and has been reported to play a role in the nuclear export of viral stem-loop 
structured RNAs. Further, it associates with Exportin 5, the nuclear export factor that 
facilitates pre-miRNA transport to the cytoplasm (Gwizdek et al., 2004). Moreover, NF-90 has 
also been implicated in translation regulation of specific mRNAs (Shi et al., 2005). It is 
therefore conceivable that NF-90 might be involved in nuclear miRNA maturation and 
subsequent export as well as in miRNA function in the cytoplasm.  
Previous data had already shown that Gemin3 and -4 co-sediment with a 15 S complex 
together with miRNAs and Ago proteins (Mourelatos et al., 2002). Also, DDX18 had been 
implicated in Drosha function before, presumably with a helicase function (Gregory et al., 
2004). Consistently, these proteins were also detectable in the present study. Furthermore, 
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RNA helicase A (RHA/DHX9) has been demonstrated to be required for RISC formation and 
effective silencing of cognate mRNAs (Robb and Rana, 2007). Strikingly, DDX6, another 
DEAD-box helicase that was reported to be required for miRNA function (Chu and Rana, 
2006), was not among the identified Ago interaction factors. 
Besides its function in nonsense-mediated decay, UPF1 has been shown to target correct 
mRNAs to P bodies (Sheth and Parker, 2006) and to interact with the mRNA decapping 
enzymes DCP1 and DCP2. Notably, the present co-immunoprecipitation experiments point 
towards an RNA-independent interaction between UPF1 and Ago1/2, hence it would be 
tempting to speculate that the function of UPF1 in P bodies is closely connected to the 
miRNA pathway. 
Mass spectrometry analysis also detected DHX36 (RHAU), a DExH-box protein involved in 
deadenylation of AU-rich mRNAs (Tran et al., 2004). It has been reported that miRNAs are 
involved in deadenylation of specific mRNAs in Zebrafish as well as in mammals (Giraldez et 
al., 2006; Wu et al., 2006). DHX36 could therefore be an Ago associated factor that recruits 
the deadenylation machinery to specific miRNA targets. Interestingly, among the Ago 
interactors tested for co-immunoprecipitation with Ago1 and -2, DHX36 was the only protein 
that showed a distinct binding behavior: while interaction with Ago2 was insensitive to RNase 
treatment, the interaction with Ago1 seemed to be dependent on RNA. Unfortunately, this 
result could not be confirmed in in vitro pull-down experiments, where DHX36 associated 
indiscriminately with all four Ago proteins. Still, this in vitro observation could be due to the 
absence of further interaction partners and may not reflect the actual protein interplay within 
the cell.  
Besides DEAD/DExH box-containing proteins, poly(A)-binding proteins and a large number 
of mRNA binding proteins involved in translation, such as YB-1, IMP1 and -3, HuR and 
FMRp as well as its homologues FXR1 and FXR2, were present in the analysis.  
An RNA-binding protein that showed RNA-dependent interactions with Ago1 and -2 in this 
study was HuR (ELAV1). HuR has been reported to influence the stability of A-rich mRNAs 
(Eberhardt et al., 2007). Moreover, it was shown to release the miR-122 repressed CAT-1 
mRNA from cytoplasmic P bodies upon cellular stress and to activate its translation by 
facilitating its entry into polysomes (Bhattacharyya et al., 2006a). The Y-Box binding 
protein 1 (YB-1) competes with the eIF4E-translation initiation complex for the binding to the 
5‟-cap-structures of mRNAs, thereby repressing translation. Further it also seems to stabilize 
repressed mRNAs in a cap-dependent manner (Evdokimova et al., 2006). Like HuR, YB-1 
co-purified with Ago1 and -2 in an RNA-dependent manner. As YB-1 depletion results in an 
up-regulation of a KRAS 3‟-UTR reporter construct, its cooperation with Ago proteins in 
translational repression seems possible. IMP1 and -3 modulate localization, translation and 
mRNA stability of their targets (Yisraeli, 2005). Upon environmental stress, IMP1 retains 
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specific mRNAs in stress granules and prevents their premature decay in P bodies (Stohr et 
al., 2006).  
The human fragile X mental retardation protein (FMRp) as well as its Drosophila homologue 
dFMR associates with Dicer, Ago2, miRNAs and other miRNA pathway components (Caudy 
et al., 2002; Ishizuka et al., 2002; Jin et al., 2004a; Jin et al., 2004b; Xu et al., 2008). 
Recently, it was further shown to be involved in the regulation of miRNA maturation as 
phosphorylation of FMRp precludes its binding to Dicer and results in an accumulation of 
80 nt RNA species, presumably pre-miRNAs (Cheever and Ceman, 2009). Consistently, 
FMRp and also FXR2 were found in Ago complex III which shows Dicer activity. However, 
this would rather suggest that FMRp and FXR2 associate with large translationally silenced 
mRNPs. FXR1, on the other hand, has been shown to enhance translation of AU-rich 
mRNAs together with Ago2 under specific cellular conditions (Vasudevan and Steitz, 2007). 
Interestingly, FXR1 is also present in our mass spectrometry data supporting the concept 
that Ago proteins interact with a variety of mRNPs and within such an interaction network 
specific proteins influence Ago activity. 
Notably, a number of proteins were identified with only one of the two Ago proteins. 
Especially mentionable is SART3, a protein implicated in pre-mRNA splicing and 
transcriptional regulation (Bell et al., 2002). SART3 was found with a comparatively high 
number of matched peptides in all three Ago1 complexes, but not at all with Ago2. Co-
immunoprecipitation approaches suggested a RNA-independent interaction. An exclusive 
binding to Ago1, however, could neither be verified by co-immunoprecipitation nor by in vitro 
pull-down experiments. The same is true for other proteins that seemingly co-purified with 
only one Ago protein. Further, it cannot be excluded that overexpression of tagged proteins 
in some cases interferes with endogenous interaction behavior. 
Generally, the present mass spectrometry data in combination with verifying experiments 
suggest that Ago1 and Ago2 bind a highly similar set of proteins. This is also affirmed by 
mass spectrometry data from another study on Ago3 and Ago4, though in this case analysis 
was restricted to visible protein bands in the SDS PAGE gel and therefore confines to a 
restricted view on associated protein factors (Weinmann et al., 2009). 
Meanwhile, proteins associated with Ago1-4, Dicer and TNRC6A-C as well as bound mRNAs 
were analyzed in another study (Landthaler et al., 2008). To a certain degree, its results 
resembled those of the present study. Besides a large number of hnRNPs, Landthaler and 
colleagues identified 6 DEAD/DExH-box containing proteins including DDX5 and RHA, but 
not DDX6, and a number of additional RNA binding proteins, e.g. IMP1 and -3, HuR and 
YB-1, and protein components of the small and large ribosomal subunits. Co-
immunoprecipitation results for YB-1, IMP3 and HuR were consistent with those of the 
present work. In general, the number of proteins listed in the above study is lower compared 
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to the present work. This could partly be attributed to differences in sample preparation, e.g. 
a double purification strategy that may reduce experimental noise but also might interfere 
with binding conditions thereby eliminating existing Ago-protein interactions. As also 
observed in the present work, Landthaler et al. report that the set of immunoprecipitated 
proteins is highly similar for Ago1 through -4. Further, also the set of mRNAs co-purifying 
with the four Ago proteins is strikingly similar, suggesting that Ago1-4 bind to similar mRNPs. 
This could also explain the high analogy detected on the proteomic level. Generally, the 
above study confirms the results obtained by the present work. 
 
Taken together, the present data suggest that miRNA-containing Ago complexes are 
recruited to miRNA target mRNAs that already carry a variety of different mRNA binding or 
regulatory proteins (Figure 42). Depending on the composition of such cytoplasmic RNPs, 
these regulatory units are either directed to P bodies or other cellular sites. Ago-containing 
miRNPs therefore contribute to a global mRNA regulatory network which is unique to each 
individual mRNA. MiRNP complexes are probably highly dynamic structures that are 
constantly rearranged in order to determine the fate of a given mRNA in response to 
environmental or cellular signals. Trans-acting factors establish a regulatory network that is 
able to fine-tune the translational regulation of specific mRNAs. Ideally, an investigation of 
miRNA function will therefore have to include the analysis of the whole protein network 
associated with a given mRNA. 
 
 
3.3. PTCD3 AS A NOVEL P BODY COMPONENT 
PTCD3, a member of the pentatricopeptide (PPR) domain protein family, was identified in 
complex II of Ago1 and Ago2. PPR domain proteins constitute a large protein family in 
plants, located mainly in mitochondria and chloroplasts. They are characterized by a 
degenerate 35-amino acid motif, repeated in tandem up to 30 times, that are supposed to 
bind RNA and act as platform for RNA processing complexes (reviewed in Schmitz-
Linneweber and Small 2008). In mammals, however, only seven PPR proteins were 
identified to date, all of which were predicted to be mitochondrial (Holzmann et al. 2008; 
Lightowlers and Chrzanowska-Lightowlers 2008). Still, a minor portion of the cellular pool of 
the PPR protein LRPPRC has been found to share RNA targets with hnRNP A1 in the 
nucleus, indicating a function outside mitochondria (Mili and Pinol-Roma 2003).  
The human PTCD3 protein has previously been reported to associate with the small subunit 
of the mitochondrial ribosome and to be involved in mitochondrial translation (Davies, 
Rackham et al. 2009). Surprisingly, in our hands, overexpressed PTCD3 co-localized with 
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co-expressed Ago2 as well as with endogenous Lsm4, indicating its localization in 
cytoplasmic P bodies. Also, co-immunoprecipitation experiments with overexpressed 
proteins indicated a RNA-independent interaction of PTCD3 with Ago1 and Ago2. However, 
PTCD3 depletion did not significantly interfere with luciferase levels of miRNA-regulated 
reporter constructs (not shown). While immunofluorescence results point towards PTCD3 as 
a new P body component, this finding will have to be further validated and an endogenous 
Ago-PTCD3 interaction will have to be characterized functionally to eliminate the possibility 
that the described observations might be attributed to overexpression. 
 
 
3.4. ANALYSIS OF AGO2-RBM4 INTERACTIONS 
Prior to this work, RBM4 had been reported to be a primarily nuclear RNA-binding protein 
with implications in alternative splicing and exon selection (Lai et al., 2003; Lin and Tarn, 
2005). Meanwhile, additional roles for RBM4 in translational regulation have been described 
(Kojima et al., 2007; Lin et al., 2007; Lin and Tarn, 2009). 
Co-immunoprecipitation experiments verified the interaction between Ago1/2 and RBM4 
identified by mass spectrometry. While RNase treatment decreased signal levels in these 
experiments, in vitro pull-down assays indicated a strong binding of GST-RBM4 to Ago1-4. 
However, when RNase was included in the pull-down sample, a signal decrease was 
detectable as well. Since the chosen conditions for the RNase treatment also destroyed Ago-
bound miRNAs, this might be attributed to a conformational change in the Ago protein upon 
target RNA binding which in turn may promote RBM4 binding.  
Also, in vitro binding to an Ago2 mutant deficient in miRNA binding (paz9; Liu et al., 2005) 
seemingly contradicts northern blotting results that demonstrate co-precipitation of 
endogenous miR-19b with FLAG/HA-RBM4 (compare Figure 31B and Figure 32). However, 
given the low miRNA levels in the RBM4-northern blot sample, co-purified miR-19b probably 
rather originated from associated endogenous Ago proteins than from direct binding of the 
miRNA to RBM4. 
Sucrose gradient centrifugation revealed that a large portion of endogenous RBM4 co-
migrated with Ago complex III and associated mRNPs, which is consistent with a role of 
RBM4 in translational regulation. Still, RBM4 was also found to co-sediment with Ago 
complexes I and II. Corresponding with aforementioned reports (Lai et al., 2003; Markus and 
Morris, 2006), RBM4 was also detected in low-molecular weight fractions of nuclear extracts. 
To identify the protein domains involved in binding of Ago2 to RBM4, in vitro pull-down 
experiments were performed with a number of protein fragments and mutants. These studies 
revealed that on the Ago2 side, interaction is mainly mediated by the PIWI domain, with a 
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minor additional signal from the N-terminal domain. Within the RBM4 protein, the minimal 
Ago binding domains include the second RNA recognition motif (RRM2), the CCHC-type 
Zn finger domain and the intermediate second linker sequence (L2, Figure 43). Pull-down 
experiments from wild-type HEK 293 lysates using immobilized recombinant GST-RBM4 
mutants confirmed the in vitro data.  
 
 
Figure 43: Ago2-RBM4 interaction model on a common target mRNA 
 
Besides RBM4, the Ago2 PIWI domain is also bound by the miRNA-processing enzyme 
Dicer (Tahbaz et al., 2004). This raised the question whether RBM4 might compete with 
Dicer for Ago binding due to sterical hindrances. To address this, Ago2 was precipitated from 
HEK 293 lysates supplemented with various amounts of GST-RBM4 and levels of co-
precipitated endogenous Dicer were analyzed. However, no changes could be detected in 
Dicer levels. Also, neither Dicer- nor RISC activity was altered upon GST-RBM4 addition, 
indicating that RBM4 binding does not prevent Dicer binding to Ago2 and functions aside 
small RNA maturation and siRNA-mediated RNA cleavage (Figure 44). Still, Dicer was not 
very efficient in these assays. 
The finding that RBM4 binds to Ago2 via the RRM2-L2-Zn finger domains is in contrast to 
previous reports, claiming that protein-protein interaction is mediated by the alanine-rich C-
terminal domain of RBM4 (Lai et al., 2003). However, previous studies in Drosophila stated 
that the RRM2 as well as the Zn-finger domain of the Drosophila homologue LARK are 
involved in translational repression (McNeil et al., 2001). This would be consistent with a 
proposed role of this RBM4 part in Ago binding and consequently in miRNA-mediated 
translational repression. 
RNA recognition motifs have been shown to have different RNA and/or protein binding 
properties depending on their exact sequence and structure (Maris et al., 2005; Eulalio et al., 
2009b). Given that a considerable number of proteins identified in the mass spectrometry 
approach carry RRM domains, it would be tempting to speculate that these domains function 
as a general binding platform that guides Ago proteins to their target mRNAs. To investigate 
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the importance of these domains in some of the further identified Ago interactors, in vitro pull-
down assays were performed with RRM-deletion mutants of SART3, Matrin3 and IMP3. 
However, no effect on Ago binding could be detected in either of the mutants, indicating that 
Ago binding is conveyed by structures other than the RRM domain in these proteins. 
 
 
 
Figure 44: Model of putative RBM4 functions in concert with Ago proteins 
RBM4 binds Ago proteins as well as RNA and presumably stabilizes Ago binding to a target mRNA and enhances 
translational repression. Involvement of RBM4 in small RNA processing or mRNA cleavage was not observed. 
 
To elucidate the exact mode of Ago binding to RBM4 and the function of the individual 
domains in the RBM4 binding properties, it would now be interesting to perform a structural 
analysis of Ago or its PIWI domain together with the minimal binding RBM4 fragment (RRM2-
L2-Zn finger) on a common target mRNA.  
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3.5. APPROACHES TO IDENTIFY mRNA TARGETS COMMON TO AGO2 AND 
RBM4 PROTEINS 
Besides its usefulness for structural investigations, the identification of mRNA targets 
common to RBM4 and Ago proteins would also be interesting in terms of a closer 
biochemical characterization of the in vivo binding and interaction properties of the proteins. 
To demonstrate the functional relevance of RBM4 in miRNA-guided translational regulation, 
luciferase reporter constructs carrying the 3‟-UTR of several Ago targets were used. RBM4 
as well as TNRC6B knock-down in these experiments resulted in an increase of the 
luciferase signal, indicating that RBM4 is indeed involved in translational repression. 
However, to identify a common RBM4 and Ago target that shows stronger regulation, several 
additional constructs were tested.  
It was shown that the RBM4 homologue LARK regulates expression of the circadian clock 
protein Period1 (Per1) in mouse by binding to the 3‟-UTR of the Per1 mRNA (Kojima et al., 
2007). Moreover, the Flotillin1 (FLOT1) and RhoC 3‟-UTRs were identified as RBM4 targets 
(Lin and Tarn, 2005). A miRNA database check revealed several predicted miRNA binding 
sites in all of these 3‟-UTR sequences, suggesting miRNA-guided regulation in addition to 
RBM4 binding. However, knock-down of RBM4 did not significantly increase luciferase 
levels. As, furthermore, neither transfection of inhibitory 2‟OMe antisense oligonucleotides 
nor knock-down of TNRC6B – which served as a positive control – showed effects on the 
luciferase signals, Per1, FLOT1 and RhoC could not be proven to be regulated by the 
miRNA pathway and therefore seemed unsuitable for further investigations on RBM4-Ago 
interactions. 
Reports about RNA binding preferences of RBM4 are controversial. While Huang et al. 
claimed that the Drosophila homologue LARK precipitated A-rich elements with one or more 
“ACAAA” motifs, Lin and Tarn identified RBM4 binding to CU-rich RNA elements (Lin and 
Tarn, 2005; Huang et al., 2007). Based on a newly developed method called “RNAcompete” 
and subsequent bioinformatical data analysis, the labs of Morris and Hughes identified a 
binding preference of RBM4 to GC-rich sequences within an unstructured RNA context (Ray 
et al., 2009; Kazan et al., 2010). Data from anisotropy measurements obtained in 
collaboration with Birgitta Wöhrl (University of Bayreuth) using the RBM4 Δ4 mutant and 
short CU-rich RNA oligonucleotides yielded KD values in the lower micromolar range, 
indicating a rather weak binding of RBM4 to these RNA sequences (Ströh, 2009). 
Unfortunately, GC-rich sequences were not included in the measurements. Based on these 
data, artificial reporter constructs were created carrying a miR-21 binding site and the 
putative RBM4 binding motifs (either CU- or GC-rich) within a 190 nt arbitrary DNA sequence 
lacking further miRNA binding sites. However, specific regulation of the luciferase levels 
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could not be observed with any of these reporter constructs. To test for the effect of RBM4 
binding in a more natural setting, the putative RBM4 binding motifs were introduced into the 
HMGA2 3‟-UTR reporter construct. Though knock-down of RBM4 increased HMGA2-coupled 
luciferase levels as expected, the introduction of RBM4 binding motifs could not further 
enhance this effect. Notably, also a reporter construct carrying the mutated HMGA2 3‟-UTR 
lacking let-7a binding sites was up-regulated in RBM4-depleted cells, but not in TNRC6B 
knock-down cells, pointing towards a general effect of RBM4 in translation regulation rather 
than specific miRNA-mediated repression in this setting. Still, RBM4 could immunoprecipitate 
both RNA A- (CU-rich motif) and RNA G-(GC-rich motif) containing HMGA2 reporter mRNA 
from HEK 293 lysates, unfortunately not providing further convincing evidence for either 
binding motif. However, as the RNA A-motif is flanked by G residues, it cannot be excluded 
that the presence of these residues may have influenced RBM4 binding. Together, 
requirements for RBM4 binding and interaction with Ago proteins are obviously more 
complex and cannot easily be simulated based on the current knowledge. Apart from the 
controversial reports concerning RBM4 binding preferences, it is yet unknown in which 
distance RBM4 binding to the RNA takes place with respect to miRNA sites or whether the 
presence of several miRNA or RBM4 binding sites might influence protein interaction and 
subsequent target mRNA regulation. Against this background, it would be even more 
interesting to identify common natural targets of RBM4 and Ago proteins.  
In a first attempt to achieve this, the PAR-CLiP method (Hafner et al., 2010) has been 
applied to mRNAs that co-purified with endogenous RBM4. In this method, photoactivatable 
4-thiouridine was incorporated into cellular mRNA transcripts, followed by UV-induced cross-
linking of these transcripts to associated proteins. After partial RNase T1 digestion, RNA 
fragments bound to RBM4 were radioactively labeled at the 5‟ end and subjected to SDS-
PAGE. After removal of protein components, RNA was reverse transcribed, amplified and 
used for Solexa sequencing to identify RNA identity and, simultaneously, the RNA motif 
bound by RBM4. Surprisingly, only little RNA fragments could be annotated to mRNA 
sequences, while the rRNA fraction was disproportionally high (Mihaela Zavolan, University 
of Basel, personal communication). This could be explained on the one hand by a severe 
depletion of uridine residues in the RBM4 binding motif – assuming a preference of RBM4 for 
GC-rich RNA sequences – resulting in low cross-linking efficiencies using 4-thiouridine. On 
the other hand, treatment of immunoprecipitated RBM4 targets with RNase T1, which cuts 
RNA after G residues, might lead to an over-digestion of the RNA fragments providing 
fragments that are too short for sequencing or mapping. While these preliminary results point 
towards a preference of RBM4 to GC-rich RNA sequences, the experiment will have to be 
modified in order to confirm this theory and to identify shared RBM4-Ago mRNA targets, 
allowing for a more detailed analysis of the action and interaction mode of these proteins. 
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Notably, a recent publication from the Tarn lab has underlined the relevance of RBM4 for 
Ago-mediated translational repression (Lin and Tarn, 2009). The authors demonstrated that 
RBM4 is phosphorylated upon cell differentiation of murine myoblasts and transiently 
translocates to cytoplasmic granules where it co-localizes with P body components as 
GW182, DCP1 or Ago2. RBM4 was further shown to associate with certain muscle-specific 
miRNAs upon differentiation and overexpression of RBM4 resulted in repression of a target 
reporter construct in a dose-dependent manner (Lin and Tarn, 2009), similar to the effects 
observed with the KRAS 3‟-UTR construct (Figure 28). Further immunoprecipitation and 
reporter assay approaches implied that RBM4 might enhance association of Ago-miRNA 
complexes with their target mRNA, presumably by promoting or stabilizing the interaction. 
However, overexpression of RBM4 probably also had general effects on translation as 
transient expression of RBM4 in HEK 293 cells which lack endogenous miR-1 resulted in 
down-regulation of a miR-1 reporter construct. This was also detectable with a natural target 
construct carrying a miR-1 binding site. Still, co-expression of miR-1 and RBM4 further 
enhanced the inhibitory effect conveyed by miR-1 or RBM4 expression alone. Notably, all of 
these experiments were performed in an overexpression background with an ectopically 
expressed miRNA. Therefore, further studies on this topic using a more natural setting are 
still elusive, which again underlines the importance of identifying natural mRNA targets that 
are simultaneously regulated by RBM4 and the miRNA machinery. 
Interestingly, while the above study suggests that RBM4 promotes Ago binding to a target 
mRNA and to enforce miRNA-mediated translational regulation, the Drosophila RBM4 
homologue LARK has been shown to physically interact with and stabilize dFMR, collectively 
regulating eye development as well as circadian behavior in flies (Sofola et al., 2008). FMRp 
is also a known component of the miRNA machinery in Drosophila and humans (Meister and 
Tuschl, 2004, Table 1), hence it would be tempting to speculate that RBM4 and FMRp work 
together with Ago proteins in miRNA-guided regulatory processes. As, depending on its 
phosphorylation status, FMRp also seems to have an effect on miRNA maturation (Cheever 
and Ceman, 2009), it might provide a link between miRNA function and processing in a more 
complex chain of regulatory events within the cell, presumably involving a number of 
additional protein factors whose role is yet unknown. 
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4. MATERIALS AND METHODS 
4.1. MATERIALS 
4.1.1. Chemicals and enzymes 
Unless stated otherwise, chemicals were purchased from Amersham Biosciences 
(Buckinghamshire, UK), Applichem (Darmstadt, Germany), Biorad (Hercules, USA), Merck 
(Darmstadt, Germany), Qiagen (Hilden, Germany), Roth (Karlsruhe, Germany) and Sigma-
Aldrich (Munich, Germany).  
Radiochemicals were purchased from Perkin Elmer (Waltham, USA), enzymes from New 
England Biolabs (Ipswich, USA) and Fermentas (Burlington, Canada). 
DNA oligonucleotides were ordered from Metabion (Martinsried, Germany), siRNAs and 
2‟OMe-oligonucleotides were produced by in-house service facilities. 
 
 
4.1.2. Plasmids 
pCS2-myc6-FA 
encodes for an N-terminal myc6-tag and a FseI-AscI cloning cassette (donation from O. 
Stemmann, University of Bayreuth) 
pET28a encodes for N- and C-terminal His-tag (Novagen, Bloemfontein, South Africa) 
pGEX6P-1 encodes for an N-terminal GST-tag (Amersham-Pharmacia) 
pIRES-VP5 encodes for an N-terminal Flag/HA tag (Meister et al., 2004) 
pMIR-RNL 
is modified from the commercially available pMIR-REPORT vector (Ambion; Beitzinger et 
al., 2007). It encodes for the Phototinus pylaris luciferase (termed firefly in this work) 
under the control of a CMV promotor. A Renilla reniformis luciferase (termed renilla) 
under the control of a SV40 promotor was PCR-amplified from the pRL-SV40 plasmid 
(Promega, Madison, USA) and inserted into the SspI site of pMIR-REPORT. The firefly 
coding sequence is flanked by a multiple cloning site (MCS) at its 3‟ end, allowing for the 
introduction of regulatory sequences into the 3‟-UTR. 
pMIR-RNL-Tk 
is based on the pMIR-RNL vector. The CMV promotor of the firefly luciferase was 
replaced by a HSV-Tk promotor which was PCR-cloned from the pRL-Tk plasmid 
(Promega, Madison, USA). 
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4.1.3. Antibodies 
Antigen Source Dilution Application 
Reference / 
Manufacturer 
α-Ago1 1C9 
rat hybridoma supernatant, 
monoclonal  
1:10 WB 
(Beitzinger et al., 
2007) 
α-Ago2 11A9 
rat hybridoma supernatant, 
monoclonal  
1:50 WB (Rudel et al., 2008) 
α-alpha-tubulin mouse, monoclonal 1:5000 WB Sigma-Aldrich  
α-Ddb1 goat, polyclonal 1:500 WB Serotec 
α-DDX5 goat, polyclonal 1:2000 WB Abcam 
α-Dicer 13D6 mouse, monoclonal 1:1000 WB Abcam 
α-HA 16B12 mouse, monoclonal HA.11 
1:1000 
1:200 
WB 
IF 
Covance 
α-hnRNP C1/C2 4F4 mouse, monoclonal  1:1000 WB Abcam 
α-hnRNP U 3G6 mouse, monoclonal  1:1000 WB Abcam 
α-IMP1 rabbit, monoclonal 1:1000 WB 
kindly provided by S. 
Hüttelmayer, 
University of Halle 
(Huttelmaier et al., 
2005) 
α-IMP3 rabbit, monoclonal 1:1000 WB 
kindly provided by S. 
Hüttelmayer, 
University of Halle 
α-Lsm4 chicken, monoclonal 1:200 IF Geneway 
α-myc rabbit, polyclonal 
1:3000 
1:200 
WB 
IF 
Sigma 
α-NF-45 rabbit, polyclonal 1:1000 WB (Isken et al., 2007) 
α-NF-90 rabbit, polyclonal 1:1000 WB (Isken et al., 2007) 
α-RBM4 6E10 
rat hybridoma supernatant, 
monoclonal 
1:10 WB (Pfuhl et al., 2008) 
α-RCC1 rabbit, polyclonal  1:2000 WB (Hetzer et al., 2000) 
α-RmC 16D2 rat, monoclonal undiluted IP 
E. Kremmer, 
Helmholtz-Zentrum, 
Munich 
α-rpS6 rabbit, monoclonal 1:1000 WB Cell signaling tech. 
α-SART3 rabbit, polyclonal 1:125 WB this work 
α-SMNRP 7B10 mouse, monoclonal  1:1000 WB (Meister et al., 2000) 
α-TRBP rabbit, polyclonal 1:125 WB (Loef, 2006) 
α-YB-1 rabbit, polyclonal 1:1000 WB Abcam 
α-chicken IgG, 
FITC-conjugated 
rabbit, polyclonal 1:500 IF Sigma 
α-goat IgG, 
peroxidase conjugated 
rabbit, polyclonal 1:5000 WB Abcam 
α-mouse IgG, 
TexasRed-conjugated 
horse, polyclonal 1:500 IF Vector laboratories 
 MATERIALS & METHODS  
86 
 
Antigen Source Dilution Application 
Reference / 
Manufacturer 
α-mouse IgG, 
peroxidase conjugated 
goat, polyclonal 1:5000 WB Sigma 
α-rabbit IgG, 
FITC-conjugated 
goat, polyclonal 1:500 IF Sigma 
α-rabbit IgG, 
peroxidase conjugated 
goat, polyclonal 1:7500 WB Sigma 
α-rat IgG, 
peroxidase conjugated 
goat, polyclonal 1:5000 WB Jackson laboratories 
 
 
4.1.4. Bacterial strains and cell lines 
cell lines: 
HEK 293 
HeLa 
bacterial strains: 
E. coli XL1 blue 
E. coli BL21 
 
 
4.1.5. Cell culture media 
For cultivation of cell lines, the following medium was used:   
DMEM complete 
500 ml 
10% 
1% 
DMEM (PAA, Pasching, Austria) 
fetal bovine serum (Biochrom, Berlin, Germany) 
Penicillin/Streptomycin (PAA, Pasching, Austria) 
OptiMEM (Invitrogen)   
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4.1.6. Buffers and solutions 
DNA loading dye (5x) 
15 g 
50 ml 
0.025 % 
Saccharose 
H2O 
Xylene cyanol 
RNA loading dye (1x) 
90 % 
0.025 % 
0.025 % 
Formamide 
Xylene cyanol 
Bromophenol blue 
in 1x TBE 
Protein sample buffer (4x) 
400 mM 
5 mM 
50 % 
1 % 
0.01 % 
Tris pH 6.8 
EDTA 
Glycerol 
SDS 
Bromophenol blue 
Coomassie staining solution 
45 % (v/v) 
10 % (v/v) 
0.35 % (w/v) 
methanol 
acetic acid 
Coomassie brilliant blue G250 
Coomassie destaining solution 
30 % (v/v) 
10 % (v/v) 
methanol 
acetic acid 
LB (lysogenic broth) medium 
1 % (w/v) 
1 % (w/v) 
0.5 % (w/v) 
Trpyton 
NaCl 
Yeast extract 
Phosphate buffered saline (PBS) 
130 mM 
774 mM 
226 mM 
NaCl  
Na2HPO4 
NaH2PO4 
TBE buffer (1x) 
89 mM 
89 mM 
2.5 mM 
Tris pH 8.3 
boric acid 
EDTA 
5 % stacking gel  
(SDS-PAGE) 
5 % 
75 mM 
0.1 % 
0.1 %  
0.05 % 
Acrylamide-Bis solution (37.5:1, 30 % w/v) (Serva) 
Tris-HCl pH 6.8 
SDS 
APS  
TEMED 
10 % separation gel  
(SDS-PAGE) 
10 % 
400 mM 
0.1 % 
0.1 %  
0.05 % 
Acrylamide-Bis solution (37.5:1, 30 % w/v) (Serva) 
1.5 M Tris-HCl pH 8.8 
SDS 
APS  
TEMED 
SDS running buffer (1x) 
200 mM 
25 mM 
25 mM 
Glycine 
Tris pH 7.5 
SDS 
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Towbin buffer  
(1x, for semi-dry western blotting) 
38,6 mM 
48 mM 
0.0037 % (w/v) 
20 % 
Glycine 
Tris 
SDS 
Methanol 
Wash buffer  
(for western blotting ) 
300 mM 
150 mM 
0.25 % 
Tris pH 7.5 
NaCl 
Tween-20 
Chemiluminescence detection 
100 mM  
1.2 mM 
 
0.68 % 
Tris pH 8.5 
Luminol                                                                in 10 ml 
 
p-cumaric acid                                                    in 150 l 
H2O2 (30 %)                                                             11 l 
components were mixed directly before use 
2x HEPES  
(for calcium phosphate transfection) 
274 mM 
54.6 mM 
1.5 mM 
NaCl 
HEPES 
Na2HPO4 
Cell lysis buffer 
150 mM 
25 mM 
2 mM 
1 mM 
0.5 mM 
0.5 % 
KCl 
Tris pH 7.5 
EDTA 
NaF 
DTT 
NP-40 
Roeder A buffer 
10 mM 
10 mM 
1.5 mM 
0.5 mM 
0.5 mM  
Hepes-KOH pH 7.9 
KCl 
MgCl2 
DTT 
PMSF 
Roeder C low buffer 
5 % (v/v) 
420 mM 
1.5 mM 
0.5 mM 
0.2 mM 
20 mM 
0.5 mM 
Glycerol 
KCl 
MgCl2 
DTT 
EDTA 
Hepes-KOH pH 7.9 
PMSF 
Dicer lysis buffer 
150 mM 
20 mM 
0.25 % 
1.5 mM 
0.5 mM 
NaCl 
Tris pH 7.5 
NP-40 
MgCl2 
AEBSF 
Lysis buffer  
(for polysome gradients) 
1/10 V 
0.5 % 
0.5 % 
60 U/ml 
3 mM 
10x hypotonic buffer 
Triton X-100 
Na-deoxycholate 
Ribolock 
DTT 
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Hypotonic buffer 
(10x, for polysome gradients) 
50 mM 
15 mM 
25 mM 
Tris pH 7.5 
KCl 
MgCl2 
Polysome gradient buffer  
20 mM 
80 mM 
5 mM 
Tris pH 7.5 
NaCl 
MgCl2 
Gradient buffer (10x) 
1.5 M 
0.25 M 
20 mM 
KCl 
Tris pH 7.5 
EDTA 
IP wash buffer 
300 mM 
50 mM 
5 mM 
0.05 % 
NaCl 
Tris pH 7.5 
MgCl2 
NP-40 
8% denaturing RNA gel  
(RNA-PAGE) 
 
32 % 
 
58 % 
10 % 
0.1 % 
0.05 % 
SequaGel Concentrate (national diagnostics, Atlanta, 
USA) 
SequaGel Diluent 
SequaGel Buffer  
APS 
TEMED 
TM buffer for 5‟-cap labeling 
1 mM 
0.2 mM 
10 U/ml 
100 mM 
1.5 mM 
0.5 mM 
ATP 
GTP 
Ribolock 
KCl 
MgCl2 
DTT 
Urea buffer for T1 digestion 
10 M 
1.5 mM 
0.05 % 
0.05 % 
Urea 
EDTA 
Bromophenol blue 
Xylene cyanol 
Elution buffer 
300 mM 
2 mM 
NaCl 
EDTA 
Proteinase K buffer 
300 mM 
200 mM 
25 mM 
2 % 
NaCl 
Tris pH 7.5 
EDTA 
SDS 
Proteinase K storage buffer 
20 mg/ml 
50 mM 
1 mM 
50 % (v/v) 
Proteinase K 
Tris, pH 8.0 
CaCl2 
Glycerol 
Hybridization solution 
7.5 ml 
0.6 ml 
21 ml 
0.6 ml 
0.3 ml 
20x SSC 
1M Na2HPO4, pH 7.2 
10% SDS 
50x Denhardt´s solution 
Sonicated salmon sperm DNA (10mg/ml) 
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20x SSC 
3 M 
0.3 M 
NaCl 
Sodium citrate 
adjust pH to 7.1 
Denhardt´s solution (50x) 
1 % 
1 % 
1 % 
Albumin fraction V 
Polyvinylpyrrolidon K30 
Ficoll 400 
Lysis buffer pH 7.5  
(for recombinant protein expression) 
500 mM 
50 mM 
5 mM 
NaCl 
Tris pH 7.5 
MgCl2 
Wash buffer pH 8.0  
(for recombinant protein expression) 
500 mM 
50 mM 
5 mM 
NaCl 
Tris pH 8.0 
MgCl2 
Renilla buffer 
2.2 mM 
220 mM 
0.44 mg/ml 
1.1 M 
1.3 mM 
1.43 M 
EDTA 
K2PO4 pH 5.1 
BSA 
NaCl 
NaN3 
Coelenterazine (P.J.K. GmbH, Kleinblitterdorf, 
Germany) 
Firefly buffer 
470 M 
530 M 
270 M 
20 mM 
5.34 mM 
0.1 mM 
33.3 mM 
D-Luciferine (P.J.K. GmbH, Kleinblitterdorf, Germany)  
ATP (P.J.K. GmbH) 
Coenzyme A (P.J.K. GmbH) 
Tricine 
Magnesiumsulfate heptahydrate 
EDTA 
DTT 
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4.2. METHODS 
4.2.1. Molecular biological methods 
4.2.1.1. General methods 
Molecular biological methods (DNA/RNA gel electrophoresis, -extraction, -precipitation and 
concentration determination of nucleic acid, PCR, etc.) that are not described in detail here, 
were performed as described in Sambrook et al. (Sambrook, 1989) or according to the 
manufacturer´s instructions. There, also the composition of buffers and solutions not listed 
above can be found.  
Plasmid DNA from E. coli was isolated using the “Plasmid MiniKit I” (Omega BioTek, 
Darmstadt, Germany) or the “NucleoBond Xtra Midi”-Kit (Macherey Nagel, Düren, Germany). 
For elution of DNA fragments from agarose gels, the “NucleoSpin”-Kit (Macherey Nagel, 
Darmstadt, Germany) was used. RNA isolation from cells was carried out using the “Prep 
Ease RNA Spin Kit” (USB, High Wycombe, UK). 
Transformation of Plasmid-DNA into E. coli strains XL1 Blue and BL21(DE) was performed 
according to the calcium phosphate method (Sambrook, 1989). 
 
4.2.1.2. Cloning of protein-coding DNA fragments from human cDNA 
libraries 
To amplify cDNAs for the protein expression constructs used in this work, the “Human Brain 
(whole) Marathon-Ready cDNA” library (Clontech, Mountain View, USA) was used as 
template in a polymerase chain reaction (PCR). Specific primers were designed to carry 
restriction sites for the restriction enyzmes used in the cloning reaction at their 5‟- or 3‟-ends, 
respectively. PCR amplifications were performed using the Phusion Polymerase (Finnzymes, 
Espoo, Finland). PCR products were cloned into vectors that allow for protein expression in 
cell culture (pIRES-VP5, pCS2-myc6-FA, pDEST puro) or bacterial cultures (pGEX6P-1, 
pET28a) as well as in vitro coupled T7-transcription/translation (pET28a). Based on the 
cDNA constructs, mutants were cloned in an analogous manner. 
The following table lists the protein coding constructs used in this thesis. 
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Table 6: protein coding plasmid constructs 
protein 
amino 
acids 
construct plasmid 
5’-/3’- 
restriction 
site 
changes in 
amino acid 
sequence 
Ago1 1-857 FH-Ago1 pIRES-VP5 NotI/EcoRI - 
  myc-Ago1 pCS2-myc6-FA FseI/AscI - 
  His-Ago1 pET28a EcoRI/NotI - 
Ago2 1-859 FH-Ago2 pIRES-VP5 NotI/EcoRI - 
  myc-Ago2 pCS2-myc6-FA FseI/AscI - 
  His-Ago2 pET28a EcoRI/NotI - 
 1-226 His-A2 N pET28a EcoRI/NotI - 
 227-371 His-A2 MID pET28a EcoRI/NotI - 
 372-516 His-A2 PAZ pET28a EcoRI/NotI - 
 372-516 His-A2 paz9 pET28a EcoRI/NotI (Liu et al., 2005) 
 517-817 His-A2 PIWI pET28a EcoRI/NotI - 
Ago3 1-860 FH-Ago3 pIRES-VP5 NotI/EcoRI - 
  His-Ago3 pET28a EcoRI/NotI - 
Ago4 1-861 FH-Ago4 pIRES-VP5 NotI/EcoRI - 
  His-Ago4 pET28a EcoRI/NotI - 
DDX5 1-614 FH-DDX5 pIRES-VP5 NotI/BamHI - 
DDX30 1-1252 FH-DDX30 pIRES-VP5 NotI/EcoRI - 
DDX47 1-455 FH-DDX47 pIRES-VP5 NotI/EcoRI - 
DHX36 1-979 FH-DHX36 pIRES-VP5 NotI/BamHI - 
  GST-DHX36 pGEX6P-1 BamHI/XhoI - 
Dicer 1-1922 FH-Dicer pDEST puro  - 
GFP 1-239 FH-GFP pIRES-VP5 NotI/EcoRI - 
  myc-GFP pCS2-myc6-FA FseI/AscI - 
hnRNP C  FH-hnRNP C pIRES-VP5 NotI/EcoRI - 
hnRNP U 1-824 FH-hnRNP U pIRES-VP5 NotI/EcoRI - 
HuR 1-326 FH-HuR pIRES-VP5 NotI/EcoRI - 
IMP1 1-577 FH-IMP1 pIRES-VP5 NotI/EcoRI - 
IMP3 1-579 FH-IMP3 pIRES-VP5 NotI/EcoRI - 
  GST-IMP3 pGEX6P-1 EcoRI/XhoI - 
 72-579 GST-IMP3 RRM pGEX6P-1 EcoRI/XhoI  1-71 
Importin8 1-1037 FH-Importin8 pIRES-VP5 NotI/BamHI - 
  GST-Importin8 pGEX6P-1 BamHI/NotI - 
Matrin3 1-847 FH-Matrin3 pIRES-VP5 NotI/BamHI - 
  GST-Matrin3 pGEX6P-1 BamHI/NotI - 
  
GST-Matrin3 
RRM 
pGEX6P-1 BamHI/NotI  497-567 
PABP-C1 1-636 FH-PABP-C1 pIRES-VP5 NotI/BamHI - 
PACT 1-313 GST-PACT pGEX6P-1 BamHI/XhoI - 
PTCD3 1-689 FH-PTCD3 pIRES-VP5 NotI/EcoRI - 
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protein 
amino 
acids 
construct plasmid 
5’-/3’- 
restriction 
site 
changes in 
amino acid 
sequence 
PTCD3  GST-PTCD3 pGEX6P-1 BamHI/XhoI - 
RBM4 1-364 FH-RBM4 pIRES-VP5 NotI/BamHI - 
  GST-RBM4 pGEX6P-1 BamHI/XhoI - 
 145-364 GST-RBM4 RRM pGEX6P-1 BamHI/XhoI  1-144 
 177-364 GST-RBM4 N pGEX6P-1 BamHI/XhoI  1-176 
 1-176 GST-RBM4 C pGEX6P-1 BamHI/XhoI  177-364 
 1-159 
GST-RBM4 
RRM+L2 
pGEX6P-1 BamHI/XhoI  160-364 
 3-68 GST-RBM4 1 pGEX6P-1 BamHI/XhoI  1-2, 69-364 
 79-144 GST-RBM4 2 pGEX6P-1 BamHI/XhoI  1-78, 145-364 
 1-176 GST-RBM4 3 pGEX6P-1 BamHI/XhoI  77-144 
 69-176 GST-RBM4 4 pGEX6P-1 BamHI/XhoI  1-68, 177-364 
 160-176 GST-RBM4 5 pGEX6P-1 BamHI/XhoI  1-159, 177-364 
 1-364 GST-RBM4 6 pGEX6P-1 BamHI/XhoI  160-179 
 69-364 GST-RBM4 7 pGEX6P-1 BamHI/XhoI  1-68 
 1-364 GST-RBM4 8 pGEX6P-1 BamHI/XhoI  77-144 
 1-144 GST-RBM4 9 pGEX6P-1 BamHI/XhoI  145-364 
 1-364 GST-RBM4 10 pGEX6P-1 BamHI/XhoI 
aa 145-159 
replaced by 
AAAAAAAGAAA
AAAA 
 69-215 GST-RBM4 11 pGEX6P-1 BamHI/XhoI  1-68, 216-364 
 1-215 GST-RBM4 12 pGEX6P-1 BamHI/XhoI  216-364 
 1-215 GST-RBM4 13 pGEX6P-1 BamHI/XhoI  77-144 
 1-364 GST-RBM4 14 pGEX6P-1 BamHI/XhoI 
Cys162 and Cys165 
mutated to Tyr 
 1-364 GST-RBM4 15 pGEX6P-1 BamHI/XhoI 
domain swap 
RRM1RRM2 
RHA/DHX9 1-1270 FH-RHA pIRES-VP5 NotI/BamHI - 
SART3 1-963 FH-SART3 pIRES-VP5 NotI/EcoRI - 
  GST-SART3 pGEX6P-1 EcoRI/XhoI - 
  
GST-SART3 
RRM 
pGEX6P-1 EcoRI/XhoI  802-873 
Sip1 1-280 His-Sip1 pET28a BamHI/NotI - 
TRBP 1-345 GST-TRBP pGEX6P-1 BamHI/NotI - 
UPF1/RENT1 1-1118 FH-UPF1 pIRES-VP5 NotI/EcoRI - 
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4.2.1.3.  Cloning of luciferase reporter constructs 
The constructs used for luciferase reporter assays are based on the pMIR-REPORT miRNA 
reporter plasmid (Ambion). Modifications to this vector have been described in section 4.1.2. 
To yield the miR-21 cleavage reporter construct, the following DNA oligonucleotides were 
annealed, digested with SacI and NaeI and inserted into the SacI and NaeI restriction sites of 
the pMIR-RNL-Tk vector: 5‟-CGCTGAGCTCATCGCCACCTTGTTTAAGCCTCAACATC 
AGTCTGATAAGCTAATTAGACCTACGCACTCCAGGCCGGCTCGC-3‟ and 5‟-GCGAGCCG 
GCCTGGAGTGCGTAGGTCTAATTAGCTTATCAGACTGATGTTGAGGCTTAAACAAGGTG
GCGATGAGCTCAGCG-3‟. Analogously, a construct carrying a mutated miR-21 binding site 
was cloned using the following DNA oligonucleotides: 
5‟-CGCTGAGCTCATCGCCACCTTGTTTAAGCCTCAACATCAGCACCATTCTATAATTAGA
CCTACGCACTCCAGGCCGGCTCGC-3‟ and 5‟-GCGAGCCGGCCTGGAGTGCGTAGGT 
CTAATTATAGAATGGTGCTGATGTTGAGGCTTAAACAAGGTGGCGATGAGCTCAGCG-3‟. 
A 3‟-UTR fragment from the KRAS mRNA was PCR-amplified from a published construct 
(Johnson et al., 2005) and inserted into the SacI and NaeI restriction sites of the pMIR-RNL-
Tk vector. The SERBP1, DNAJB11 and Raver2 reporter constructs have been reported 
before (Beitzinger et al., 2007). Additionally, the HMGA2 3‟-UTR sequence was PCR 
amplified from HEK 293 cDNA using oligonucleotides 5‟-CTCTGAGCTCTACTAATA 
GTTTGTTGATCTG-3‟ and 5‟-CGCTGCCGGCGACCAAACTTTATTACTCATT-3‟ and cloned 
into the pMIR-RNL-Tk construct via the SacI and NaeI restriction sites. An HMGA2 3‟-UTR 
reporter construct with mutated let-7a binding sites (Weinmann et al., 2009) was used as 
control. 
FLOT1-, RhoC- and Per1 3‟-UTRs were cloned into the pMIR-RNL-Tk vector via the SacI 
and NaeI restriction sites accordingly. 
To produce an artificial 3‟-UTR containing a miR-21 binding site as well as a putative RBM4 
binding site, a random 190 nt-sequence was created using the website 
http://www.bioinformatics.org/sms2/random_dna.html. A miR-21 binding site 
(5‟-TCAACATCAGTCTGATAAGCTA-3‟) was placed in position 51-72 and the potential 
RBM4 binding motifs RNA A (5‟-GGTCTCTCTG-3‟), RNA C (5‟-TGCTCTTTA-3‟) or RNA G 
(5‟-GGCGCGGGC-3‟) in position 131-140 of the 3‟-UTR. According to miRBase, this 
sequence did not harbor any miRNA sites except the miR-21 binding site. Additionally, a 
construct carrying a control RNA (5‟-GGAAAAAAAG-3‟, ctrl. I) was created. In another 
control plasmid, the miR-21 binding site was replaced by a mutated sequence 
(5‟-TCAACATCAGCACCATTCTATA-3‟, ctrl. II) besides the control RNA sequence. DNA 
fragments were cloned into the pMIR-RNL vector using the SacI and NaeI restriction sites. 
The putative RBM4 binding motifs were introduced into the HMGA2 3‟-UTR by PCR-based 
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mutagenesis in position 1471-1480 of the 3‟-UTR sequence. This sequence alteration did 
neither interfere with known let-7 binding sites nor with additional miRNA sites as identified 
by PicTar or TargetScan. The PCR product was inserted into the SacI and NaeI restriction 
sites of the pMIR-RNL plasmid. 
 
4.2.1.4. Preparation of cell extracts 
Standard cell extracts were prepared by scraping cells in 500 μl/15 cm dish cell lysis buffer. 
Cell debris was sedimented in a 10-minute centrifugation at 17000 g and 4 °C and 
supernatants were transferred to new reaction tubes. 
For Dicer assays, cell lysates were prepared in the same way, except that EDTA-free Dicer 
lysis buffer was used.  
Polyribosome fractionation from HEK 293 cells was carried out according to Pillai et al. (Pillai 
et al., 2005). For lysate preparation, cells were treated for 5 minutes with 100 μg/ml 
cyclohexamide to block translation and washed once with PBS and 1x hypotonic lysis buffer, 
each containing 100 μg/ml cyclohexamide. Cells were lysed by scraping in 500 μl/15 cm dish 
hypotonic lysis buffer containing cyclohexamide and cell debris was removed by 
centrifugation at 3500 g for 8 minutes at 4 °C.  
The preparation of nuclear and cytoplasmic extracts was based on the method described by 
Dignam et al. (Dignam et al., 1983). 1 x 109 HEK 293 cells were collected by centrifugation at 
350 g for 10 minutes and washed once in PBS. The volume of the cell pellet was estimated 
and cells were resuspended in 5 volumes Roeder A buffer and incubated for 10 minutes on 
ice. After another centrifugation step, cells were resuspended in 2 volumes Roeder A buffer, 
transferred to a glass douncer and lysed with 10 pestle strokes. Cell nuclei were sedimented 
by a 10-minute centrifugation at 1200 g and 4 °C and cytoplasmic extracts were transferred 
to new reaction tubes. The pelleted nuclei were resuspended in 3 ml buffer Roeder C-low 
and homogenized with 15 pestle strokes in a glass douncer. Samples were centrifuged at 
17000 g for 30 minutes at 4 °C and supernatants were transferred to new reaction tubes. 
 
4.2.1.5. Immunoprecipitation and pull-down of proteins 
For immunoprecipitation of FLAG/HA-tagged proteins, 20 μl FLAG agarose beads (Sigma, 
St. Louis, USA) were added to the lysates and incubated for 2-3 h at 4 °C. After washing 
three times with IP wash buffer and once with PBS, samples were transferred to fresh 
reaction tubes and used for further experiments. For subsequent western blotting analysis, 
samples were mixed with 20 μl protein sample buffer and heated to 95 °C for 5 minutes 
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before separation by SDS-PAGE. Myc-tagged proteins were immunoprecipitated in the same 
manner using 20 μl anti-myc-agarose (Sigma) per sample. 
For immunoprecipitation of endogenous Ago1, Ago2 or RBM4, the corresponding antibodies 
were coupled to 20 μl Protein G Sepharose (GE Healthcare) for 3-12 h at 4 °C, followed by a 
2-3 h incubation with cell lysates. Hybridoma supernatants were used undiluted for antibody 
coupling. Further steps were performed analogous to the FLAG-immunoprecipitation. 
After the washing steps, samples destined for RNase A treatment were incubated with 
100 mg/ml RNase A (Qiagen) for 1 h at 4 °C, washed twice with PBS and transferred to fresh 
reaction tubes. 
Pull-down experiments in cell lysates were performed with various recombinantly expressed 
RBM4 mutants and fragments. GST fusion proteins were incubated with Glutathion 
Sepharose (GE Healthcare) for 2 h at 4 °C. Beads were washed twice with PBS and 
HEK 293 lysates were added. After incubation at 4 °C for 2 h, beads were washed three 
times with IP wash buffer and once with PBS, transferred to fresh reaction tubes and 
analyzed for endogenous Ago2 by western blotting. 
 
4.2.1.6. Preparation of sucrose density gradients 
For standard sucrose gradient centrifugation, a gradient ranging from 15 % to 55 % sucrose 
in 1x gradient buffer was used. Gradients were set up in 14x89 mm polyallomer centrifuge 
tubes (Beckman, Palo Alto, USA) using the Gradient Master 107ip system (Biocomp, New 
Brunswick, Canada) according to manufacturer´s instructions and cooled to 4 °C. Cells were 
lysed in 500 μl/15cm plate cell lysis buffer and cell debris was removed by centrifugation at 
17000 g for 10 minutes at 4 °C. A maximum volume of 750 μl was loaded per gradient. 
Lysates were separated by centrifugation at 30000 rpm in a SW41 rotor for 18 h at 4 °C in an 
Optima L-90K ultracentrifuge (Beckman Coulter GmbH). Acceleration was set to “low” and 
the brake was turned off. 500 μl fractions were taken manually and 20 μl/fraction were used 
directly for western blotting in order to check for protein distribution. 5-25 % gradients were 
prepared accordingly. To determine indicated S values, Catalase (11S), apoferritin (17S) and 
thyroglobin (19S) (all Sigma) were separated on a 15-55 % sucrose gradient and protein 
distribution was visualized by SDS-PAGE and subsequent coomassie staining. 
For polyribosome fractionation, gradients ranging from 0.5-1.5 M sucrose in 20 mM Tris 
pH 7.5, 80 mM NaCl and 5 mM MgCl2 were prepared. Lysates were separated by 
centrifugation at 36000 rpm in a SW41 rotor for 2 h at 4 °C and fractionated. For western 
blotting, 20 μl/fraction were mixed with 4x protein sample buffer. 
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4.2.1.7. RNA extraction from cultured cells 
Extraction of total RNA was performed using peqGold TriFast (Peqlab, Erlangen, Germany) 
according to the manufacturer´s protocol. After precipitation, the RNA pellet was washed with 
80 % ethanol, air-dried and dissolved in ddH2O. 
RNA from immunopurified samples was directly isolated from antibody coupled beads by 
adding 200 μl Proteinase K buffer containing 40 μg Proteinase K. The samples were 
incubated at 65 °C for 20 minutes, followed by RNA extraction using 200 μl 
phenol/chloroform/isoamylalcohol (25:24:1). For subsequent RNA precipitation, the aqueous 
phase was mixed with 2.5 volumes of absolute ethanol, incubated at -20 °C O/N and RNA 
was pelleted by centrifugation at 17 000 g for 30 minutes at 4 °C. Pellets were washed with 
70 % (mRNA preparation) or 80 % (miRNA isolation) ethanol, air-dried and dissolved in an 
appropriate volume of ddH2O. Input samples were prepared accordingly. 
 
4.2.1.8. Reverse transcription (RT) - cDNA synthesis 
Prior to cDNA synthesis, RNA was subjected to DNase I treatment in order to remove 
potential DNA contaminations. 11.5 μl RNA were incubated with 1 μl DNase I, 1.5 μl of the 
corresponding 10x buffer and 1 μl RiboLock (all Fermentas) at 37 °C for 30 minutes followed 
by enzyme inactivation at 70 °C for 10 minutes. The subsequent cDNA synthesis reaction 
with a final reaction volume of 30 μl was performed using First Strand cDNA Synthesis Kit 
(Fermentas) according to manufacturer´s instructions. The cDNA samples were diluted 1:10 
with supplied DEPC-H2O and used for quantitative PCR. 
 
4.2.1.9. Quantitative PCR (qPCR) 
Quantitative PCR analysis was carried out in 15 μl reactions containing 7.5 μl Mesa Green 
qPCR MasterMix Plus (Eurogentec, Cologne, Germany), 0.2 μl each of forward and reverse 
primers (10 μM) and 5 μl cDNA in a MyiQ BioRad (Hercules, USA) real-time detection 
system.   
The primers utilized for real-time PCR analysis are listed in the following table. 
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Table 7: Primers used for quantitative PCR 
Name Target mRNA Primer sequence (5’3’) 
RBM4 RBM4 (ORF) 
CTTGAGGTGGGATGTGTGTG 
GCAGGAGAGGAAAGGAAAGG 
YB-1 YB-1 (ORF) 
AAGTGATGGAGGGTGCTGAC 
TGCGTCGGTAATTGAAGTTG 
IMP3 IMP3 (ORF) 
AGTTGTTGTCCCTCGTGACC 
AGCCTTCTGTTGTTGGTGCT 
FMRp FMRp (ORF) 
CACCTCAAAGCGAGCACATA 
CAATAGCAGTGACCCCAGGT 
GAPDH GAPDH (ORF) 
TGGTATCGTGGAAGGACTCATGAC 
ATGCCAGTGAGCTTCCCGTTCAGC 
luc firefly luciferase (ORF) 
GTGTTCGTCTTCGTCCCAGT 
GCTGGGCGTTAATCAGAGAG 
renilla renilla luciferase (ORF) 
ATGGGATGAATGGCCTGATA 
CAACATGGTTTCCACGAAGA 
KRAS KRAS (3‟-UTR) 
TTTTAGGACTCTTCTTCCATATTA 
TGGGGCATGTGGAAGGTAGGGAGG 
 
4.2.1.10. Semi-quantitative RT-PCR for miRNAs 
For detection of miRNA association with Ago complexes, HEK 293 cells were transiently 
transfected with FLAG/HA-Ago1 or -Ago2, cell lysates were subjected to gradient 
centrifugation and Ago complexes were immunoprecipitated from individual fractions using 
FLAG agarose. RNA was isolated and reverse transcription and semi-quantitative PCR was 
performed using mirVana qRT-PCR miRNA Detection Kit, miRVana qRT-PCR Primer Sets 
for miRNAs let-7a and miR-16 (all Ambion) and Taq polymerase (Fermentas). Aliquots from 
the PCR product were taken after different cycle numbers and separated on a 3 % agarose 
gel. 
 
4.2.1.11. RNA polyacrylamide gel electrophoresis (RNA-PAGE) 
RNA samples were separated by denaturing RNA polyacrylamide gel electrophoresis using 
the SequaGel System Kit (national diagnostics, Atlanta, USA) with an acrylamide 
concentration of 8% (RISC assay), 12 % (Dicer assay) or 15 % (northern blotting). The gel 
was pre-run for 10-15 minutes at 300 V. As running buffer, 1x TBE was used. Before loading, 
the pockets were rinsed thoroughly with running buffer and the gel was run at 300-500 V 
(northern blotting, Dicer assay) or 65 W (RISC assay). 
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4.2.1.12. Dicer assay 
To assay for Dicer activity, an in vitro transcribed pri-miR-27a substrate was used 
(Landthaler et al., 2004; Meister et al., 2005). The template for pri-miR-27a transcription was 
generated by PCR amplification from human genomic DNA using the primers 5-
GGCTGGAACGGAGGGCACAGCTAG-3‟ and 5‟-GGTAACTGGCTGCTAGGAAGGTGCGG-
3‟. In a second round of PCR, a T7 promotor sequence was introduced using the following, 
partially overlapping, primers: 5‟-AGGCAGACAGGCGGCAGCAG-3‟ and 5‟-
TAATACGACTCACTATACGAGGATGCTGCCCGG-3‟. For in vitro transcription, 3 μl PCR 
product were incubated with 8 μl 5x NTP Mix (A/C/G/U = 5/5/8/0.1 mM), 8 μl 5x T7 buffer, 
0.2 μl DTT (1M), 1 μl T7 polymerase and 5 μl α-32P-UTP (3000 Ci/mmol) in a 40 μl reaction 
at 37 °C for 2 h. RNA sample buffer was added and RNA was purified by 10 % denaturing 
RNA-PAGE. After detection by autoradiography, the RNA was gel eluted in 300 μl elution 
buffer (300 mM NaCl, 2 mM EDTA) O/N at 4 °C under vigorous shaking and recovered by 
ethanol precipitation.  
To provide a size marker, 10 pmol of an arbitrary single-stranded siRNA oligonucleotide was 
incubated with 0.1 μl γ-32P-ATP and 0.1 μl T4 polynucleotide kinase in a 10 μl reaction for 5 
minutes at 37 °C. Purification was performed in parallel to the Dicer substrate and the size 
marker was highly diluted before use.  
Cell lysis and immunoprecipitations were performed as described earlier (section 4.2.1.5). 
For Dicer activity assays, 10 μl of Ago- or Dicer containing beads were incubated in 20 μl 
PBS containing 5 mM ATP, 7.5 mM MgCl2, 10 U/ml RNasin (Promega, Madison, USA) and in 
vitro transcribed RNA (2 Bq/cm2) at 37 °C. After 1 h, the reaction was stopped by proteinase 
K digestion and RNA precipitation was performed as described before. Samples were 
analyzed by 12 % denaturing RNA-PAGE and signals were detected by autoradiography. 
 
4.2.1.13. RISC assay  
The RISC cleavage assay as well as the RNA substrate used in this work have been 
described previously (Meister et al., 2004; and as a detailed protocol in Stöhr, 2011).  
In short, the RNA cleavage substrate was obtained by in vitro transcription of a PCR product 
containing a perfect complementary sequence to miR-19b. 20 μl 5x NTP mix 
(A/C/G/U = 5/5/8/2 mM), 20 μl T7 transcription buffer, 0.5 μl DTT (1M), 1 μl T7 RNA 
polymerase and 5 μl PCR product in a total reaction volume of 100 μl were incubated for 2 h 
at 37 °C before adding RNA sample buffer. RNA was separated by 8 % denaturing RNA-
PAGE, detected by UV shadowing, gel eluted in 300 μl elution buffer O/N at 4 °C and 
recovered by ethanol precipitation. 
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Subsequently, the RNA substrate was 32P-cap labeled: 40 pmol in vitro transcribed RNA was 
incubated with 2 μl Guanylyltransferase (Gibco/BRL, Bethesda, MD), 2 μl 10x buffer (0.4 M 
Tris pH 8.0, 60 mM MgCl2, 100 mM DTT, 20 mM spermidine), 0.25 μl RNasin (Promega, 
Madison, USA), 1 μl S-adenosyl-methionine (500 μM, Sigma), 1 μl DTT (100 mM) and 2 μl 
α-32P-GTP (3000 Ci/mmol) in a 20 μl reaction at 37 °C for 3 h. Purification of the labeled 
RNA substrate by RNA-PAGE was performed as described above (section 4.2.1.12).  
10 μl of Ago- or Dicer containing beads were incubated in a 25 μl reaction containing 5 nM 
target RNA, 1 mM ATP, 0.2 mM GTP, 10 U/ml RNasin (Promega, Madison, USA), 100 mM 
KCl, 1.5 mM MgCl2 and 0.5 mM DTT for 1.5 h at 30 °C. RNA was Proteinase K digested, 
extracted as described before and analyzed by 8 % denaturing RNA-PAGE using a 
sequencing gel apparatus Model S2 (Gibco/BRL, Bethesda, MD). For a marker, substrate 
RNA subjected to digestion by RNase T1 was used (Stöhr, 2011). 
Signals were detected by autoradiography using BioMax MS films and an intensifying 
HE Transcreen screen (both Kodak). 
 
4.2.1.14. Northern blotting 
Northern blotting was performed as described before (Lagos-Quintana et al., 2001) using the 
following probe against miR-19b: 5‟-TCAGTTTTGCATGGATTTGCACA-3‟. Samples were 
mixed with an equal volume of denaturing RNA sample buffer and heated to 95 °C for 
5 minutes. RNA was separated by RNA-PAGE on a 12 % denaturing polyacrylamide gel and 
transferred to Hybond-N membrane (Amersham Bioscience, Buckinghamshire, UK) by 
semidry blotting using 0.5x TBE with constant amperage (3 mA/cm2) for 1 h. To cross-link the 
RNA, the membrane was subjected to UV radiation (1200 J for 30s) and subsequently 
incubated at 80 °C for 1 h. 
Pre-hybridization was performed in 5x SSC, 20 mM Na2HPO4 pH 7.2, 7 % SDS, 
1x Denhardt´s solution and 10 μg sonicated salmon sperm DNA for 1 h at 50 °C. A 5‟-32P-
labeled probe (see below) was added for hybridization O/N at 50 °C. Subsequently, the 
membrane was washed twice with 5x SSC and 1 % SDS and once with 1x SSC and 1x SDS 
for 10 minutes each. Exposure to Kodak BioMax MS films was performed with an intensifying 
HE Transcreen screen (Kodak, Stuttgart, Germany) at -80 °C. 
For northern probe preparation, 10 pmol of the DNA oligonucleotide were radiolabeled in a 
30 μl T4-Polynucleotide kinase reaction with 30 μCi of -32P-ATP at 37 °C for 30 minutes. 
The reaction was stopped by addition of 30 μl EDTA (30 mM) and incubation at 95 °C for 
5 minutes. Subsequently, the probe was purified using MicroSpin G-25 columns (Amersham 
Bioscience, Buckinghamshire, UK). 
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4.2.1.15. Mass spectrometry analysis 
Lysates from transiently FLAG/HA-Ago1 or -Ago2 transfected HEK 293 cells were separated 
by sucrose density centrifugation. Fractions corresponding to complexes I to III, respectively, 
were pooled, subjected to immunoprecipitation using FLAG beads and separated by SDS-
PAGE. After coomassie staining, gel lanes were cut into pieces of similar size (23 slices) and 
subjected to in-gel trypsinization (Shevchenko et al., 1996). Extracted peptides were 
analyzed by liquid chromatography-coupled tandem MS LC-MS/MS on a Q-ToF Ultima 
mass spectrometer (Waters). MSMS spectra of doubly and triply charged precursors were 
acquired for max. 3.3 s (0.1 s interscan time). Raw data were processed and transformed 
into a peaklist using MassLynx software 4.0 (Waters) with the following settings: i) 
Smoothing: smooth window (channels) 3.0, number of smooths 3 using Savitzky Golay 
algorithm; ii) Centroiding: min. peak width at half high: 4, centroid top, 80 %. 
The peak list of fragment spectra was searched against the NCBI non-redundant database 
(NCBInr) with a mass accuracy of 0.2 Da for the parent ion (MS) and 0.2 Da for the fragment 
ions (MS/MS) using Mascot. The peptides were constrained to be tryptic with a maximum of 
one missed cleavage. Carbamidomethylation of cysteines was considered as a fixed 
modification whereas oxidation of methionine residues was considered as a variable 
modification. The highest scoring peptide from each protein as well as single hit peptides 
entry was manually inspected to eliminate false positives in the data set. 
 
4.2.1.16. Recombinant protein expression 
For recombinant expression of proteins or protein fragments, the corresponding plasmids 
were introduced into E. coli BL21(DE3) by heat shock transformation. LB medium was 
inoculated with transformed bacteria and cultured at 37 °C to an OD600 of about 0.8. After 
induction with 1 mM IPTG, cultures were transferred to 18 °C and incubated O/N. Bacteria 
were harvested by centrifugation (6000 g, 10 min, 4 °C), resuspended in 35 ml lysis buffer for 
recombinant protein expression and disrupted by sonication (4 x 30 s, amplitude 35 %) on 
ice using a Sonopuls H2070 sonicator with a TT13 sonotrode (both Bandelin electronic, 
Berlin, Germany). After centrifugation at 20000 g for 30 minutes at 4 °C, supernatants were 
either shock-frozen and stored at -80 °C or directly used for affinity purification. 
 
4.2.1.17. Affinity purification of recombinant GST- and His-fusion proteins 
For affinity purification of GST fusion proteins, E. coli extracts were incubated with Glutathion 
sepharose (GE Healthcare) for 2 h at 4 °C, followed by three washes with lysis buffer pH 7.5. 
Beads were transferred to PolyPrep columns (Biorad) and washed with wash buffer pH 8.0. 
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Purified GST fusion proteins were eluted using wash buffer pH 8.0 containing 3 mg/ml L-
Glutathione (Sigma) and dialyzed O/N at 4 °C against PBS containing 100 μM AEBSF. 
 
4.2.1.18. Western Blotting 
For Western blot analysis, proteins were separated by 10 % SDS-PAGE (unless percentage 
stated otherwise) and transferred to Hybond ECL nitrocellulose membrane (GE Healthcare) 
by semi-dry western blotting at 7 V and room temperature for 3 h using 1x Towbin blotting 
buffer.  
The membrane was blocked by incubation in wash buffer containing 10 % milk powder for 
30-60 minutes followed by 3 five-minute washes with wash buffer. Primary antibodies were 
added to the blot in the indicated dilutions and incubated for a minimum time of 1 h, followed 
by three ten-minute washes with wash buffer. After one-hour incubation with the peroxidase-
conjugated secondary antibody, membranes were again subjected to 3 ten-minute washes in 
wash buffer followed by a two-minute incubation in chemiluminescence detection solution. 
Signals were detected using Hyperfilm ECL films (GE Healthcare). 
 
4.2.1.19. Immunofluorescence (IF) 
HEK 293 cells were seeded onto coverslips in 6 well plates to give a cell density of 25 %. 5 h 
after seeding, cells were transfected with 0.1 μg DNA per well and plasmid as described in 
section 4.2.2.2. 2 days after transfection, cells were fixed for 15 minutes in ice-cold PBS 
containing 3.7 % formaldehyde. The reaction was stopped by adding PBS/100 mM glycine 
for 5 minutes and cells were permeabilized in PBS/0.2 % Triton X-100/3 % BSA for 10 min. 
Cover slips were washed once with IF buffer (PBS/0.1 % TWEEN-20/0.2 % BSA) and 
primary antibodies were added for 1 h. After 3 washes with IF buffer, cells were incubated 
with secondary antibodies for 1 h in the dark. Cells were washed once with IF buffer 
containing a final concentration of 1 μg/ml DAPI and then three times with IF buffer and 
mounted to slides using Vectashield mounting medium (Vectorlabs). Images were recorded 
using a TCS SP2 confocal laser microscope (Leica Microsystems, Germany). 20 z-sections 
of the cells were recorded and processed to maximum projections using the Leica confocal 
software. Adobe Photoshop was used to superimpose the images. 
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4.2.1.20. Coupled in vitro transcription/translation 
For coupled in vitro transcription and translation from pET28a constructs, the TnT T7 Quick 
Coupled Transcription/Translation System (Promega, Madison, USA) was used.  
2 μg plasmid DNA, 0.5 μl RiboLock, 2 μl Easy Tag L-35S-Methionine (1000 Ci/mmol) and 
40 μl reticulocyte lysate were incubated for 3 h at 30 °C. To check for successful translation, 
1 μl per sample was separated by SDS-PAGE, the gel was incubated for 30 minutes in 
30 % acetic acid and for 45 minutes in Amplify Reagent (GE Healthcare). The gel was dried 
and autoradiography was detected using BioMax MS films and a Transcreen LE intensifying 
screen (both Kodak). 
 
4.2.1.21. In vitro pull-down analysis 
To assay for direct binding of two proteins, one component was expressed as a GST-fusion 
protein, while the other component was radioactively labeled during in vitro translation (see 
above). Test samples from GST-protein lysates were separated by SDS-PAGE and protein 
amounts were leveled by estimating the intensity of protein bands in the gel after coomassie 
staining. Levels of radioactively labeled proteins were adjusted by checking autoradiography 
signals from the test gel described above. 
For the actual binding assay, GST-fusion proteins were incubated with 20 μl Glutathion 
Sepharose (GE Healthcare) in a rotating wheel for 2 h at 4 °C. Samples were washed twice 
with PBS and transferred to new reaction tubes. Radioactively labeled proteins were added 
to the beads and samples were incubated on ice for 1.5 h. Beads were stirred every 
10 minutes. Subsequently, samples were washed three times with IP wash buffer and once 
with PBS and transferred to new reaction tubes. The supernatant was removed completely 
and proteins were denatured by adding 20 μl protein sample buffer and heating to 95 °C for 
5 minutes. Samples were separated by SDS-PAGE, followed by coomassie staining and a 
45-minute incubation in Amplify Reagent (GE Healthcare). The gel was dried and 
autoradiography was detected using BioMax MS films and a Transcreen LE intensifying 
screen (both Kodak). 
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4.2.2. Cell biological methods 
4.2.2.1. Culturing of mammalian cells 
HEK 293 and HeLa cells were cultured in Dulbecco´s Modified Eagle´s Medium (DMEM, 
PAA, Pasching, Austria) supplied with 10 % (v/v) fetal bovine serum (FBS, Gibco) and 
1 % (v/v) penicillin/streptomycin (PAA, Pasching, Austria) at 37 °C and 5 % CO2. Cells were 
passaged every 2-3 days after incubation with trypsin-EDTA (PAA, Pasching, Austria) and 
seeded to new culture plates. HeLa cells were washed once with PBS prior to trypsin-EDTA 
treatment. 
 
4.2.2.2. Calcium phosphate transfections 
The calcium phosphate transfection method was used for transient transfection of HEK 293 
cells. Cells were plated 3-5 h prior to transfection at about 30 % confluency. Per 15 cm dish, 
10 μg plasmid DNA was mixed with 153 μl CaCl2 (2M) in a volume of 1250 μl. 1250 μl 
2x HEPES buffer was added drop-wise under gentle agitation. The transfection mixture was 
sprinkled onto the cells and incubated for 2 d before harvest. 
 
4.2.2.3. SiRNA transfections 
For knock-down experiments, HeLa cells were reverse transfected in 6-well format with 
100 pmol siRNA per well using 5 μl Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, 
USA) according to manufacturer´s instructions. For knock-down experiments, cells were 
cultured in medium without penicillin/streptomycin.  
Cells were harvested 4 days post-transfection, total RNA was extracted and mRNA levels 
were analyzed by qPCR. 
The following siRNAs were used in this work: 
 
Table 8: siRNA sequences 
name 5’3’ sequence (sense strand)  5’3’ sequence (antisense strand) 
Ago1 GAGAAGAGGUGCUCAAGAAUT UUCUUGAGCACCUCUUCUCUT 
Ago2 GCACGGAAGUCCAUCUGAAUT UUCAGAUGGACUUCCGUGCUT 
Ago3 GAAAUUAGCAGAUUGGUAAUT UUACCAAUCUGCUAAUUUCUT 
Ago4 GGCCGGAGCUAAUAGCAAUUT AUUGCUAUUAGCUCCGGCCUT 
ctrl. UUGUCUUGCAUUCGACUAAUT UUAGUCGAAUGCAAGACAAUT 
FMRp #1 GGCAGCUUGCCUCGAGAUUUT AAUCUCGAGGCAAGCUGCCUT 
FMRp #2 CCUCCUGUAGGUUAUAAUAUT UAUUAUAACCUACAGGAGGUT 
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name 5’3’ sequence (sense strand)  5’3’ sequence (antisense strand) 
FMRp #3 GAACGUCUAAGAUCUGUUAUT UAACAGAUCUUAGACGUUCUT 
FMRp #4 ACAGGUACUUUGUCUAAGAUT UCUUAGACAAAGUACCUGUUT 
RBM4 #1 UUACGGCUUUGUGCACAUAUT UAUGUGCACAAAGCCGUAAUT 
RBM4 #2 GGAGCUUCGAGCCAAGUUUUT AAACUUGGCUCGAAGCUCCUT 
RBM4 #3 GAGUGUCCGAUAGAUCGUUUT AACGAUCUAUCGGACACUCUT 
TNRC6B GGCCUUGUAUUGCCAGCAAUT UUGCUGGCAAUACAAGGCCUT 
YB-1 #1 AACCUUCGUUGCGAUGACCUT GGUCAUCGCAACGAAGGUUUT 
YB-1 #2 GCAGACCGUAACCAUUAUAUT UAUAAUGGUUACGGUCUGCUT 
YB-1 #3 AGAAGGUCAUCGCAACGAAUT UUCGUUGCGAUGACCUUCUUT 
ZBP3 #1 UCCAGAACGCACUAUUACAUT UGUAAUAGUGCGUUCUGGAUT 
 
4.2.2.4. Luciferase assays 
HeLa cells were seeded in culture medium to 96 well plates 5 h prior to transfection to give 
50 % confluency. SiRNAs were transfected at 10 nM final concentration using HiPerfect 
(Qiagen) according to the manufacturer´s instructions. After 2 d, cells were passaged in an 
1:3 ratio and seeded into a new 48 well plate. On the following day, medium was changed to 
OptiMEM (Invitrogen). Cells were subsequently transfected with reporter plasmids using 
0.5 μl/well Lipofectamine (Invitrogen, Carlsbad, USA) and 0.125 μg/well reporter plasmid 
according to manufacturer´s instructions. Medium was changed to culture medium after 24 h 
and cells were lyzed after another 24 h in 50 μl/well passive lysis buffer (Promega, Madison, 
USA). 
In later experiments, knock-down was performed using RNAiMAX as described above. Cells 
were seeded to 96 well plates after 2.5 d in culture medium without penicillin/streptomycin 
and transfected 6 h later using 0.25 μl Lipofectamine 2000 (Invitrogen, Carlsbad, USA) and 
50 ng/well reporter plasmid. After 36 h, cells were lyzed in 50 μl/well passive lysis buffer 
(Promega, Madison, USA). 
Luminescence was measured in a Mithras LB 940 luminometer (Berthold Technologies, Bad 
Wildbad, Germany) using firefly luciferase buffer and renilla luciferase buffer (sterile filtered). 
Samples were assayed in 3-4 replicates. For each siRNA, the firefly/renilla luminescence 
ratios of the reporter plasmids were normalized to the corresponding empty vector.  
For miRNA inhibition experiments, 20 pmol of the 2‟-O-methyl (2‟-OMe) oligoribonucleotides 
were co-transfected with reporter plasmid (50 ng/well) in 96-well format with Lipofectamine 
2000 (Invitrogen) according to manufacturer´s instructions. Cells were lyzed 24 h later in 
50 μl/well passive lysis buffer (Promega) and luminescence was measured and normalized 
as described above.  
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For over-expression experiments, reporter plasmids (50 ng/well) were co-transfected with 
FLAG/HA-tagged constructs as indicated using 0.25 μl/well Lipofectamine 2000 (Invitrogen) 
according to manufacturer´s instructions. After 36 h, cells were lyzed in 50 μl/well passive 
lysis buffer (Promega) and luminescence was measured as described above. Again, results 
were normalized to those of the empty vector. 
 
Table 9: luciferase reporter constructs 
reporter construct name vector backbone insert reference 
miR-21 cleavage pMIR-RNL-Tk 
miR-21 cleavage site 
(perfect complementary) 
cloned in this work 
miR-21 cleavage mutant pMIR-RNL-Tk 
mutated miR-21 cleavage site  
(mismatches in pos. 3-6 and 9-12 
of miR-21) 
cloned in this work 
KRAS pMIR-RNL-Tk kras 3‟-UTR (Johnson et al., 2005) 
HMGA2 pMIR-RNL-Tk HMGA2 3‟-UTR (NM_003483.4) (Mayr et al., 2007) 
HMGA2 mut pMIR-RNL-Tk 
HMGA2 3‟-UTR with mutated let-7 
binding sites 
cloned in this work 
SERBP1 pMIR-RNL serbp1 3‟-UTR (Beitzinger et al., 2007) 
DNAJB11 pMIR-RNL dnajb11 3‟-UTR (Beitzinger et al., 2007) 
Raver2 pMIR-RNL raver 2 3‟-UTR (Beitzinger et al., 2007) 
Per1 pMIR-RNL-Tk Per1 3‟-UTR (NM_002616.2) (Kojima et al., 2007) 
FLOT1 pMIR-RNL-Tk FLOT1 3‟-UTR (NM_005803.2) (Lin and Tarn, 2005) 
RhoC pMIR-RNL-Tk RhoC 3‟-UTR (NM_175744.4) (Lin and Tarn, 2005) 
random + RNA A pMIR-RNL 
random DNA (190 nt)* 
+ miR-21 binding site  
+ putative RBM4 binding motif A 
cloned in this work 
random + RNA C pMIR-RNL 
random DNA (189 nt) *  
+ miR-21 binding site  
+ putative RBM4 binding motif C 
cloned in this work 
random + RNA G pMIR-RNL 
random DNA (190 nt) *  
+ miR-21 binding site  
+ putative RBM4 binding motif G 
cloned in this work 
random ctrl. I pMIR-RNL 
random DNA (190 nt) *  
+ miR-21 binding site  
+ ctrl. RNA binding motif 
cloned in this work 
random ctrl. II pMIR-RNL 
random DNA (190 nt) *  
+ mutated miR-21 binding site  
+ ctrl. RNA motif 
cloned in this work 
HMGA2 + RNA A pMIR-RNL 
HMGA2 3‟-UTR 
+ putative RBM4 binding motif A 
cloned in this work 
HMGA2 + RNA C pMIR-RNL 
HMGA2 3‟-UTR  
+ putative RBM4 binding motif C 
cloned in this work 
HMGA2 + RNA G pMIR-RNL 
HMGA2 3‟-UTR  
+ putative RBM4 binding motif G 
cloned in this work 
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ABBREVIATIONS 
 
 
3’-UTR 3‟-untranslated region  h hour 
5’-UTR 5‟-untranslated region  HA haemagglutinin 
AEBSF 
4-(2-Aminoethyl) benzenesulfonyl 
fluoride 
 
HEK human embryonic kidney 
Ago Argonaute 
 
HEPES 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid 
APS ammonium persulfate  HSC heat shock cognate 
ATP adenosine triphosphate  HSP heat shock protein 
AUB Aubergine  IgG immunoglobulin class G 
BSA bovine serum albumin 
 
IPTG 
Isopropyl -D-1-
thiogalactopyranoside 
bp base pair  IRES internal ribosome entry site 
casiRNA cis-acting siRNA  k kilo 
C. 
elegans 
Caenorhabditis elegans 
 
KRAS 
Kirsten rat sarcoma viral 
oncogene homologue 
Ci Curie  l liter 
DNA deoxyribonucleic acid  M molar 
cDNA complementary DNA  tRNA transfer RNA 
d deoxy  mRNA messenger RNA 
Da Dalton  miRNA microRNA 
ddH2O double-distilled water  miRNP micro-ribonucleoprotein 
DGCR8 DiGeorge syndrome critical region 8 
 
natsiRNA 
natural antisense transcript-
derived siRNA 
Dm Drosophila melanogaster  nt nucleotides 
DUF domain of unknown function    
dNTP 2‟-deoxyribonucleoside triphosphate  O/N over-night 
ds double-stranded  ORF open reading frame 
dsRBD double-stranded RNA binding domain  P phosphate 
DTT 1,4-dithiothreitol  PAA polyacrylamide 
E. coli Escherichia coli  PABP poly(A)-binding protein 
EDTA ethylenediaminetetraacetic acid 
 
PAGE 
polyacrylamide gel 
electrophoresis 
FCS fetal calf serum  PAZ piwi-argonaute-zwille 
FH Flag-HA  PBS phospate buffered saline 
g gravitational constant  P bodies processing bodies 
GFP green fluorescent protein  PCR polymerase chain reaction 
GTP guanosine triphosphate  Per1 Period1 
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piRNA Piwi-interacting RNA 
 
S 
Svedberg unit  
(sedimentation coefficient) 
PMSF phenylmethylsulfonyl fluoride  SD standard deviation 
Pol polymerase  SDS sodium dodecyl sulfate 
pre-
miRNA 
precursor miRNA 
 
siRNA small interfering RNA 
pri-
miRNA 
primary miRNA 
 
snoRNA small nucleolar RNA 
qPCR 
quantitative real time  
polymerase chain reaction 
 
ss single-stranded 
RdRP RNA dependent RNA polymerase  tasiRNA trans-acting siRNA 
rpm revolutions per minute 
 
TEMED 
N,N,N‟,N‟-
Tetramethylethylenediamine 
RT room temperature  TNRC6 trinucleotide repeat containing 6 
RISC RNA induced silencing complex  Tris tris(hydroxymethyl)aminomethane 
RNA ribonucleic acid  UBA ubiquitin-associated domain 
RNAi RNA interference  UTP uridine triphosphate 
RNP ribonucleoprotein  v/v volume in volume 
rRNA ribosomal RNA  wt wild-type 
RRM RNA recognition motif  w/v weight per volume 
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APPENDIX  
Supplementary Table 1: Mass spectrometry data on Ago 1 complex I  
protein Acc.No. Mass 
Queries 
matched 
Protein 
score 
Seq cov 
(%) 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic translation initiation factor 2C, 1 
(Ago1) [Homo sapiens] 
gi|6912352 97152 26 2058 58 87 -0,0038 K.NASYNLDPYIQEFGIK.V 
Dicer gi|21665773 217490 7 383 5 112 0,1540 K.SNAETATDLVVLDR.Y 
squamous cell carcinoma antigen recognized by 
T cells 3 (SART3) [Homo sapiens] 
gi|7661952 109865 6 158 6 40 0,0663 R.YSQYLDR.Q 
Na+/K+ -ATPase alpha 1 subunit isoform a 
proprotein [Homo sapiens] 
gi|21361181 112824 2 72 1 39 0,0775 R.LNIPVSQVNPR.D 
unnamed protein product [Homo sapiens] gi|34535987 148788 1 24 - 24 0,0190 K.EPLLHFR.R 
DNA damage binding protein 1 (Damage-specific 
DNA binding protein 1) (DDB p127 subunit) 
(DDBa) (UV-damaged DNA-binding protein 1)  
gi|418316 126901 4 92 3 50 0,0530 K.LLASINSTVR.L 
sirtuin 1 [Homo sapiens] gi|7657575 81630 1 68 1 68 0,0590 R.GDIFNQVVPR.C 
HSPC273 [Homo sapiens] gi|6841196 25891 1 66 4 66 0,0725 R.ELGENLDQILR.A 
E1B-55kDa-associated protein (hnRNP U-like) 
[Homo sapiens] 
gi|3319956 95750 1 48 0 48 0,0579 K.INEEISVK.H 
programmed cell death 1 precursor [Homo 
sapiens] 
gi|4826890 31687 1 20 2 20 0,0633 R.RTGQPLK.E 
heat shock 90kDa protein [Homo sapiens] gi|56204416 83212 12 686 24 61 0,0464 K.SIYYITGESK.E 
Skb1Hs (PRMT5) [Homo sapiens] gi|48145599 72638 12 749 25 75 0,0108 K.AAILPTSIFLTNK.K 
aralar2 [Homo sapiens] gi|6523256 74093 3 115 6 86 0,0492 K.TVELLSGVVDQTK.D 
chaperonin (HSP60) gi|306890 60986 7 374 21 55 0,0037 R.VTDALNATR.A 
translation initiation factor eIF-2b delta subunit 
[Homo sapiens] 
gi|6563202 57563 1 60 2 60 0,0320 R.VGTAQLALVAR.A 
elongation factor Tu [Homo sapiens] gi|31092 50095 5 194 10 54 0,0206 K.IGGIGTVPVGR.V 
RuvB-like 2 [Homo sapiens] gi|5730023 51125 2 89 4 47 0,0332 K.GTEVQVDDIKR.V 
Dnj3/Cpr3 [Homo sapiens] gi|2352904 46277 1 145 10 32 0,0337 R.ELYDRYGEQGLR.E 
trans-activation-responsive RNA-binding protein 
- human (TRBP) (fragment) 
gi|107904 38814 1 36 2 36 0,0358 R.FIEIGSGTSK.K 
KIAA0115 [Homo sapiens] gi|473947 50680 1 31 1 31 0,0317 K.SSLNPILFR.G 
MEP50 protein (MEP50) [Homo sapiens] gi|13559060 36701 5 390 22 93 0,0469 K.VWDLAQQVVLSSYR.A 
signal sequence receptor, alpha [Homo sapiens] gi|4507237 32163 1 44 3 44 0,0306 K.GEDFPANNIVK.F 
solute carrier family 25 member 3 isoform a 
precursor [Homo sapiens] 
gi|6031192 40069 1 54 3 54 0,0282 R.IQTQPGYANTLR.D 
S3 ribosomal protein [Homo sapiens] gi|7765076 26699 2 206 25 68 0,0322 R.ELAEDGYSGVEVR.V 
solute carrier family 25, member 5 [Homo 
sapiens] 
gi|4502099 32874 7 190 22 49 0,0239 K.LLLQVQHASK.Q 
Solute carrier family 25, member A6 [Homo 
sapiens] 
gi|15928608 32905 7 204 22 49/48 
0,0239/
0,0088 
K.LLLQVQHASK.Q / 
R.GNLANVIR.Y 
solute carrier family 25 member 4 variant [Homo 
sapiens] 
gi|62089114 29328 3 131 11 47 0,0142 R.GNLANVIR.Y 
transmembrane protein 33 [Homo sapiens] gi|8922491 27933 1 56 4 56 0,0113 R.ALLANALTSALR.L 
ribosomal protein L23 [Homo sapiens] gi|4506605 14856 1 28 5 28 0,0137 K.NLYIISVK.G 
Ribosomal protein S27-like protein [Homo 
sapiens] 
gi|13277528 9472 1 58 9 58 0,0133 R.LTEGCSFR.R + Carb. 
ribosomal protein L38 [Homo sapiens] gi|3088356 4291 1 38 27 38 0,0253 K.QSLPPGLAVK.E 
ribosomal protein S6 gi|225901 28633 1 28 3 28 0,0224 K.LIEVDDER.K 
 
 
Supplementary Table 2: Mass spectrometry data on Ago1 complex II 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic translation initiation factor 2C, 1 
(Ago1) [Homo sapiens] 
gi|6912352 
gi|38649144 
97152 
97151 
30 
5 
2142 
332 
62 
12 
76/76 
63 
0,0133/
0,0398 
0,0179 
K.LLANYFEVDIPK.I / 
K.NASYNLDPYIQEFGIK.V 
R.VLPAPILQYGGR.N 
splicing factor 3b, subunit 1 isoform 1 [Homo 
sapiens] 
gi|54112117 145738 6 460 8 69 0,0353 R.GGDSIGETPTPGASK.R 
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protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
Splicing factor 3B subunit 2 (Spliceosome 
associated protein 145) (SAP 145) (SF3b150) 
(Pre-mRNA splicing factor SF3b 145 kDa 
subunit) 
gi|2498883 97596 5 158 6 57 0,0227 R.AAVLLEQER.Q 
RNA helicase A [Homo sapiens] gi|1806048 140788 9 382 10 58 0,0264 R.GISHVIVDEIHER.D 
KIAA0017 protein [Homo sapiens] gi|40788938 139414 9 302 7 62 0,0263 R.SVAGGFVYTYK.L 
DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1 (Ddx30) [Homo sapiens] 
gi|20336294 133854 4 189 6 44 0,0273 K.AIFQQPPVGVR.K 
hnRNP U protein [Homo sapiens] gi|32358 88890 4 286 5 110 0,0361 R.NFILDQTNVSAAAQR.R 
squamous cell carcinoma antigen recognized by 
T cells 3 (SART3) [Homo sapiens] 
gi|7661952 109865 4 151 5 58 0,0224 R.ALEYLKQEVEER.F 
spliceosomal protein SAP 155 [Homo sapiens] gi|4033735 145723 1 51 0 51 0,0237 R.QQAADLISR.T 
gemin4 [Homo sapiens] gi|7657122 119913 1 45 - 45 0,0193 R.GLTQIQSR.I 
F-box and leucine-rich repeat protein 13 [Homo 
sapiens] 
gi|24432072 83887 1 35 2 17 0,0223 
K.THFCTWRDIAR.T  
+ Carb 
KIAA1488 protein (Dhx36) [Homo sapiens] gi|7959237 97766 1 27 1 27 0,0334 R.LGGIAYFLSR.L 
RNA helicase Gu - human (fragment)  gi|2135315 89196 4 117 - 40 0,043 K.STYEQVDLIGK.K 
transcription factor NF-AT 90K chain – human gi|1082856 73293 3 114 - 52 0,0559 R.EDITQSAQHALR.L 
ATP-dependent RNA helicase #46 [Homo 
sapiens] 
gi|2696613 92770 1 112 3 44 0,06 R.YGVIILDEAHER.T 
motor protein [Homo sapiens] gi|516764 79659 2 88 3 46 0,0521 R.GVYSEETLR.A 
hypothetical protein LOC55037 [Homo sapiens] gi|38683855 78500 4 232 7 53 0,0595 K.DISEAALKER.I 
ZNF326 protein [Homo sapiens] gi|31807861 33426 2 109 7 61 0,0775 R.SGYGFNEPEQSR.F 
NSAP1 protein [Homo sapiens] gi|5031512 62617 2 102 4 60 0,0886 R.TGYTLDVTTGQR.K 
Skb1Hs (PRMT5) [Homo sapiens] gi|2323410 72740 3 90 5 32 0,0664 R.GPLVNASLR.A 
mRNA-binding protein CRDBP [Homo sapiens] gi|7141072 63417 3 145 6 50 0,1205 R.DQTPDENDQVIVK.I 
poly(A) binding protein, cytoplasmic 1 [Homo 
sapiens] 
gi|46367787 70626 4 128 - 66 0,0246 R.IVATKPLYVALAQR.K 
E2IG3 [Homo sapiens] gi|6457340 63528 1 35 1 35 0,084 K.GGIPNVEGAAK.L 
ribosomal protein L4 [Homo sapiens] gi|16579885 47667 1 153 6 56 0,0646 K.AAAAAAALQAK.S 
heterogeneous nuclear ribonucleoprotein H2 (H') 
[Homo sapiens] 
gi|6065880 49232 1 61 3 61 0,0995 K.HTGPNSPDTANDGFVR.L 
DNA-binding protein B (Homo sapiens) gi|181486 39954 9 538 28 115 0,1146 
K.GAEAANVTGPGGVPVQGS
K.Y 
elongation factor Tu [Homo sapiens] gi|31092 50095 4 130 9 37 0,0854 R.YEEIVKEVSTYIK.K 
HNRPF protein [Homo sapiens] gi|16876910 45671 1 66 3 66 0,0805 K.HSGPNSADSANDGFVR.L 
Rev interacting protein Rip-1 gi|1326184 33263 2 60 6 37 0,0634 R.SVSFEQAVR.I 
translation initiation factor (Ddx48) [Homo 
sapiens] 
gi|496902 46803 1 13 3 13 0,1046 R.GIYAYGFEKPSAIQQR.A 
NF45 protein gi|532313 44669 2 117 5 65 0,0579 K.VLQSALAAIR.H 
LYAR [Homo sapiens] gi|49065522 43626 1 92 3 92 0,0949 R.ELLEQISAFDNVPR.K 
KIAA0264 [Homo sapiens] gi|1665795 47767 1 89 4 58 0,0533 R.LIDNISSR.E 
MEP50 protein (MEP50) [Homo sapiens] gi|13559060 36701 1 31 4 31 0,0842 R.YRSDGALLLGASSLSGR.C 
mitochondrial ribosomal protein S5 [Homo 
sapiens] 
gi|13994259 47976 2 105 5 73 0,0862 R.AIITICR.L + Carb 
ionizing radiation resistance conferring protein – 
human 
gi|7430427 43584 3 104 - 45 0,0508 R.NATDAVGIVLK.E 
Mitochondrial ribosomal protein S22 [Homo 
sapiens] 
gi|14424546 41254 2 169 12 30 0,0572 K.DQAAEGINLIK.V 
60S acidic ribosomal protein P0 (L10E) gi|3041728 33236 2 229 14 57 0,1075 R.GTIEILSDVQLIK.T 
ribosomal protein L6 [Homo sapiens] gi|36138 32841 3 99 10 46 0,0912 R.SVFALTNGIYPHK.L 
Hypothetical protein PRO1855 [Homo sapiens] gi|16877878 34909 2 42 7 28 0,152 K.LVTLPVSFAQLK.N 
ribosomal protein S3a [Homo sapiens] gi|4506723 29926 7 279 35 57 0,1812 R.EVQTNDLKEVVNK.L 
prohibitin 2 [Homo sapiens] gi|6005854 33276 2 143 12 74 0,1698 K.LLLGAGAVAYGVR.E 
ribosomal protein S2 [Homo sapiens] gi|15055539 31305 8 442 40 63 0,1102 R.GTGIVSAPVPK.K 
mitochondrial ribosomal protein S2 [Homo 
sapiens] 
gi|55958121 30460 1 32 2 32 0,1113 K.GIILFISR.N 
ribosomal protein S6 gi|337514 28614 3 173 31 59 0,1626 L.LFNLSKEDDVR.E 
S3 ribosomal protein [Homo sapiens] gi|7765076 26699 6 350 33 72 0,1654 R.ELAEDGYSGVEVR.V 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma subunit isoform H (heart) 
precursor [Homo sapiens] ?alpha subunit found 
gi|4885079 32860 1 106 8 67 0,1784 R.IYGLGSLALYEK.A 
solute carrier family 25 member 3 isoform a 
precursor [Homo sapiens] 
gi|6031192 40069 1 50 3 50 0,187 R.IQTQPGYANTLR.D 
ribosomal protein S4 gi|227229 29664 4 208 18 64 0,1729 K.VNDTIQIDLETGK.I 
ribosomal protein L7 [Homo sapiens] gi|35903 29164 3 178 12 81 0,1303 R.IALTDNALIAR.S 
ribosomal protein L14 [Homo sapiens] gi|1620022 23788 1 49 5 49 0,1671 K.LVAIVDVIDQNR.A 
unnamed protein product [Homo sapiens] gi|34392 24191 1 33 3 33 0,11 K.ATFDAISK.T 
prohibitin [Homo sapiens] gi|4505773 29786 4 203 16 83 0,1505 R.FDAGELITQR.E 
ADP.ATP translocase gi|339721 28042 4 182 15 63 0,1574 R.AAYFGIYDTAK.G 
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protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
ribosomal protein L13 [Homo sapiens] gi|15431297 24247 1 / 2 101 / 79 11 / 8 67 / 46 
0,2710 
/ 
0,1869 
K.STESLQANVQR.L / 
R.VATWFNQPAR.K 
ribosomal protein L10 [Homo sapiens] gi|5174431 24561 5 290 38 52 0,2486 R.GAFGKPQGTVAR.V 
ribosomal protein L13a [Homo sapiens] gi|6912634 23562 4 244 29 68 0,2626 K.YQAVTATLEEK.R 
ribosomal protein S9 gi|550023 22558 4 123 16 48 0,2173 R.LFEGNALLR.R 
mitochondrial ribosomal protein S23 [Homo 
sapiens] 
gi|16554604 21757 2 55 11 37 0,3242 K.APIQDIWYHEDR.I 
ribosomal protein L19 [Homo sapiens] gi|4506609 
 
1 56 4 56 0,1872 K.LLADQAEAR.R 
mitochondrial ribosomal protein S15 [Homo 
sapiens] 
gi|16554611 29823 1 46 3 46 0,2045 K.IVANPEDTR.S 
ribosomal protein L29 [Homo sapiens] gi|793843 17656 1 93 10 51 0,2829 K.AQAAAPASVPAQAPK.R 
Ribosomal protein S5 [Homo sapiens] gi|550021 22763 1 45 4 45 0,2053 R.QAVDVSPLR.R 
Ribosomal protein L17 [Homo sapiens] gi|42542645 21402 6 391 51 46 0,2477 R.YSLDPENPTK.S 
ribosomal protein L24 [Homo sapiens] gi|4506619 17768 3 327 30 62 0,2436 R.TDGKVFQFLNAK.C 
ribosomal protein S7 [Homo sapiens] gi|4506741 22113 2 36 8 18 / 18 
0,1832 
/ 
0,2003 
R.ELNITAAK.E / 
K.HVVFIAQR.R 
RPL21 protein [Homo sapiens] gi|38649057 18553 1 36 9 36 0,3273 R.VYNVTQHAVGIVVNK.Q 
FUS interacting protein (serine-arginine rich) 1 
[Homo sapiens] 
gi|55961039 22122 1 31 6 31 0,2568 R.YLRPPNTSLFVR.N 
ribosomal protein L26 gi|292435 17278 4 169 28 43 0,1556 K.YVIYIER.V 
ribosomal protein L11 [Homo sapiens] gi|14719845 20112 3 152 19 77 0,2808 K.VLEQLTGQTPVFSK.A 
ribosomal protein L23a [Homo sapiens] gi|1574942 17629 2 117 13 68 0,2592 R.LAPDYDALDVANK.I 
ribosomal protein L18a [Homo sapiens] gi|11415026 20749 1 24 3 24 0,1656 K.NFGIWLR.Y 
ribosomal protein L27a [Homo sapiens] gi|4506625 16551 4 142 14 76 0,1704 K.TGAAPIIDVVR.S 
ribosomal protein L28 gi|550019 15752 3 132 17 62 0,2314 K.QTYSTEPNNLK.A 
ribosomal protein L35 [Homo sapiens] gi|6005860 14543 2 122 21 49 0,2655 R.VLTVINQTQKENLR.K 
Ribosomal protein S18 [Homo sapiens] gi|75517276 17708 3 233 30 89 0,1868 R.AGELTEDEVER.V 
ribosomal protein S26 [Homo sapiens] gi|296452 12922 2 221 31 124 0,2636 R.DISEASVFDAYVLPK.L 
ribosomal protein L23 [Homo sapiens] gi|4506605 14856 2 148 30 34 0,1091 K.NLYIISVK.G 
ribosomal protein homologous to yeast S24 
[Homo sapiens] 
gi|36142 14707 2 135 25 59 0,2588 K.HGYIGEFEIIDDHR.A 
ribosomal protein S23 [Homo sapiens] gi|3088342 6465 2 110 38 69 0,1774 K.VANVSLLALYK.G 
PREDICTED: similar to ribosomal protein S27 
[Homo sapiens] 
gi|51463957 18745 1 86 - 41 0,2139 K.DLLHPSPEEEKR.K 
ribosomal protein L38 [Homo sapiens] gi|3088356 4291 2 79 59 51 0,2235 R.YLYTLVITDKEK.A 
splicing factor 3B, 14 kDa subunit [Homo 
sapiens] 
gi|7706326 14576 2 71 16 42 0,2498 R.GTAYVVYEDIFDAK.N 
ribosomal protein L31 [Homo sapiens] gi|1655596 14084 2 67 28 32 0,2614 K.LYTLVTYVPVTTFK.N 
mitochondrial ribosomal protein S16 [Homo 
sapiens] 
gi|7705626 15335 2 41 18 38 0,1442 K.LVALNLDR.I 
ribosomal protein L35a [Homo sapiens] gi|16117791 12530 1 36 13 28 0,1292 K.IEGVYAR.D 
PHD-finger 5A [Homo sapiens] gi|14249398 12397 1 33 6 33 0,1486 K.TDLFYER.K 
 
 
Supplementary Table 3: Mass spectrometry data on Ago1 complex III 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic translation initiation factor 2C, 1 
(Ago1) [Homo sapiens] 
gi|6912352 97152 24 1797 60 89 0,2587 K.LLANYFEVDIPK.I 
Transcription factor (TFIIIC) alpha chain, partial 
[Homo sapiens] 
gi|2342740 209464 2 105 1 43 0,1593 R.GYYSPGIVSTR.N 
RNA helicase A – human  gi|1082769 141984 20 1135 26 64 0,1842 K.LAQFEPSQR.Q 
hnRNP U protein [Homo sapiens] gi|32358 88890 12 401 16 95 0,2567 
K.SSGPTSLFAVTVAPPGAR.
Q 
MYB binding protein 1a [Homo sapiens] gi|7657351 148758 12 628 13 69 0,1538 K.ALVDILSEVSK.A 
ubiquitin gi|229532 8446 1 26 12 26 0,1429 R.TLSDYNIQK.E 
Dicer [Homo sapiens] gi|5019620 218673 2 62 0 62 0,1331 R.AQTASDAGVGVR.S 
U5 snRNP-specific 200kD protein [Homo 
sapiens] 
gi|3255965 194356 2 46 0 27 0,1184 R.TYTQLVR.L 
polymerase (RNA) I polypeptide A, 194kDa 
[Homo sapiens] 
gi|7661686 194068 1 32 - 32 0,1293 R.GYLTPTSAR.E 
proliferation-inducing protein 32 [Homo sapiens] gi|45643460 162923 11 421 9 84 0,2010 K.SLYDEVAAQGEVVR.K 
PELP1 [Homo sapiens] gi|21426922 136556 7 320 7 65 0,1701 R.LPSLGAGFSQGLK.H 
coatomer protein [Homo sapiens] gi|1002369 138244 6 247 6 53 0,1850 K.LVGQSIIAYLQK.K 
DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1 (Ddx30) [Homo sapiens] 
gi|20336294 133854 14 662 16 76 0,2654 R.ENYLEENLLYAPSLR.F 
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protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
regulator of nonsense transcript stability 
(RENT1) [Homo sapiens] 
gi|1575536 123039 8 293 9 51 / 51 
0,1395 
/ 
0,1640 
R.YGVIIVGNPK.A / 
R.EAIIPGSVYDR.S 
squamous cell carcinoma antigen recognized by 
T cells 3 (SART3) [Homo sapiens] 
gi|7661952 109865 
      
Splicing factor 3B subunit 3 (Spliceosome 
associated protein 130) (SAP 130) (SF3b130) 
(Pre-mRNA splicing factor SF3b 130 kDa 
subunit) (STAF130) 
gi|19863446 135507 2 82 - 46 0,1859 R.FLAVGLVDNTVR.I 
spliceosomal protein SAP 155 [Homo sapiens] gi|4033735 145723 1 32 1 14 0,1482 K.TEILPPFFK.H 
unnamed protein product [Homo sapiens] gi|7023011 113841 3 84 2 52 0,1564 R.QSILNSLSR.G 
novel S-100\/ICaBP type calcium binding domain 
and EF hand domain containing protein [Homo 
sapiens] 
gi|12314268 24325 1 54 - 54 0,2037 R.SVVTVIDVFYK.Y 
KIAA1488 protein (Dhx36) [Homo sapiens] gi|7959237 97766 1 38 1 38 0,1752 R.LGGIAYFLSR.L 
matrin 3 [Homo sapiens] gi|6563246 95138 1 36 1 36 0,1478 K.SFQQSSLSR.D 
Chain A, Human Dna Topoisomerase I (70 Kda) 
In Non-Covalent Complex With A 22 Base Pair 
Dna Duplex 
gi|3659924 69975 5 210 11 65 0,2323 R.TYNASITLQQQLK.E 
gemin4 [Homo sapiens] gi|7657122 119913 3 123 - 52 0,2582 R.LLETVIDVSTADR.A 
Nucleolin (Protein C23) gi|128841 76298 3 94 - 42 0,3323 R.SISLYYTGEKGQNQDYR.G 
serine protein kinase SRPK1 – human  gi|630737 74273 1 45 - 45 0,2781 K.SAEAYTETALDEIR.L 
RNA helicase Gu - human (fragment)  gi|2135315 89196 5 142 - 41 0,2663 K.STYEQVDLIGKK.T 
NF-90 [Homo sapiens] gi|5006602 82749 9 470 18 47 0,2972 
K.AVSDWIDEQEK.G / 
R.IFVNDDR.H 
nbla10363 [Homo sapiens] gi|19911062 105622 3 132 4 41 0,1882 K.SLQATALR.I 
fragile X mental retardation syndrome related 
protein 2 [Homo sapiens] 
gi|4758410 74083 4 122 6 62 0,3632 K.AGYSTDESSSSSLHATR.T 
novel protein [Homo sapiens] gi|5578958 81192 1 50 3 31 0,3445 R.GLHSQNFTQALLER.M 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 
[Homo sapiens] 
gi|55664207 82514 2 48 4 27 0,2840 R.GVTYLFPIQVK.T 
motor protein [Homo sapiens] gi|516764 79659 1 41 1 41 0,3122 K.VVSQYHELVVQAR.D 
90kDa heat shock protein gi|306891 83242 1 37 1 37 0,2755 K.ADLINNLGTIAK.S 
general transcription factor IIIC, polypeptide 4, 
90kDa [Homo sapiens] 
gi|6912400 91943 1 31 1 31 0,2307 K.QVDLIDLVR.W 
RNA helicase (Ddx18) [Homo sapiens] gi|1498229 68416 3 201 7 77 0,3234 K.LGNGINIIVATPGR.L 
motor protein [Homo sapiens] gi|516768 83626 3 117 5 52 0,2728 R.YSTSGSSGLTTGK.I 
ZNF326 protein [Homo sapiens] gi|47125447 57787 2 112 4 72 0,3989 R.ESVLTATSILNNPIVK.A 
FMR1 gi|182673 74981 1 22 1 22 0,2391 R.LQIDEQLR.Q 
polyadenylate binding protein II [Homo sapiens] gi|693937 58481 16 808 39 66 0,2400 R.IVATKPLYVALAQR.K 
putative G-binding protein [Homo sapiens] gi|3153873 65375 2 78 4 52 0,2486 R.ADVDVQPYAFTTK.S 
IGF-II mRNA-binding protein 1 (ZBP-1) [Homo 
sapiens] 
gi|56237027 63441 10 499 21 92 0,3391 K.ITISSLQDLTLYNPER.T 
IGF-II mRNA-binding protein 3 (ZBP-3) [Homo 
sapiens] 
gi|30795212 63666 6 274 12 61 0,2814 R.DQTPDENDQVVVK.I 
E2IG3 [Homo sapiens] gi|6457340 63528 6 207 11 49 0,1862 K.GGIPNVEGAAK.L 
PBK1 protein [Homo sapiens] gi|3668141 58097 3 103 5 37 0,1655 R.LLPSLIGR.H 
NSAP1 protein [Homo sapiens] gi|5031512 62617 2 65 3 44 0,2641 R.NLANTVTEEILEK.A 
hNop56 [Homo sapiens] gi|2230878 66807 2 62 3 39 0,1809 R.VVSLSEYR.Q 
G22P1 [Homo sapiens] gi|49457432 69829 1 53 1 53 0,2187 R.DSLIFLVDASK.A 
KIAA1273 protein [Homo sapiens] gi|6382028 68066 2 47 3 35 0,1802 R.QTVLESIR.T 
Similar to ribophorin I [Homo sapiens] gi|14124942 64542 1 31 1 31 0,1624 K.IILPEGAK.N 
heterogeneous nuclear ribonucleoprotein L 
[Homo sapiens] 
gi|11527777 64046 1 55 1 55 0,2128 R.SSSGLLEWESK.S 
t-complex polypeptide 1 [Homo sapiens] gi|36796 60356 1 37 1 37 0,1868 R.YPVNSVNILK.A 
testis-specific poly(A)-binding protein [Homo 
sapiens] 
gi|11610605 70072 1 33 2 33 0,2196 R.IVATKPLYVALAQR.K 
ribophorin II precursor – human gi|88567 69273 1 29 - 29 0,1694 R.YIANTVELR.V 
Ost-I [Homo sapiens] gi|41386665 102111 1 13 1 13 0,1875 R.HLCDQFSAEIAR.R + Carb. 
ribosomal protein L4 [Homo sapiens] gi|16579885 47667 5 279 19 43 0,1513 R.NIPGITLLNVSK.L 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 47 
isoform 1 [Homo sapiens] 
gi|20149629 50615 2 85 5 43 0,1470 R.DIIGLAETGSGK.T 
nuclear RNA helicase (Ddx39) [Homo sapiens] gi|1905998 49046 1 45 2 45 0,1370 R.ILVATNLFGR.G 
translation initiation factor (KIAA0111) [Homo 
sapiens] 
gi|496902 46803 6 207 15 51 0,1949 R.ETQALILAPTR.E 
Ribosomal protein P0 [Homo sapiens] gi|12654583 34253 7 519 43 76 0,0606 K.TSFFQALGITTK.I 
Mov10 gi|14424568 43599 6 52 6 52 0,06 R.ITGNPVVTNP.I 
NF45 protein gi|532313 44669 8 469 25 64 / 64 
0,0115 
/ 
0,0249 
K.VLQSALAAIR.H / 
K.ILPTLEAVAALGNK.V 
PAK/PLC-interacting protein 1 [Homo sapiens] gi|14211689 44076 1 44 2 44 0,1426 K.LALSVGTDK.T 
unnamed protein product [Homo sapiens] gi|31092 50095 1 37 2 37 0,1690 K.IGGIGTVPVGR.V 
KIAA1756 protein [Homo sapiens] gi|12698057 116668 1 30 0 30 0,0590 R.AELEKVLR.A 
 APPENDIX  
115 
 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
R32184_1 [Homo sapiens] gi|3025445 47276 1 26 2 26 0,1660 K.SVLGGQDQLR.V 
WS beta-transducin repeats protein [Homo 
sapiens] 
gi|4704417 47537 1 24 2 24 0,1765 K.YLATCADDR.T + Carb. 
HNRPC protein [Homo sapiens] gi|13937888 33578 4 349 20 71 0,0539 R.VFIGNLNTLVVK.K 
RNA polymerase I subunit isoform 2 [Homo 
sapiens] 
gi|4759046 38623 2 93 5 49 0,0182 R.VVLGEFGVR.N 
ribosomal protein L6 [Homo sapiens] gi|36138 32841 7 265 22 50 0,0414 K.FVIATSTK.I 
EBNA1 binding protein 2 [Homo sapiens] gi|5803111 34798 1 55 3 55 0,0383 R.ESYDDVSSFR.A 
B23 nucleophosmin (280 AA) [Homo sapiens] gi|825671 30919 2 109 7 57 0,0379 K.GPSSVEDIK.A 
hnRNP-E2 [Homo sapiens] gi|460773 38556 1 56 3 56 0,0448 K.IANPVEGSTDR.Q 
HuR RNA binding protein gi|1022961 36039 1 73 3 73 0,0541 R.VLVDQTTGLSR.G 
putative dimethyladenosine transferase [Homo 
sapiens] 
gi|3646270 17915 1 46 6 46 0,0453 K.SSAVQQLLEK.N 
prohibitin 2 [Homo sapiens] gi|6005854 33276 10 513 35 90 0,0478 K.FNASQLITQR.A 
ribosomal protein S3a [Homo sapiens] gi|4506723 29926 4 278 38 56 0,0516 R.EVQTNDLKEVVNK.L 
ribosomal protein S6 gi|337514 28614 2 289 16 73 0,0372 K.LIEVDDER.K 
SMN-interacting protein 1 isoform alpha [Homo 
sapiens] 
gi|4506961 
 
1 32 2 32 0,0362 R.TPQEYLR.R 
PREDICTED: hypothetical protein XP_499151 
[Homo sapiens] 
gi|51467206 12243 1 22 - 22 0,1148 K.VCSWPVDLDSK.G 
distal-less homeobox 4 isoform a [Homo sapiens] gi|20143962 26246 1 22 6 22 0,0799 
-.MTSLPCPLPGRDASK.A  
+ Oxid. 
ribosomal protein L7a [Homo sapiens] gi|4506661 29977 11 535 50 92 0,0422 R.AGVNTVTTLVENK.K 
Ribosomal protein L8 [Homo sapiens] gi|15341853 27993 7 311 27 76 0,0493 R.ASGNYATVISHNPETK.K 
ribosomal protein S2 [Homo sapiens] gi|15055539 31305 6 277 25 48 0,0565 K.TYSYLTPDLWK.E 
S3 ribosomal protein [Homo sapiens] gi|7765076 26699 3 165 18 67 0,0604 R.ELAEDGYSGVEVR.V 
solute carrier family 25 member 3 isoform a 
precursor [Homo sapiens] 
gi|6031192 40069 1 50 3 50 0,0594 R.IQTQPGYANTLR.D 
scar protein gi|337930 27386 10 423 42 90 0,0455 K.VNDTIQIDLETGK.I 
ribosomal protein L7 [Homo sapiens] gi|35903 29164 6 304 36 83 0,0317 R.IALTDNALIAR.S 
prohibitin [Homo sapiens] gi|4505773 29786 6 308 23 89 0,0292 K.AAIISAEGDSK.A 
ADP.ATP translocase gi|339721 28042 2 79 9 42 0,0444 R.AAYFGIYDTAK.G 
Unknown (protein for MGC:117326) [Homo 
sapiens] 
gi|76779245 36999 10 440 27 98 0,0343 R.IALTDNALIAR.S 
ribosomal protein S4 gi|227229 29664 2 82 9 57 0,0297 R.LSNIFVIGK.G 
ribosomal protein S8 [Homo sapiens] gi|55961080 2186 2 79 13 64 0,0221 K.ISSLLEEQFQQGK.L 
60S ribosomal protein L13 gi|6831614 24378 1 72 5 72 0,0266 K.STESLQANVQR.L 
ribosomal protein L13 [Homo sapiens] gi|15431297 24247 2 139 16 72 -0,0036 K.STESLQANVQR.L 
ribosomal protein L14 [Homo sapiens] gi|1620022 23788 1 86 5 86 0,0163 K.LVAIVDVIDQNR.A 
ribosomal protein L19 [Homo sapiens] gi|4506609 
 
1 72 4 72 -0,0192 K.LLADQAEAR.R 
ribosomal protein L18 [Homo sapiens] gi|4506607 21621 7 453 41 103 -0,0268 K.ILTFDQLALDSPK.G 
ribosomal protein L13a [Homo sapiens] gi|6912634 23562 4 237 28 68 -0,0100 K.YQAVTATLEEK.R 
ribosomal protein L15 [Homo sapiens] gi|15431293 24131 4 140 18 65 -0,0128 R.SLQSVAEER.A 
ribosomal protein S9 gi|550023 22558 9 373 39 49 0,0154 R.LGVLDEGK.M 
ribosomal protein L10 [Homo sapiens] gi|5174431 24561 2 83 17 35 -0,0132 R.GAFGKPQGTVAR.V 
Ribosomal protein S5 [Homo sapiens] gi|15929961 22862 1 51 4 51 -0,0091 R.QAVDVSPLR.R 
ribosomal protein L29 [Homo sapiens] gi|793843 17656 2 130 15 56 -0,0696 K.AQAAAPASVPAQAPKR.T 
ribosomal protein S7 [Homo sapiens] gi|4506741 22113 5 196 18 46 -0,0254 K.VETFSGVYK.K 
Ribosomal protein L17 [Homo sapiens] gi|42542645 21402 3 198 23 51 -0,0285 R.YSLDPENPTK.S 
L21 ribosomal protein gi|619788 17646 2 80 17 43 -0,0441 R.VYNVTQHAVGIVVNK.Q 
ribosomal protein L24 [Homo sapiens] gi|4506619 17768 3 191 21 45 -0,0534 R.TDGKVFQFLNAK.C 
ribosomal protein L18a [Homo sapiens] gi|11415026 20749 2 43 30 43 -0,0278 R.IFAPNHVVAK.S 
ribosomal protein L11 [Homo sapiens] gi|14719845 20112 7 363 31 97 -0,0372 K.VLEQLTGQTPVFSK.A 
ribosomal protein L26 [Homo sapiens gi|4506621 17248 3 243 26 33 -0,0321 K.DDEVQVVR.G 
ribosomal protein L12 [Homo sapiens] gi|55665101 17808 3 165 24 65 -0,0607 K.HSGNITFDEIVNIAR.Q 
ribosomal protein L23a [Homo sapiens] gi|1574942 17629 2 108 13 59 -0,0328 R.LAPDYDALDVANK.I 
ribosomal protein L27a [Homo sapiens] gi|4432754 3706 1 57 32 57 -0,0284 K.TGAAPIIDVVR.S 
ribosomal protein L28 gi|550019 15752 5 338 43 52 / 52 
-0,0343 
/ -
0,0738 
K.GVVVVIKR.R / 
K.QTYSTEPNNLKAR.N 
ribosomal protein L11 [Homo sapiens] gi|495126 20103 3 215 16 55 -0,0786 K.VLEQLTGQTPVFSKAR.Y 
ribosomal protein S13 [Homo sapiens] gi|553640 13313 4 101 24 50 -0,0420 K.GLTPSQIGVILR.D 
PREDICTED: similar to 60S ribosomal protein 
L32 [Homo sapiens] 
gi| 51467067 52271 1 64 - 39 -0,0630 R.AAQLAIRVTNPNAR.Q 
ribosomal protein L35 [Homo sapiens] gi|6005860 14543 2 142 21 47 -0,0744 R.VLTVINQTQKENLR.K 
ribosomal protein S26 [Homo sapiens] gi|296452 12922 2 168 31 73 -0,0614 R.DISEASVFDAYVLPK.L 
ribosomal protein L23 [Homo sapiens] gi|4506605 14856 2 247 51 39 -0,0393 K.GSAITGPVAK.E 
Ribosomal protein S15a [Homo sapiens] gi|12804561 14770 3 209 60 74 -0,0769 K.HGYIGEFEIIDDHR.A 
ribosomal protein L37a [Homo sapiens] gi|4506643 10268 1 132 39 102 -0,0533 
K.TVAGGAWTYNTTSAVTVK.
S 
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PREDICTED: similar to ribosomal protein S27 
[Homo sapiens] 
gi|51463957 18745 1 94 - 41 -0,0609 K.DLLHPSPEEEKR.K 
 
 
Supplementary Table 4: Mass spectrometry data on Ago2 complex I 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic initiation factor 2C2 (Ago2) [Homo 
sapiens] 
gi|29171734 97146 12 1104 40 91 0,0204 R.SVSIPAPAYYAHLVAFR.A 
solute carrier family 25 member 3 isoform a 
precursor [Homo sapiens] 
gi|6031192 40069 5 217 14 62 0,0382 R.IQTQPGYANTLR.D 
Dicer [Homo sapiens] gi|5019620 218673 6 353 5 112 0,0632 K.SNAETATDLVVLDR.Y 
KIAA1093 protein [Homo sapiens] gi|14133235 183156 3 169 3 74 0,0779 K.TGSVGSWGAAR.G 
HsGCN1 [Homo sapiens] gi|2282576 211377 1 41 0 41 0,0405 K.ASLLDPVPEVR.T 
Na+,K+ ATPase [Homo sapiens] gi|1359715 111901 1 122 3 47 0,0305 R.LNIPVSQVNPR.D 
RNA-binding protein 10 (RNA-binding motif 
protein 10) (DXS8237E) 
gi|12644371 103396 1 40 1 40 0,0326 R.DGLGSDNIGSR.M 
HSPC273 [Homo sapiens] gi|6841196 25891 1 95 10 74 0,1177 R.ELGENLDQILR.A 
importin 4 [Homo sapiens] gi|18700635 118642 1 70 1 41 0,0912 R.ELLLPDTER.I 
DNA damage binding protein 1 (Damage-specific 
DNA binding protein 1) (DDB p127 subunit) 
(DDBa) (UV-damaged DNA-binding protein 1) 
(UV-DDB 1) 
gi|418316 126901 1 31 2 24 0,1030 K.VTLGTQPTVLR.T 
importin 8 [Homo sapiens gi|53759103 119861 1 30 0 30 0,1061 K.IINFAPSLLR.I 
eukaryotic translation initiation factor 2C, 3 
(Ago3) [Homo sapiens] 
gi|56204478 71165 12 1104 16 91 0,0204 R.SVSIPAPAYYAHLVAFR.A 
Heat shock protein 90 [Homo sapiens] gi|56204416 83212 8 520 13 81 0,0209 R.GVVDSEDLPLNISR.E 
PREDICTED: similar to liver 
phosphofructokinase isoform b; 6-
phosphofructokinase, liver type; liver-type 1-
phosphofructokinase; phosphofructokinase 1 
gi|55657570 85437 1 53 - 48 0,0934 R.FDEATQLR.G 
initation factor 4B [Homo sapiens] gi|288100 69183 1 32 2 32 0,1246 R.AASIFGGAKPVDTAAR.E 
MTHSP75 gi|292059 73734 2 25 6 33 0,0469 R.QAVTNPNNTFYATKR.L 
Skb1Hs [Homo sapiens] gi|82581643 72520 10 710 25 66 0,1128 K.YSQYQQAIYK.C 
aralar2 [Homo sapiens] gi|6523256 74093 2 100 2 61 0,1153 R.LQVAGEITTGPR.V 
proteasome subunit p58 [Homo sapiens] gi|2656092 60968 1 44 2 44 0,0964 R.VYEFLDKLDVVR.S 
glycoprotein-associated amino acid transporter 
hb0,+AT1 [Homo sapiens] 
gi|5823978 53436 1 32 1 32 0,0358 K.VLSYISVRR.L 
Chaperonin [Homo sapiens] gi|49522865 61016 5 348 10 79 0,0927 K.NAGVEGSLIVEK.I 
mitogen-activated protein kinase kinase kinase 7 
interacting protein 1 isoform alpha [Homo 
sapiens] 
gi|5174703 54610 1 64 2 64 0,1068 K.YGYTDIDLLSAAK.S 
TATA binding protein interacting protein 49 kDa 
[Homo sapiens] 
gi|4506753 50196 1 61 2 61 0,0746 K.QAASGLVGQENAR.E 
elongation factor Tu gi|556301 50132 4 196 10 65 0,0505 K.THINIVVIGHVDSGK.S 
RuvB-like 2 [Homo sapiens] gi|5730023 51125 2 140 4 82 0,0451 R.GLGLDDALEPR.R 
trans-activation-responsive RNA-binding protein 
- human (TRBP) (fragment) 
gi|107904 38814 1 46 2 46 0,0250 R.FIEIGSGTSK.K 
unnamed protein product [Homo sapiens] gi|31092 50095 3 88 6 39 0,0260 K.IGGIGTVPVGR.V 
HNRPF protein [Homo sapiens] gi|16876910 45671 1 64 4 51 0,0328 R.YIEVFKSSQEEVR.S 
26S proteasome regulatory chain 4 [validated] – 
human 
gi|345717 49210 1 46 - 46 0,0247 K.GVILYGPPGTGK.T 
MEP50 protein (MEP50) [Homo sapiens] gi|13559060 36701 4 343 21 89 0,0813 K.VWDLAQQVVLSSYR.A 
brain tumor associated protein LRRC4 [Homo 
sapiens] 
gi|14495561 72671 1 47 1 47 0,0122 R.MAELKCR.T 
otopetrin 2 [Homo sapiens] gi|30039714 62195 1 43 1 43 0,0044 R.EAVAIVSTPR.S 
Cl channel gi|228672 25872 1 92 5 92 0,0186 K.GLGTGTLYIAESR.L 
7-dehydrocholesterol reductase [Homo sapiens] gi|3171089 53073 1 38 1 38 0,0129 R.YTAAVPYR.L 
oxidase (cytochrome c) assembly 1-like [Homo 
sapiens] 
gi|4826880 55262 1 37 1 37 0,0062 R.NQLELAAR.G 
[Human pre-mRNA splicing factor SF2p32, 
complete sequence.], gene product 
gi|338043 30888 4 469 33 81 0,0706 R.EVSFQSTGESEWK.D 
emerin [Homo sapiens] gi|4557553 28976 1 40 3 40 0,0357 R.APGAGLGQDR.Q 
Solute carrier family 25, member A6 [Homo 
sapiens] 
gi|15928608 32905 12 420 33 66 0,0461 K.LLLQVQHASK.Q 
solute carrier family 25, member 5 [Homo 
sapiens] 
gi|4502099 32874 11 362 32 71 0,0513 K.DFLAGGVAAAISK.T 
transmembrane protein 33 [Homo sapiens] gi|8922491 27933 2 90 8 60 0,0839 R.ALLANALTSALR.L 
ADP.ATP translocase gi|339721 28042 1 25 4 25 0,0780 R.AAYFGIYDTAK.G 
signal sequence receptor, delta [Homo sapiens] gi|5454090 18987 1 87 13 44 0,0744 R.FFDEESYSLLR.K 
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ribosomal protein S20 [Homo sapiens] gi|3088340 6853 1 38 20 38 0,0502 R.LIDLHSPSEIVK.Q 
ribosomal protein L23 [Homo sapiens] gi|4506605 14856 2 86 20 35 0,0407 K.GSAITGPVAK.E 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4, 9kDa [Homo sapiens] 
gi|75517917 9364 2 52 22 37 0,0487 K.FYSVNVDYSK.L 
ribosomal protein S27 [Homo sapiens] gi|4432748 7686 1 49 17 49 0,0437 -.DLLAPSPEEEKR.K 
ribosomal protein L38 [Homo sapiens] gi|3088356 4291 1 29 27 29 0,0371 K.QSLPPGLAVK.E 
c-myc binding protein [Homo sapiens] gi|1785851 11945 1 24 10 24 0,0610 K.LAQYEPPQEEK.R 
 
 
Supplementary Table 5: Mass spectrometry data on Ago2 complex II 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic translation initiation factor 2C, 2 
(Ago2) [Homo sapiens] 
gi|29171734 97146 20 1819 53 86 0,0231 R.SVSIPAPAYYAHLVAFR.A 
ubiquitin gi|229532 8446 1 30 12 30 -0,0019 R.TLSDYNIQK.E 
proliferation-inducing protein 32 [Homo sapiens] gi|45643460 162923 3 224 4 65 -0,008 K.LTVAENEAETK.L 
hornerin [Homo sapiens] gi|28557150 48569 1 48 3 48 -0,0294 R.GPYESGSGHSSGLGHR.E 
RNA helicase A [Homo sapiens] gi|1806048 140788 7 444 11 87 -0,0199 R.ELDALDANDELTPLGR.I 
splicing factor 3b, subunit 1 isoform 1 [Homo 
sapiens] 
gi|54112117 145738 2 133 3 47 -0,0142 R.ATVNTFGYIAK.A 
Splicing factor 3B subunit 3 (Spliceosome 
associated protein 130) (SAP 130) (SF3b130) 
(Pre-mRNA splicing factor SF3b 130 kDa 
subunit) (STAF130) 
gi|19863446 135507 6 222 - 53 -0,0221 R.FLAVGLVDNTVR.I 
coatomer protein [Homo sapiens] gi|1002369 138244 2 85 2 39 -0,0162 R.TLDLPIYVTR.V 
Splicing factor 3B subunit 2 (Spliceosome 
associated protein 145) (SAP 145) (SF3b150) 
(Pre-mRNA splicing factor SF3b 145 kDa 
subunit) 
gi|2498883 97596 1 62 1 62 -0,0147 R.AAVLLEQER.Q 
hnRNP U protein [Homo sapiens] gi|32358 88890 9 390 13 96 -0,0305 R.NFILDQTNVSAAAQR.R 
DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1 (Ddx30) [Homo sapiens 
gi|20336294 133854 5 257 7 46 -0,0193 K.AIVLAAIFR.C 
RNA-binding protein 10 (RNA-binding motif 
protein 10) (DXS8237E) 
gi|12644371 103396 1 63 1 63 -0,0462 R.ESATADAGYAILEKK.G 
gemin4 [Homo sapiens] gi|7657122 119913 2 81 - 57 -0,0126 R.LLETVIDVSTADR.A 
DHX36 protein (KIAA1488) [Homo sapiens] gi|23243423 111426 1 70 2 61 -0,0344 R.LGGIAYFLSR.L 
RNA helicase Gu - human (fragment)  gi|2135315 89196 3 142 - 59 0,0074 R.AAVIGDVIR.V 
NF-90 gi|1082856 73293 2 118 - 47 0,0057 R.IFVNDDR.H 
ATP-dependent RNA helicase #46 [Homo 
sapiens] 
gi|2696613 92770 1 81 2 38 0,0033 R.YGVIILDEAHER.T 
hypothetical protein LOC55037 [Homo sapiens] gi|38683855 78500 3 129 3 45 0,0180 R.SPALQVLR.E 
Gemin3 gi|14209614 92163 1 30 0 30 1,2 K.EGLEKPVEIIR.H 
polyadenylate binding protein II [Homo sapiens] gi|693937 58481 7 262 20 66 0,0315 R.IVATKPLYVALAQR.K 
Skb1Hs (PRMT 5) [Homo sapiens] gi|2323410 72740 3 166 4 65 0,0228 R.GPLVNASLR.A 
thyroid autoantigen 70kDa (Ku antigen) [Homo 
sapiens] 
gi|57165052 69799 1 36 2 36 0,0367 K.NIYVLQELDNPGAK.R 
E2IG3 [Homo sapiens] gi|6457340 63528 1 36 1 36 0,005 K.GGIPNVEGAAK.L 
sodium bicarbonate cotransporter-like protein 
[Homo sapiens] 
gi|10567590 118582 1 20 1 20 0,0657 K.FEEKVEEGGER.W 
DNA-binding protein B (YB-1) gi|181486 39954 4 222 11 87 -0,1458 
K.GAEAANVTGPGGVPVQGS
K.Y 
RuvB-like 2 [Homo sapiens] gi|12653319 51125 2 69 4 44 -0,0949 R.GLGLDDALEPR.Q 
Ribosomal protein L4 [Homo sapiens] gi|12655035 47667 1 68 4 32 -0,1009 R.NIPGITLLNVSK.L 
unnamed protein product [Homo sapiens] gi|31092 50095 1 55 2 55 -0,0852 K.IGGIGTVPVGR.V 
KIAA0115 [Homo sapiens] gi|473947 50680 1 45 1 45 -0,0815 K.SSLNPILFR.G 
nuclear RNA helicase (Ddx39) [Homo sapiens] gi|1905998 49046 1 18 2 18 -0,1250 R.ILVATNLFGR.G 
NF45 protein gi|532313 44669 4 258 12 70 -0,0847 K.VLQSALAAIR.H 
ribosomal protein L3 gi|337580 45440 2 89 7 38 -0,08 R.HGSLGFLPR.K 
KIAA1756 protein [Homo sapiens] gi|12698057 116668 1 38 0 38 -0,1676 R.AELEKVLR.A 
MRPS27 protein [Homo sapiens] gi|38014602 25008 2 105 10 55 -0,0913 R.EALDVLGAVLK.A 
HNRPC protein [Homo sapiens] gi|13937888 33578 3 184 12 71 -0,1095 R.VFIGNLNTLVVK.K 
7-dehydrocholesterol reductase [Homo sapiens] gi|3171089 53073 1 38 1 38 -0,0803 R.YTAAVPYR.L 
protein translation initiation factor 2C2; EIF2C2 
[Homo sapiens] 
gi|6468775 42502 1 29 0 29 -0,0889 R.ELLIQFYK.S 
Mitochondrial ribosomal protein S22 [Homo 
sapiens] 
gi|14424546 41254 2 98 6 60 -0,1498 K.ILTPIIFKEENLR.T 
ribosomal protein L6 [Homo sapiens] gi|36138 32841 2 79 5 45 -0,0726 K.FVIATSTK.I 
fibrillarin gi|182592 33797 1 51 3 51 -0,1100 R.TNIIPVIEDAR.H 
ribosomal protein S2 [Homo sapiens] gi|15055539 31305 6 475 35 54 -0,1249 K.TYSYLTPDLWK.E 
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hypothetical protein LOC84319 [Homo sapiens] gi|14150167 31792 1 31 3 31 -0,0925 K.QGGLNLSPLK.F 
prohibitin 2 [Homo sapiens] gi|6005854 33276 6 389 29 78 -0,1100 K.FNASQLITQR.A 
ribosomal protein S3a [Homo sapiens] gi|4506723 29926 6 245 28 52 -0,0928 K.LITEDVQGK.N 
ribosomal protein S6 gi|337514 28633 4 182 25 58 -0,09 K.LIEVDDR.K 
S3 ribosomal protein [Homo sapiens] gi|7765076 26699 12 725 65 75 -0,1272 R.ELAEDGYSGVEVR.V 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma subunit isoform H (heart) 
precursor [Homo sapiens] 
gi|4885079 32860 2 160 12 59 -0,0931 K.SEVATLTAAGK.E 
Ribosomal protein L8 [Homo sapiens] gi|15341853 27993 1 49 4 49 -0,0799 R.AVVGVVAGGGR.I 
solute carrier family 25 member 3 isoform a 
precursor [Homo sapiens] 
gi|6031192 40069 1 27 1 27 -0,0692 R.TVEALYK.F 
scar protein gi|337930 27386 7 330 32 64 -0,1010 K.DANGNSFATR.L 
prohibitin [Homo sapiens] gi|4505773 29786 5 159 19 62 -0,0952 K.AAIISAEGDSK.A 
PREDICTED: similar to SLC25A5 protein [Homo 
sapiens] 
gi|51460683 40069 3 127 - 50 -0,1368 R.VKLLLQVQHASK.Q 
Solute carrier family 25, member A6 [Homo 
sapiens] 
gi|15928608 32905 3 126 10 47 -0,1097 R.AAYFGVYDTAK.G 
Similar to ribosomal protein S8 [Homo sapiens] gi|13542987 9277 3 161 41 99 -0,1323 K.ISSLLEEQFQQGK.L 
ribosomal protein S9 gi|550023 22558 9 351 36 52 -0,0945 R.LFEGNALLR.R 
ribosomal protein S5 gi|550021 22763 1 147 14 58 -0,0871 R.QAVDVSPLR.R 
ribosomal protein L24 [Homo sapiens] gi|4506619 17768 2 197 26 50 -0,1190 R.QINWTVLYR.R 
ribosomal protein L29 [Homo sapiens] gi|793843 17656 1 38 9 38 -0,1299 K.AQAAAPASVPAQAPK.R 
ribosomal protein L13a [Homo sapiens] gi|6912634 23562 1 31 3 31 -0,0735 R.KFAYLGR.L 
Ribosomal protein L17 [Homo sapiens] gi|42542645 21402 4 231 34 59 -0,1090 R.YSLDPENPTK.S 
homology to rat ribosomal protein L23 gi|306549 16730 2 99 14 68 -0,1240 R.LAPDYDALDVANK.I 
ribosomal protein L27a [Homo sapiens] gi|4432754 3706 1 76 32 76 -0,0830 K.TGAAPIIDVVR.S 
ribosomal protein L26 gi|292435 17278 3 186 26 47 -0,1496 K.ANGTTVHVGIHPSK.V 
ribosomal protein L27a [Homo sapiens] gi|4506625 16551 4 170 29 76 -0,1032 K.TGAAPIIDVVR.S 
ribosomal protein L11 [Homo sapiens] gi|495126 20103 1 111 7 111 -0,1332 K.VLEQLTGQTPVFSK.A 
Ribosomal protein S18 [Homo sapiens] gi|75517910 17708 1 90 11 70 -0,0951 R.VLNTNIDGR.R 
ribosomal protein L31 [Homo sapiens] gi|1655596 14084 2 46 / 32 11 / 7 46 / 32 
-0,1070 
/ -
0,1004 
K.LYTLVTYVPVTTFK.N / 
R.SAINEVVTR.E 
ribosomal protein S26 [Homo sapiens] gi|296452 12922 2 147 20 100 -0,1180 R.DISEASVFDAYVLPK.L 
Ribosomal protein S15a [Homo sapiens] gi|12804561 14770 1 92 20 45 -0,0610 K.IVVNLTGR.L 
ribosomal protein L35 [Homo sapiens] gi|6005860 14543 2 78 18 45 -0,0876 R.VLTVINQTQK.E 
histone H2A.5 - human  gi|70686 14047 1 68 12 56 -0,0626 R.AGLQFPVGR.V 
pro-ubiquitin gi|340062 17434 2 43 21 26 -0,136 K.CCLTYCFNKPEDK.- + Carb. 
Ring finger protein 149 [Homo sapiens] gi|32425835 43151 1 15 2 15 -0,1652 K.GREILELVQK.G 
 
 
Supplementary Table 6: Mass spectrometry data on Ago2 complex III 
protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
eukaryotic translation initiation factor 2C, 2 
(Ago2) [Homo sapiens] 
gi|29171734 97146 17 1170 40 62 
-0,0935 
(-
0,147) 
K.AVQVHQDTLR.T  
(R.SVSIPAPAYYAHLVAFR.A) 
ubiquitin gi|229532 8446 2 56 21 56 / 21 
-0,1095 
/ -
0,0765 
K.TITLEVEPSDTIENVK.A / 
R.TLSDYNIQK.E 
Dicer [Homo sapiens] gi|5019620 218673 1 46 0 36 -0,0649 R.YTAVVLNR.L 
MYB binding protein 1a [Homo sapiens] gi|7657351 148758 1 36 2 40 -0,0738 R.SPSLLQSGAK.K 
proline and glutamic acid rich nuclear protein 
isoform [Homo sapiens] 
gi|3168604 109069 1 51 1 51 -0,1009 R.TGSAVAPVHPPNR.S 
RNA helicase A gi|1082769 141984 4 146 3 39 -0,0787 K.VFDPVPVGVTK.V 
DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1 (Ddx30)[Homo sapiens] 
gi|20336294 133854 2 33 1 18 -0,0661 K.NLLNSVIGR.A 
Splicing factor 3B subunit 3 (Spliceosome 
associated protein 130) (SAP 130) (SF3b130) 
(Pre-mRNA splicing factor SF3b 130 kDa 
subunit) (STAF130) 
gi|19863446 135507 1 27 - 27 -0,0797 R.FLAVGLVDNTVR.I 
hnRNP U protein [Homo sapiens] gi|32358 88890 4 213 6 52 -0,1008 K.LLEQYKEESK.K 
matrin 3 [Homo sapiens] gi|6563246 95138 1 39 1 39 -0,0686 K.SFQQSSLSR.D 
gemin4 [Homo sapiens] gi|7657122 119913 3 150 - 75 -0,1312 K.VLQPHPVTPSDTETR.W 
hect domain and RLD 5 [Homo sapiens] gi|7705931 116773 1 54 - 54 -0,0795 K.FLVFLTGTDR.L 
polyadenylate binding protein II [Homo sapiens] gi|693937 58481 9 414 24 66 -0,1173 R.IVATKPLYVALAQR.K 
Skb1Hs [Homo sapiens] gi|2323410 72740 1 41 1 41 -0,0620 R.EFIQEPAK.N 
mRNA-binding protein CRDBP [Homo sapiens] gi|7141072 63417 2 118 5 52 -0,1047 R.DQTPDENDQVIVK.I 
FXR1 gi|1730139 69649 10 40 15 41 0,04 R.LQIDEQLR.Q 
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protein Acc.No. Mass 
Queries 
matched 
Protein
score 
Seq cov 
% 
Peptide
score 
Pep 
delta 
Pep sequence 
Ribosomal protein L4 [Homo sapiens] gi|12655035 47667 4 287 21 50 -0,2030 
R.QPYAVSELAGHQTSAESW
GTGR.A 
Y box-binding protein [Mus musculus] gi|55451 35822 3 158 11 85 -0,1388 R.SVGDGETVEFDVVEGEK.G 
unnamed protein product [Homo sapiens] gi|31092 50095 1 47 2 47 -0,0860 K.IGGIGTVPVGR.V 
ribosomal protein L3 gi|337580 45440 4 218 14 57 -0,1166 K.NNASTDYDLSDK.S 
KIAA1756 protein [Homo sapiens] gi|12698057 116668 1 33 0 33 -0,1734 R.AELEKVLR.A 
NF45 protein gi|532313 44669 2 134 9 53 -0,0943 K.VLQSALAAIR.H 
HNRPC protein [Homo sapiens] gi|14250048 33578 2 106 8 45 -0,0822 R.VPPPPPIAR.A 
ribosomal protein L6 [Homo sapiens] gi|36138 32841 4 169 11 60 -0,0788 K.FVIATSTK.I 
Stomatin (EPB72)-like 2 [Homo sapiens] gi|14603403 38494 1 43 2 43 -0,1070 R.ATVLESEGTR.E 
Mov10 
gi|14424456
8 
43599 7 23 5 23 0,8 R.ITGNPVVTNP.I 
EBNA1 binding protein 2 [Homo sapiens] gi|5803111 34798 1 36 3 36 -0,0823 R.QAQAAVLAVLPR.L 
HNRPC protein [Homo sapiens] gi|13937888 33578 3 152 12 58 -0,0926 K.SDVEAIFSK.Y 
B23 nucleophosmin gi|190238 9189 1 40 10 40 -0,0821 K.GPSSVEDIK.A 
RNA binding motif protein 4 isoform 1 [Homo 
sapiens] 
gi|4506445 40914 1 32 - 32 -0,0791 R.AEDAVEAIR.G 
Ribosomal protein P0 [Homo sapiens] gi|12654583 34253 5 310 21 61 -0,1265 R.GTIEILSDVQLIK.T 
fibrillarin gi|182592 33797 1 35 3 35 -0,1090 R.TNIIPVIEDAR.H 
prohibitin 2 [Homo sapiens] gi|6005854 33276 1 41 3 41 -0,0566 R.VLPSIVNEVLK.S 
ribosomal protein S6 gi|225901 28633 2 64 / 38 4 / 3 64 / 38 
-0,0725 
/ -
0,0504 
K.DIPGLTDTTVPR.R / 
K.LIEVDDER.K 
ribosomal protein L7a [Homo sapiens] gi|4506661 29977 6 236 21 73 -0,0820 R.AGVNTVTTLVENK.K 
Ribosomal protein L8 [Homo sapiens] gi|15341853 27993 5 187 21 80 -0,1253 R.ASGNYATVISHNPETK.K 
S3 ribosomal protein [Homo sapiens] gi|7765076 26699 3 177 14 57 -0,0749 R.TEIIILATR.T 
unnamed protein product [Homo sapiens] gi|34392 24191 1 39 4 39 -0,0797 K.TYSYLTPDLWK.E 
ribosomal protein S4 gi|227229 29664 1 52 3 52 -0,0589 R.LSNIFVIGK.G 
ADP.ATP translocase gi|339721 28042 2 77 8 43 -0,1026 R.YFPTQALNFAFK.D 
Ribosomal protein L7 [Homo sapiens] gi|14250762 29207 5 228 20 61 -0,0853 R.IALTDNALIAR.S 
ribosomal protein L10a [Homo sapiens] gi|15431288 24816 2 84 13 37 -0,0633 R.DTLYEAVR.E 
ribosomal protein S9 gi|550023 22558 4 139 18 47 -0,0619 R.LFEGNALLR.R 
ribosomal protein L18 [Homo sapiens] gi|4506607 21621 2 126 13 74 -0,0864 K.TAVVVGTITDDVR.V 
ribosomal protein L13a [Homo sapiens] gi|6912634 23562 1 70 9 54 -0,0788 K.YQAVTATLEEK.R 
ribosomal protein L10 gi|414587 23903 1 42 4 42 -0,0652 R.SLQSVAEER.A 
L21 ribosomal protein gi|619788 17646 1 35 9 35 -0,1089 R.VYNVTQHAVGIVVNK.Q 
ribosomal protein L24 [Homo sapiens] gi|4506619 17768 1 109 14 52 -0,0820 R.QINWTVLYR.R 
unnamed protein product [Homo sapiens] gi|527578 16582 (1) 77 9 77 -0,1049 
R.DLTTAGAVTQCYR.D  
+ Carb: 
ribosomal protein L11 [Homo sapiens] gi|495126 20103 1 95 11 77 0,0258 K.VLEQLTGQTPVFSK.A 
ribosomal protein L27a [Homo sapiens] gi|4432754 3706 1 76 32 76 0,0092 K.TGAAPIIDVVR.S 
amino acid starvation-induced protein gi|202990 13865 1 30 11 30 -0,1136 K.EQIVPKPEEEVAQK.K 
ribosomal protein L12 [Homo sapiens] gi|55665101 17808 2 163 24 42 -0,0017 K.IGPLGLSPK.K 
ribosomal protein L26 [Homo sapiens] gi|4506621 17248 2 59 10 36 0,0115 K.DDEVQVVR.G 
ribosomal protein S26 [Homo sapiens] gi|456351 13035 1 78 13 78 -0,1098 R.DISEASVFDAYVLPK.L 
ribosomal protein L28 gi|550019 15752 1 32 8 32 -0,1066 K.QTYSTEPNNLK.A 
ribosomal protein S13 gi|553640 13313 3 129 34 54 -0,0858 K.GLTPSQIGVILR.D 
ribosomal protein L35 [Homo sapiens] gi|6005860 14543 2 123 21 48 -0,1371 R.VLTVINQTQKENLR.K 
ribosomal protein L27 [Homo sapiens] gi|4506623 15788 2 109 20 45 -0,0541 K.VVLVLAGR.Y 
ribosomal protein S16 – mouse gi|70920 16319 2 89 - 49 -0,0849 K.GPLQSVQVFGR.K 
RPL23 protein [Homo sapiens] gi|38571606 14875 1 83 18 37 -0,0601 K.NLYIISVK.G 
60S ribosomal protein L34 gi|132910 13499 2 69 12 36 -0,0671 R.AFLIEEQK.I 
acidic ribosomal phosphoprotein P1 [Homo 
sapiens] 
gi|31979223 11392 1 53 14 53 -0,1187 K.AAGVNVEPFWPGLFAK.A 
ribosomal protein L35a [Homo sapiens] gi|16117791 12530 1 47 14 21 -0,0686 K.AIFAGYKR.G 
ribosomal protein homologous to yeast S24 
[Homo sapiens] 
gi|36142 14707 1 47 6 47 -0,0634 K.IVVNLTGR.L 
Ribosomal protein S27-like protein [Homo 
sapiens] 
gi|13277528 9472 (1) 42 9 42 -0,0701 R.LTEGCSFR.R + Carb. 
ribosomal protein S20 [Homo sapiens] gi|3088340 6853 1 33 20 33 -0,1046 R.LIDLHSPSEIVK.Q 
RPL37A protein [Homo sapiens] gi|34783045 10137 (1) 28 8 28 -0,0723 K.YTCSFCGK.T + Carb. 
unnamed protein product [Homo sapiens] gi|32111 14164 1 27 27 27 -0,0586 R.AGLQFPVGR.V 
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